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In the present study we provide sufficient evidence that rat liver cytosolic 
CEH might belong to the group of interconvertible enzymes, whose activities are 
controlled by phosphorylation and dephosphorylation. In particular, we provide 
detailed evidence that in vitro conditions favouring phosphorylation in cytosolic 
and partially purified (0-40% ASF of cytosol) fraction enhance the rate of CE 
hydrolysis, whereas, marked decreases in CEH are correlated with the presence of 
phosphatase activity. CEH activity in cytosol and 0-40% ASF of cytosol was 
significantly increased by tiie addition of ATP-Mg and cAMP indicating the 
involvement of endogenous cAMP-dependent protein kinase. Addition of bovine 
heart cAMP-dependent protein kinase along with ATP-Mg and cAMP to cytosol 
and partially purified fraction of CEH was associated with maximal activation of 
CEH enzyme. Moreover, the activation of CEH was partially aboUshed by 
synthetic: rabbit sequence protein kinase inhibitor, indicating the involvement of a 
cAMP-dependent protein kinase. Our results also demonstrate tfiat preincubation 
of cytosolic and partially purified CEH with 3 mM ATP or 5 mM Mg^ 
significantly activated CEH activity which is apparently mediated by endogenous 
PKA and other cofactors required for the phosphorylation (activation). Increasing 
concentration of Mg^ ^ (6-10 mM) abolished the activation of cytosolic and 
partially purified CEH caused by 5 mM Mg^ .^ Similarly, high concentrations of 
ATP (>3 mM) and ATP-Mg (>2 mM) consistently reduced the optimal CEH 
activation caused by lower levels of ATP or ATP-Mg. In addition, 5 mM ATP and 
ATP-Mg not only completely abolished the CEH activation but inhibited the basal 
enzyme activity by approximately 90%. The inhibitory effects of high levels of 
ATP-Mg on CEH activity were significantly counteracted by the PKA/cAMP-
promoted activation of CEH. Consistent with the above results, high concentra-
tions of ATP and ATP-Mg was associated with the activation of p-nitrophenyl 
phosphate-sensitive phosphatases with a concomitant inactivation of CEH in 
0-40% ASF of cytosol. The combined results strongly suggest the involvement of 
endogenous ATP-Mg-dependent phosphatase-mediated dephosphorylation and 
inactivation of CEH enzyme. Furthermore, activation of such type of phosphatase 
at high levels of ATP and ATP-Mg counteracts the PKA/cAMP and ATP-Mg-
promoted activations, reducing CEH activity to the control value or even inhibiting 
the basal CEH activity by more than -90%. 5 mM of Mn^ * stimulated CEH 
activity to a significantly higher degree than 5 mM Mg . This activation was 
completely blocked at 10 mM Mn^ .^ Our results demonstrate that unlike Mg^ "^ , 
high increase in CEH activity is substantially due to direct effect of free Mn 
(5 mM) on enzyme and is independent of PKA-mediated phosphorylation 
(activation) of CEH. 
Addition of nonspecific serine/threonine phosphatase inhibitors, pyrophos-
phate and glycerophosphate to 0-40% ASF was associated with inhibition of 
endogenous phosphatases and a concomitant activation of CEH. We report here a 
novel finding tiiat high concentrations (5-10 mM) of ortfaovanadate was associated 
with CEH activation apparently by inhibiting serine/threonine phosphatases in a 
manner analogous to pyrophosphate and glycerophosphate. Because tiie 
endogenous phosphatases acting on CEH is sensitive to both low (10 nM) and high 
(5 |JM) concentrations of okadaic acid/calyculin A and partially inactivated the 
phosphatase activity, it is likely that 2A phosphatase is also involved in the 
dephosphorylation and inactivation of CEH. Addition of ATP-Mg/cAMP/PKA to 
the samples treated with above three phosphatase inhibitors caused an additional 
1.5-2 fold activation of CEH indicating a PKA-mediated enhanced phosphory-
lation. This is the first evidence for the involvement of endogenous phosphatases 
in the inactivation of partially purified cytosolic CEH. The existence of an 
activation/deactivation cycle for CEH involving phosphorylation/dephosphory-
lation was established by using cAMP-dependent protein kinase/cAMP/ATP-Mg 
as activators, and the non-specific alkaline phosphatase fi-om bovine intestinal 
mucosa as an inhibitor. PKA-mediated phosphorylation and activation of CEH was 
reversed by alkaline phosphatase involving dephosphorylation and inactivation. 
The combined results confirm and extend the idea that cytosolic CEH activity can 
X I 
be modulated in vitro involving a cAMP-dependent protein kinase. Dephosphory-
lation and inactivation of CEH is mediated by endogenous cytosolic ATP-Mg-
dependent phosphatase, and okadaic acid sensitive 2A phosphatase. 
The regulation of rat liver cytosolic CEH involving phosphorylation 
(activation)/dephosphorylation (inactivation) was investigated in in vivo. Results 
presented in this thesis show that short-term (15 min) administration of cAMP was 
associated with a significant activation of CEH activity. This in vivo CEH 
activation was completely reversed following dephosphorylation with alkaline 
phosphatase. These results represent an initial demonstration of an in vivo cAMP-
dependent protein kinase-mediated phosphorylation and activation of cytosolic 
CEH in cAMP-treated rats. Similarly, in 4 h MVL-treated rats, the basal CEH 
activity was increased partially due to in vivo phosphorylation. Dephosphory-
lation of CEH widi alkaline phosphatase substantially reversed the initial 
activation of CEH, which is consistent with MVL-mediated reversible 
phosphorylation of CEH. One week feeding of cholestyramine to rats was 
associated with a significant increase in CEH activity, substantial part of which 
was due to in vivo activation (phosphorylation). In vitro dephosphorylation of 
CEH was consistent with this observation. These results demonstrate that 
cholestyramine feeding to rats triggers both PKA-mediated phosphorylation and 
activation of CEH, and inactivation of phosphatases, thus reducing the 
dephosphorylation (inactivation) of CEH and favouring an overall activation status 
of CEH. Feeding of lovastatin (mevinolin) alone or in combination with cholesty-
ramine for one week enhanced the CEH activity by 2-2.5 fold. In addition, CEH 
activity in 21 h and 36 h fasted rats was increased by approximately 2-fold. 
However, in the above four manipulations, after alkaline phosphatase-mediated 
dephosphorylation, the reversibility in terms of inhibition of activated CEH was 
minimal in comparison to corresponding controls. These results demonstrate that 
feeding of lovastatin, cholestyramine plus lovastatin or 21 h and 36 h fasting to 
rats was not associated with CEH activation involving in vivo modulation of 
1 1 1 
phosphorylation. Furthermore, our results also demonstrate that above 
manipulations were associated with significantly reduced in vitro activation of 
phosphatses and substantially low inhibition of CEH activities, thus favouring an 
overall activation of CEH. 
The combined in vitro and in vivo results demonstrate tiiat regulation of 
cytosoUc CEH activity is important in maintaining the pool of metabolically active 
fi'ee cholesterol in the cell. 
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Intro dhiction 
Cholesterol, an amphipatfaic lipid molecule is widely distributed in the 
animal kingdom. It occurs in unesterified form in all cell membranes (Myant, 
1981) but mostly in esterified form in the blood plasma. Cholesterol also serves as 
precursor of steroid hormones and bile acids. The total body cholesterol is derived 
from two sources: diet and de novo synthesis. Out of total cholesterol needed by 
the body, a little more than half arises from synthesis and the remaining is derived 
from the average diet. 
Cholesterol is synthesized by virtually all the tissues containing nucleated 
cells but mostly by liver, intestine, adrenal cortex, reproductive tissues and skin. 
Although those cells and tissues which do not synthesize cholesterol, have the 
genomic information for cholesterol synthesis and under normal circumstances 
tiiey take up cholesterol from serum lipoproteins (Swann et al, 1975; Goldstein 
and Brown, 1977). Several steps in the cholesterol biosynthetic pathway are 
subject to feedback regulation. The primary feedback loop appears to be at the site 
where 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) is converted to 
mevalonic acid by the rate limiting enzyme 3-hydroxy-3-methylglutaryl coenzyme 
A reductase (HMG-CoA reductase, EC 1.1.1.34) (Luskey, 1988). Cholesterol and 
other oxycholesterols presumably inhibit the activity of HMG-CoA reductase via 
negative feedback regulation. Modulation of enzymic activity of HMG-CoA 
reductase and flie formation of mevalonate are of major importance in cellular 
metabolism since mevalonate serve as a precursor for several metabolic pathways 
including the formation of cholesterol, ubiquinones, dolichols, isopentyl-t-RNA, 
haem A and famesylated proteins e.g. ras and lamin B (Fig. 1.1). 
Intake of dietary cholesterol and its distribution to various tissues and 
organs for utilization and storage is a complex process, it n:*eds carrier proteins for 
cholesterol transport in plasma since cholesterol is water insoluble molecule. The 
carrier proteins, which function as transport vehicles for triacylglycerol (TAG), 
and cholesterol are called apolipoproteios. These apolipoproteins cany lipids in 
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Fig LI. The biosynthetic pathways of mevalonate, sterols and isoprenoid compounds. 
globular micelle like particles, termed lipoproteins. The lipoproteins consist of a 
nonpolar core of TAG and cholesteryl esters (CE) surrounded by an amphiphilic 
coating of proteins, phospholipids and cholesterol. The association of the 
hydrophobic lipids circulating in plasma with proteins, was initially described by 
Macheboenf (1929). These apolipoproteins are structurally heterogeneous and 
have entirely different metaboUc functions (Osborne and Brewer, 1977). Fourteen 
major apolipoproteins, distributed in different lipoproteins have been identified 
and characterized in human plasma (Brewer et al, 1988). Electron microscopic 
studies indicate that Ae association of Upids with apolipoproteins occur in the 
smooth endoplasmic reticulum after initial apolipoprotein synthesis in the rough 
endoplasmic reticulum (Hamilton, 1972). 
Five major groups of Upoproteins have been identified on tiie basis of tiieir 
electrophoretic mobility and hydrated density. These are (a) chylomicrons (b) very 
low density lipoprotein (VLDL) (c) intermediate density lipoprotein (IDL) (d) low 
density lipoprotein (LDL) and (e) high density lipoprotein (HDL) (Gofinan et al, 
1954). Lipoprotein particles undergo continuous metabolic processing so that tiiey 
have some what variable properties and composition (Brown and Goldstein, 1987). 
Each lipoprotein contains about 20 A° thick monolayer of protein and polar lipids 
(Brown and Goldstein, 1984) at the surface of the particle. The density of 
lipoproteins increases with tiie decrease in the particle diameter because the 
density of the outer coating is greater than that of the inner core. The principal 
sites of mammalian plasma lipoprotein biosynthesis are the liver (Stein and Steio, 
1979) and intestine (Jones and Ockener, 1971). VLDL and HDL are the primary 
lipoproteins secreted by the liver, while chylomicron is the major lipoprotein of 
the intestinal origin. Both VLDL and HDL may also be produced by the intestine 
(Wu and Windmueller, 1978). Chylomicrons, which transport exogenous TAG and 
cholesterol fi-om the intestine to the tissues and packaged in the golgi apparatus 
and secreted through exocytosis into the intracellular space at the basal aspect of 
the cell (Shaefer et al, 1978). They then enter lacteals via tiie endothelial cells 
from loose junctions and are transported into the blood tfirough tiie thoracic duct. 
Chylomicrons adhere to the binding sites on the endothelium of skeletal muscle 
and adipose tissue. The majority of chylomicron TAG (75-80%) is hydrolyzed by 
lipoprotein lipase during circulation (Chajek and Eisenberg, 1978) which is 
activated by apo C-II, present within the chylomicrons and resulting mono-
acylglycerols as well as excess surfiEice components are removed from the 
chylomicron (Eisenberg and Levy, 1975) leaving cholesterol ester rich, TAG poor 
renmant particles, which binds to apoE receptor with high affinity in the liver and 
internalized by endocytosis (Sherrill and Dietschy, 1978). In this way chylo-
microns deliver dietary TAG to muscle and adipose tissue and dietary cholesterol 
to the liver (Fig. 1.2). 
VLDL is secreted from Ae liver in much the same way as the chylomicrons 
are formed by the intestine (Glauman et al, 1975). Hepatogenous VLDL acquires 
apo C-n and apo E from HDL when comes in the circulation due to which affinity 
of VLDL for lipoprotein lipase increases, resulting increased catalysis of TAG 
(Nilsson-Ehle et al, 1980), and VLDL are serially converted to VLDL remnants 
(M Jos et al, 1975), IDL and finally LDL. Apo E and hepatic lipase, a second 
lypolytic enzyme, are required for the efficient conversion of IDL into LDL 
(Brewer, 1955). During the conversion of VLDL into LDL nearly half of the 
VLDL remnant and IDL are taken up by the liver from the plasma. LDL tiie final 
product of VLDL metabolism interact with LDL receptor present on the surface of 
tiie liver, adrenals and peripheral cells including fibroblasts and smooth muscle 
cells (Goldstein and Brown, 1979; Yamamoto et al, 1984; Goldstein et al, 1985; 
Sudhof et al, 1985). However, evidence from VLDL turnover studies indicates 
that only a portion of plasma VLDL becomes LDL, the actual proportion of which 
differs among individuals and among pathological conditions (Kesaniemi et al, 
1982). In vivo kinetic study of VLDL and LDL metabolism in human and in non 
human primates indicate that LDL arise not only from VLDL but also from direct 
secretion of LDL into circulation (Goldberg et al, 1983). Furthermore, the studies 
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Fig. 1.2. A model for plasma triacylglycerol and cholesterol transport. 
(Adapted from Biocfaonistiy by D. Voet and J.G. Voet, J. Willey and scms. New Yoric, 1990 
ed.,p-306). 
of VLDL and LDL apo B metabolism by Soutar et al. (1977) indicate that in 
patients widi homozygous familial hypercholestero-lemia, the absolute synthetic 
rate of LDL apo B was about twice than of VLDL apo B. Thus VLDL apo B could 
not be tfie sole precursor to LDL apo B. LDL serve the cholesterol supply for 
metaboUc needs of the cells, accomplished by the receptor mediated endocytosis 
of LDL particles (Brown and Goldstein, 1979; Brown and Goldstein, 1983) which 
undergo rapid hydrolysis yielding free cholesterol for cellular needs. Most of the 
tissues in die body have been demonstrated to have the capacity to express LDL 
receptors. The liver is Ae organ that express highest level of LDL receptor 
(Pittman et al, 1982). LDL receptors remove both IDL and LDL from the plasma 
and it has been suggested that at least two third of LDL cleared from plasma each 
day is taken out of the circulation by the liver and 80-90% of this is via LDL 
receptor (Belheimer et al, 1984). The number of receptors displayed on the 
surface of the cells varies with the cellular demand for cholesterol. When the need 
is low, cells make fewer receptors and take up LDL at a reduced rate. When the 
cells of the Uver have a high demand for cholesterol they produce high level of 
m-RNA for receptors. The reverse phase appears when excess cholesterol 
accumulates in cells (Russel et al, 1983). 
HDL is involved in "reverse cholesterol transport". In this process 
cholesterol is removed from peripheral tissues and deUvered to the liver for bihary 
excretion (Glomset et al, 1966; Glomset, 1968). Nascent HDL, composed of 
apoA-1 phospholipid discs, are secreted from both the human intestine and Uver 
and acquires excess cholesterol from the tissues, which is converted to CE by 
lecithin cholesterol acyltransferase (LCAT). After formation of CE, nascent HDL 
are converted to HDL3 which are then converted to the larger particle termed, 
HDL2 by acquiring lipids and apoproteins released during the metabolism of 
chylomicrons and VLDL as well as by esterification of cholesterol removed from 
the peripheral tissues. HDL2 is converted back to nascent HDL via HDL3, in the 
liver (Glomset et al, 1966; Glomset, 1968; Eisenberg, 1984; Brewer et al, 1988; 
Grundy, 1991; Rader et al, 1991; Brinton et ai, 1994). HDL also delivers CE to 
VLDL-IDL-LDL by the cholesterol ester transfer protein (CETP) with ultimate 
transfer of cholesterol to tibe liver by apo-B-containing proteins (Tall, 1993). The 
whole process of "reverse cholesterol transport" is summarized in Fig. 1.3. 
Altfiough cholesterol is essential to life, excess of free cholesterol is known 
to be cytotoxic. Moreover, its deposition in arteries has been associated widi heart 
disease and atherosclerosis, leading causes of death in humans. Under normal 
conditions, an intricate balance is maintained between the biosynthesis, utilization 
and tran^)ort of cholesterol, keeping its harmful effects to a minimum. Liver is the 
major site for cholesterol metabolism where concentration of unsterified 
cholesterol is maintained within the narrow range as compared to esterified 
cholesterol (Yeaman, 1990). Several factors are known which cause an overall 
increase ID cholesterol concentration in tiie liver, (i) uptake of lipoproteins by 
receptor-mediated endocytosis (ii) non receptor-mediated intake of lipoproteins 
(iii) uptake of free cholesterol from the cholesterol rich lipoproteins by the cell 
membrane (iv) de novo cholesterol synthesis (v) hydrolysis of CE by cholesteryl 
ester hydrolase (CEH, EC 3.1.1.13 ). Under above situation increased cholesterol 
levels inhibit its own synthesis by inhibiting HMG-CoA reductase, and also 
suppress LDL receptors (Russel et al., 1983). Furthermore, cholesterol 
7 a-hydroxylase (C7aH, EC 1.14.13.17) and acyl-coenzyme A: cholesterol 
acyltransferase (ACAT, EC 2.3.1.26) are activated which utilize free cholesterol 
for bile acid synthesis and formation of CE respectively. Conversely, some factors 
are involved in tibe decrease of hepatic cholesterol, they are: (a) efflux of 
cholesterol from the membrane to HDL3 and nascent HDL that is catalyzed by 
LCAT (b) esterification by ACAT (c) utilization of cholesterol for synthesis of 
steroids and bile acids. Under these conditions increase in cholesterol is achieved 
by activation of HMG-CoA reductase and CEH activities as well as induction in 
synthesis of LDL receptors in order to receive cholesterol from nonhepatic tissues 
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by receptor-mediated endocytosis (Fig. 1.4). 
Thus hepatic level of cholesterol is maintained by a precise balance 
between reactions catalyzed by HMG-CoA reductase, C7aH, ACAT and CEH. 
The first two enzymes are the rate limiting enzymes for cholesterol and bile acid 
synthesis, re^ctively. ACAT catalyzes the esterificaton of fi-ee cholesterol, where 
as CEH mediates release of free cholesterol from the stored CE. 
In general, tiie catalytic activities of regulatory enzymes may be controlled 
by two mechanisms: (a) long-term regulation, which involves alteration of the 
amount of enzyme present by changes in the rate of protein synthesis and/or 
degradation. This process requires hours or days and is therefore called long-term 
regulation (b) short-term regulation, which occurs with a response time of minutes 
or less. Allosteric interactions, substrate availability, and covalent modification 
(phosphorylation/dephosphorylation) are the examples of short-term regulation. 
The reversible phosphorylation-dcphosphorylation of proteins is recognized 
as an important mechanism for the control of intracellular events in eukaryotic 
cells. Processes as diverse as metabolism, contractility, membrane transport and 
secretion, the transcription and translation of genes, cell division, fertilization, and 
even memory, are all regulated by this versatile post-translational modification 
(Cohen, 1989). Serine, threonine, and tyrosine residues of proteins are reversibly 
phosphoiylated in cells. Over 99% of all phosphorylation occur on serine and 
threonine residues. The phosphorylation of proteins are catalyzed by different 
protein kinases such as: 
i. cAMP-dependent protein kinases (PKA). 
ii. cGMP-dq)endent protein kinases (PKG). 
iii. Calcium activated phosphohpid dependent protein kinases (PKC). 
iv. Calcium calmodulin dependent protein kinases. 
V. Non specific or messenger independent protein kinases. 
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PKA is found in all animal cells and is thought to account for all of the 
effects of cAMP in most of these cells. PKA are of two types, type I and type D. 
These kinases differ only to the nature of their regulatory subunits but have 
identical catalytic subunits (Corbin et al., 1975; Hofmann et al., 1975). PKA exists 
in active and inactive forms. The inactive form (holoenzyme) is a tetramer 
containing two identical catalytic (C2) and two identical regulatory (R2) subunits 
having a molecular wt. of 38 kDa and 49 kDa, respectively in muscle cell. cAMP 
binds to the regulatory subunits and liberates active monomeric catalytic subunit 
which phosphoiylates specific substrate protein molecule. The amino acids 
phosphorylated by PKA are marked by the presence of two or more basic amino 
acids on their N-terminal side. Covalent phosphorylation of the appropriate amino 
acids in turn regulates the activity of the target protein. Upon phosphorylation 
some enzymes are activated while others are inhibited, depending on their location 
in metabolic pathways. The substrates for PKA differs in different cell types. Here 
are few major examples of interconvertible eniymes undergoing phosphorylation 
by PKA: Phosphorylated form of glycogen synthase is inactive in liver and muscle 
whereas, phosphorylase kinase in liver and muscle following phosphorylation is 
activated. Phosphorylation of hepatic pyruvate kinase is associated with activation 
of enzyme whereas, hepatic phosphofi\icto kinase-2 is inactivated by 
phosphorylation. Phosphorylation of acetyl-CoA carboxylase in liver, marrmiary 
gland and adipocytes caused inactivation. Hormone sensitive lipase was activated 
by phosphorylation in adipose tissue. Hepatic phenyl alanine hydroxylase was 
activated by PKA-mediated phosphorylation. Tyrosine hydroxylase in brain and 
adrenal medulla was activated by phosphorylation and CEH was activated upon 
phosphorylation in adrenal cortex and corpus luteum (Cohen, 1980; Cohen, 1984). 
Protein kinase G does not contain separate regulatory subunits and is not 
dissociated by cGMP binding. Infact cGMP-binding and catalytic activity reside 
on a single polypeptide chain (Gill et al., 1976; Inoue et al., 1976; Takai et al.. 
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1976; Gill et ai, 1977; Lincoln and Corbin, 1977). In contrast to cAMP, which 
affects a wide variety of processes, cGMP functions as a specialized messenger, 
being involved in smooth muscle relaxation (Casnellie and Greengard, 1974), 
platelet aggregation, and the visual system (Buck, 1992). Moreover, protein kinase 
G can also phosphorylate all five of the histone firaction (Yamamoto et ai, 1977), 
pyruvate kinase (Lincoln and Corbin, 1977), glycogen synthase (Lincoln and 
Corbin, 1977), hormone sensitive lipase (Khoo et al, 1977), cholesterol esterase 
(Khoo et al, 1977), fiuctose 1,6-diphosphatase (Riou et al, 1977), cardiac 
troponin (Blumenthal et al, 1978; Lincoln and Corbin, 1978) and certain 
ribosomal protein (Chihara-Nakshima et al, 1977) which are also substrates for 
protein kinase A. 
The allosteric activation of calmodulin by Ca^ ^ is analogous to the allosteric 
activation of PKA by cAMP, except that Ca^ /^calmodulin has no enzyme activity 
itself but acts by binding to other proteins. Ca /calmodulin regulates protein 
phosphorylation directly throi^ activation of a number of calmodulin-dependent 
protein kinases (Cohen, 1985). The first such enzymes to be discovered, myosin 
light chain kinase (activates smooth muscle contraction) and phosphorylase kinase 
(activates glycogen breakdown) had narrow specificities. However, recent work 
has identified a broad-specificity enzyme, termed the calmodulin-dependent 
'multiprotein' kinase that mediates phosphorylation of many proteins including 
glycogen synthase, tyrosine hydroxylase, tryptophan hydroxylase, synapsin-I and 
microtubule-associated protein-2. 
Protein kinase C is a family of Ca^ ,^ phospholipid-dependent kinases, that 
play a critical role in cellular signal transduction and serves as the major 
intracellular receptor for tumor-promoting phorbol esters (Niedel et al, 1983; 
Nishizuka, 1984). Cellular growth, differentiation, and secretion are major events 
which are controlled by PKC mediated phosphorylation (Nishizuka, 1988; 
Kikkawa et al, 1989). The initial rise in Ca^ ^ induced by inositol 1,4,5-
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triphosphate (IP3) is thought to alter the PKC so that it translocates from the 
cytosol to the cytoplasmic face of the plasma membrane. There it is activated by 
the combination of Ca^ ,^ diacylglycerol (DG) and the negatively charged 
membrane phospholipid phosphatidyl serine. Diacylglycerol can be replaced by 
phorbol esters. PKC phosphoiylates serine and threonine residues in many target 
proteins including the receptors for EGF, insulin, insulin like growth factor 1, 
interleukin 2, transferrin, somatomedin C, ^-adrenergic agonists and some 
important metabolic enzymes such as HMG-CoA reductase (Beg et ai, 1987) and 
glycogen synthase (Roach and Goldman, 1983; Ahmad et ai, 1984). 
Apart from above listed well known kinases some recently discovered 
protein kinases such as Cdc2, Raf, MAP kinases, and protein kinase B have been 
reported that regulate cellular growth, differentiation, and death (Hopkin, 1997). 
Dephosphorylation of phosphorylated proteins are catalyzed by 
serine/threonine phosphoprotein phosphatases, which have very broad and 
overlapping substrate specificities. Most of the protein phosphatases reported in 
the literature can be categorized into four principal catalytic subunits: Type I, 2A, 
23 and 2C on the basis of their dependency on divalent cations and sensitivity to 
various inhibitors (Cohen, 1989; Cohen et ah, 1990). Type 2B and 2C require Ca^ ^ 
and Mg respectively for their activity (Ingebritsen and Cohen, 1983a; Ingebritsen 
and Cohen, 1983b) where as type 2A like type I is active towards most substrates 
in absence of divalent cations. 
Although active protein phosphatase 1 (PP-1) in skeletal muscle is largely 
particulate, an inactive cytosolic form (PP-1 1) is also present. It has also been 
identified in adrenal cortex (Merlevede and Riley, 1966), liver (Goris et al, 1979; 
Yang et al, 1980a), heart (Goris et al, 1979; Yang et al, 1980; Price and Li, 
1985; Price et al, 1986), smooth muscle (Di Salvo and Jiang, 1982), brain (Yang 
and Fong, 1985), fiiiit flies (Orgad et al, 1987) and starfish (Pondaven and Cohen, 
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1987). The inactive enzyme consists of a catalytic component and a heat-stable 
modulator protein. Activation of enzyme is achieved by a preincubation with 
ATP-Mg and glycogen synthase kinase 3 which is tri^ered by tiie 
phosphorylation of a threonine residue on modulator protein (Hemmings et al, 
1982;Resinke/a/., 1983). 
Three major native fonns of PP-2A, temed PP-2A1 PP-2A2 and PP2A0 
have been identified (Foulkes et al, 1983; Ingebritsen et al, 1983a; Pelech and 
Cohen, 1985; Tung et al, 1985; Mumby et al, 1987). Catalytic subunit of protein 
phosphatase 2A have been purified fi'om rabbit skeletal muscle (Silbennan et al, 
1984; Tung et al, 1984), bovine heart (Chou et al, 1977; Killilea et al, 1978; 
Shacter-Noiman and Chock, 1983), porcine kidney (Schlender et al, 1986), rat 
liver (Le Vine et al, 1984), and soil amoeba (Mc Clure and Kom, 1983). 
PP-2C has been purified from canine heart (Li et al, 1978), tuikey gizzard 
(Pato and Adelstein, 1980; Pato and Adelstein , 1983), rat liver (Hiraga et al, 
1981; Mieskes, et al, 1984; Mieskes and Soling, 1985) and rabbit liver and rabbit 
skeletal muscle (Mc Gowan and Cohen, 1987). Each enzyme is a monomeric 
protein with a molecular mass of about 43 kDa on SDS-PAGE. Two iso forms of 
PP-2C have been isolated from rabbit skeletal muscle or rabbit liver, termed 
PP-2C1 and PP-2C2 (Mc Gowan and Cohen, 1987). PP-2C has also been 
identified in rabbit brain and adipose tissue (Ingebritsen et al, 1983b) and human 
erythrocyte cytosol (Usui et al, 1983). 
PP-2B has been identified in all mammalian tissues examined as a 
Ca /calmodulin-dependent, trifluoperazine-sensitive activity (Ingebritsen et al, 
1983b). The brain PP-2B is a heterodimer composed of a 61 kDa (A subunit) and a 
19 kDa (B subunit) (Klee and Krinks, 1978; Sharma et al, 1979; Wallace et al, 
1979; Aitken et al, 1984). The A subunit is a calmodulin-binding component 
(Klee et al, 1979; Sharma et al, 1979; Carlin et al, 1981) and contains the 
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catalytic site (Gupta et ai, 1985; Merat ei al, 1985) while the B subimit is a 
calcium binding component (Klee et ai, 1979; Aitken et ai, 1984; Klee et ai, 
1985). Calmodulin-regulated protein phosphatases isolated from skeletal muscle 
(Stewart et ai, 1983), platelets (Wolf and Hofinann, 1980; Tallant and Wallace, 
1985), placenta (Fallen et ai, 1985), heart (Wolf and Hofinann, 1980) and sea 
urchin eggs (Isawa and Ishiguro, 1986) are also composed of two subunits with 
molecular masses similar to those of the A and B subunits of brain PP-2B. 
I 
The serine/threonine-specific protein phosphatases which have very broad 
and overlapping specificities in vitro, account for virtually all-detectable 
phosphatase activity in muscle and liver extracts toward some 20 phosphoproteins 
that control glycogen metabolism, muscle contractility, protein synthesis, 
cholesterol synthesis, fatty acid synthesis, glycolysis/gluconeogenesis, and 
aromatic amino acid breakdown. The specificities of these enzymes are likely to be 
even wider in vivo (Cohen, 1989). PP-1, PP-2A and PP-2C accounts for all the 
HMG-CoA reductase phosphatase and AMP-activated kinase phosphatase activity 
in rat liver extracts (Ingebritsen et ai, 1983b; Ingebritsen et ai, 1983c). However, 
major HMG-CoA reductase phosphatase associated with liver microsomes is PP-1 
(Schelling et ai, 1988). PP-1, PP-2A and PP-2C account for virtually all the 
phosphatase activity in rat liver and rabbit liver extracts toward several enzymes 
including 6-phosphofiiicto-2-kinase/fiiictose 2,6-bisphosphatase, pyruvate kinase, 
6-phosphofiTJCto-l-kinase (glycolysis/gluconeogenesis), acetyl- CoA carboxylase 
and ATP citrate lyase (fatty acid synthesis) and phenylalanine hydroxylase (amino 
acid breakdown) (Ingebritsen et ai, 1983b; Ingebritsen et ai, 1983c, Alemany 
et ai, 1984; Pelech et ai, 1984). 
The most effective substrates for PP-2B are proteins that regulate the 
activities of protein kinases and phosphatases, namely inhibitor-1 (Nimmo and 
Cohen, 1978) and its isoform dopamine and cAMP-regulated phosphoprotein 
(Hemmings et ai, 1984), the regulatory RII subunit of PKA (Blumenthal et ai. 
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1986), the a subunit of phosphorylase kinase (Stewart et al, 1983), and the 
calmodulin-dependent cAMP phosphodiesterase (Shanna et al, 1988). 
Pyrophosphate and glycerophosphate have been used as non-specific 
serine/tfareonine-phosphatase inhibitors, while okadaic acid has been used as 
specific inhibitor to distinguish type I and 2 A (Cohen, 1991). PP-1 is inhibited by 
nanomolar concentrations of two small heat and acid stable proteins, termed 
inhibitor-1 (I-l) and inhibitor-2 (1-2). I-l is active when phosphorylated by PKA 
whereas 1-2 do not require phosphorylation for its activity (Cohen, 1989). PP-1 is 
also inhibited by sodium fluoride. In addition to serine/threonine phosphatases 
there are protein-phosphotyrosine phosphatases in most mammalian and avian 
cells and tissues as well as in bacterial and yeast cultures (William Lau et al, 
1989) which are inhibited by less than 1 mM concentrations of sodium 
orthovanadate (Gordon, 1991). Apart firom above mentioned serine/threonine/ 
tyrosine phosphatases, nonspecific alkaline phosphatases fi'om different sources 
have also been utilized for dephosphorylation of phosphoproteins in vtro. 
Considering the vital role of four enzymes namely HMG-CoA reductase, 
C7aH, ACAT and CEH in the overall maintenance of cholesterol homeostasis in 
the body, the following published information on their isolation, characterization, 
and long- and short-term regulation of enzyme activities including regulation of 
gene expression is being summarized. 
1.1. HMG-CoA REDUCTASE 
HMG-CoA reductase is the rate limiting enzyme that regulates the synthesis 
of cholesterol and other polyisoprenoid compounds (Rodwell et al, 1976; 
Goldstein and Brown, 1977; Brown and Goldstein, 1980; Ingebritsen and Gibson, 
1980; Beg et al, 1981; Beg and Brewer, 1982). In mammalian cells, HMG-CoA 
reductase is a transmembrane glycoprotein with its active site facing the cytosol 
and a carbohydrate containing site oriented toward the luminal surface of the 
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endoplasmic reticulum (Liscum et al, 1983a; Brown and Simoni, 1984). The 
protomer of HMG-CoA reductase is approximately 100,000 dalton protein (Chin 
et al., 1982; Edwards et al., 1983a; Hardeman et ah, 1983; Chin et al, 1984; Beg 
et al, 1985). Proteolysis of the native protein results in a 53,000 molecular weight 
fragment Aat contains the active ate of the enzyme (Chin et al, 1982; Edwards 
et al, 1983a; Hardeman et al, 1983; Liscum et al, 1983a; Chin et al, 1984; Beg 
et al, 1985). HMG-CoA reductase is a protein of 887 amino acids containing Aree 
potential sites for aspargine-linked glycosylation. The NH2-terminal half of the 
peptide is anchored to the membrane and contains seven hydrophobic regions, 
each of which encompasses 20 amino acids (Chin et al, 1984). The COOH-
terminal half of HMG-CoA reductase is hydrophilic and has been proposed to 
contain the catalytic site of the enzyme (Chin et al, 1984). HMG-CoA reductase 
lacks a hydrophobic NH2-terminal signal sequence (Chin et al, 1984). The 
extension of Ae catalytically active hydrophobic tail of die active enzyme into the 
cytoplasm permits the observed multifaceted regulation of HMG-CoA reductase 
and cholesterol synthesis. The complex homeostatic mechanism by which the 
enzyme activity of HMG-CoA reductase and cholesterol biosynthesis are 
coordinately regulated in response to various physiological stimuli has been 
extensively studied (Fig. 1.1). 
Isolation, purification, and characterization of rat hepatic HMG-CoA 
reductase has been well documented (Kawachi and Rudney, 1970; Brown et al, 
1973; Heller and Gould, 1973; Hellar and Gould, 1974; Heller and Shrewsburg, 
1976; Kleinsek et al, 1977; Srikantaiah et al, 1977; Edwards et al, 1979). Three 
basic control mechanisms for HMG-CoA reductase has been reported. (I) Long-
term regulation, which involves die modulation of HMG-CoA reductase activity 
by changes in enzyme concentration through transcriptional and post-
transcriptional modifications as well as enzyme degradation (Jakoi and Quarfordt, 
1974; Kirsten and Watson, 1974; Chan et al, 1981; Faust et al, 1982; Koizumi 
et al, 1982; Clarke et al, 1983; Edwards et al, 1983a; Edwards et al, 1983b; 
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Liscum et al, 1983b; Sinensky and Logel, 1983; Clarke et al., 1984). (D) Control 
of HMG-CoA reductase activity or degradation througji changes in the membrane 
composition and fluidity of the membrane structure in the immediate microsomal 
environment of the en2yme (Finkel and Volpe, 1979; Mitropoulos et al., 1981; 
Siptal and Sabine, 1981; Richert et al, 1984). (HI) Short-tenn regulation, that 
involves phosphorylation and dephosphorylation of HMG-CoA reductase 
(Ingebritson and Gibson, 1980; Beg et al, 1981; Beg and Brewer, 1982; Kennelly 
and Rodwell, 1985). Moreover, three separate systems, including bicyclic cascade 
for regulation of HMG-CoA reductase activity involving covalent modification has 
been demonstrated (Ingebritson and Gibson, 1980; Beg et al, 1987). These 
systems are mediated by different kinases including reductase kinase, PKC and 
Ca -calmodulin dependent protein kinase. HMG-CoA reductase has been also 
studied in different species including chicken liver (Beg et al, 1978; Beg et al, 
1979 ), human Uver (Beg et al, 1982; Beg et al, 1984a), and human fibroblasts 
(Beg et al, 1986). Apart from the feedback regulation of HMG-CoA reductase by 
cholesterol (Brown and Goldstein, 1980; Kita et al, 1980; Cohen et al, 1982), 
in vivo regulation of HMG-CoA reductase by cholesterol feeding (Arebalo et al, 
1981), cholestyramine and mevinolin (Edwards et al, 1983b), and mevalono-
lactone (Arebalo et al, 1980; Beg et al, 1984b) has been reported. Tocotrienols, a 
naturally occuring class of compoimds of vitamin E family, have also been 
reported to regulate HMG-CoA reductase activity at the post-transcriptional level 
(Pearce et al, 1992; Parker et al, 1993). Studies involving incubation of rat 
hepatocytes with insulin and glucagon or administration of glucagon to rats have 
been shown to modulate Ae bicyclic cascade system involving phosphorylation of 
both HMG-CoA reductase and HMG-CoA reductase kinase (Ingebritsen and 
Gibson, 1980; Gibson, 1985; Beg et al, 1987; Gibson and Parker, 1987). 
12. CHOLESTEROL 7 a-HYDROXYLASE 
Cholesterol 7 a-hydroxylase, the hepatic microsomal cytochrome P450 
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mono-oxygenase, catalyzes the initial and rate detennining step in the biosyntfietic 
pathway of bile acid (Shefer et al, 1970; Bostrom and Wikvall, 1982). The 
conversion of cholesterol into bile acids is a major pathway for Ae elimination of 
cholesterol from the body (Daiiielsson and Sjovall, 1975; Myant and 
Mitropoulous, 1977) and hence this enzyme plays an important role in cholesterol 
homeostasis. The enzyme has been purified, amino acid sequence and gene 
cloning has also been reported. The enzyme is 503 amino acid protein witfi the 
molecular weight of about 66 kDa (Li et al, 1990). The purification of C7aH, 
cloning and cDNA sequence has provided the tools to study this enzyme at 
molecular level (Jelinek et al, 1990; Li et al, 1990). In the rats and humans 
(Reihner et al, 1989; Bertolotti et al, 1991), bile acid returning to the liver, 
regulate their biosynthesis by feedback regulation and therefore suppress C7aH 
activity (Shefer et al, 1970; Bjarkhem, 1985; Heuman et al, 1988; Heuman 
et al, 1989). However, in rats, this feedback loop only pertain to the hydrophobic 
bile acids, as hydrophilic bile acids do not affect C7aH activity (Heuman et al, 
1988; Stravitz et al, 1993). The C7aH activity is decreased increasingly by bile 
acids of increasing hydrophobicity (Cholic<Chenodeoxycholic<deoxycholic) 
(Heuman et al, 1989). In rat hver, C7aH has also been shown to be regulated at 
the level of gene expression by hydrophobic bile aids (Jelinek et al, 1990; Li 
et al, 1990; Pandak et al, 1991; Stravitz et al, 1993; Twisk et al, 1993). More 
recent studies of C7aH gene have provided the evidence of bile acid responsive 
element (Hoekman et al, 1993; Chiang and Stroup, 1994), which appears to be 
responsible for this effect. 
Specific hormones have been reported to regulate C7aH activity in vivo 
(Story et al, 191 A; Bjarkhem, 1985; Ness et al, 1990; Vlahcevic et al, 1991), in 
primary hepatocytes (Princen et al, 1989) and in hepatoma cell lines (Leighton 
et al, 1991). The recognition of the role of hormones in the regulation of C7aH 
was that it also undergoes diurnal changes in rats with maximum specific activity 
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in mid daik and minimum at midlight, like HMG-CoA reductase. The C7aH 
specific activity, mRNA and protein are increased 2-3 fold during mid dark as 
compared to mid light (Chiang et al, 1990; Noshiro et ai, 1990). The 
phenomenon is attributed to the action of glucocorticoids as adrenelectomy 
abolishes this e£fect (Balasubramaniam et al, 1972; Pooler and Dnane, 1988). 
Thyroid hormone has also been reported to increase C7aH activity and mRNA 
level in vivo (Ness et al, 1990). Liver mRNA level of C7aH are also increased in 
req)onse to cholestyramine, a bile acid sequestrate or cholesterol (Jelinek 
et al., 1990; Li et al, 1990), whereas, the inhibition of cholesterol synthesis with 
die HMG-CoA reductase inhibition by lovastatin or Ay9944 results in decrease of 
C7aH activity and hence, bile acid syndesis (Pandak et al, 1990a; Pandak 
et al, 1990b). These observations indicate that the alterations in cholesterol 
availability are coupled with parallel changes in the C7aH gene expression. Under 
circumstances of cholesterol or mevalonate overload, C7aH is upregulated, while 
in presence of decreased cholesterol supply, the enzyme is down regulated. In 
either case, cholesterol homeostasis is effectively maintained. 
The short-term modulation of C7aH involving reversible phosphorylation is 
controversial (Goodwin et al, 1982; Sanghvi et al, 1983; Sanghvi, 1985; 
Berglund et al, 1986). Bile acids have also been reported to inhibit C7aH by 
increasing Protein Kinase C activity (Stravitz et al, 1995). Cholesterol, hormones, 
cytosolic factors (Kwok et al, 1981), diumal rhydrai, and phosphorylation 
(Scallen and Sanghvi, 1983; Tang and Chiang, 1986) are the factors that modulate 
C7aH activity. 
\3. ACYL-COENZYME A : CHOLESTEROL ACYLTRANSFERASE 
Acyl-coenzyme A : cholesterol acyltransferase is an intracellular, integral 
microsomal enzyme that uses cholesterol and fatty acyl-CoA to form CE (Chang 
and Doolittle, 1983; Suckling and Stange, 1985). The enzyme is highly regulated 
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in various cell types and tissues; and is believed to play an important role in 
cholesterol metabolism in intestinal mucosa, hepatocytes, arterial wall and steroid 
producing tissues. (Ross and Glomeset, 1973; Chang and Doolittle, 1983; Suckling 
and Stange, 1985). The transformation of free cholesterol which is potentially 
cytotoxic into inert CE, protect Ae cell and prevents deterioration of membrane. 
ACAT has been studied extensively and its gene cloning has been reported in 
different tissues of several species (Becker et al., 1994; Chang et ai, 1995; 
Uelmen et al., 1995; Cao et al., 1996; Yang et al., 1996) including mouce liver 
(Uelmen et al., 1995) and human liver (Becker et al., 1994). 
The prototype for the cellular role of ACAT has been the cultured 
fibroblast, the model on which the LDL receptor pathway was originally based 
(Brown and Goldstein, 1976). Most of tiie detailed studies of ACAT activity have 
used the enzyme from microsomal fraction of rat Uver. ACAT activity is found to 
be associated with rough endoplasmic reticulum (RER) in contrast to HMG-CoA 
reductase and C7aH which are associated with smooth endoplasmic reticulum 
(Balasubramaniam et al., 1978a). The active site of ACAT is located towards the 
cytosolic face of RER membrane (Hashimoto and Fogelman, 1980; Lichtenstein 
and Brecher, 1980). 
The sterol side chain was found to be important in the interaction between 
the enzyme and the substrate. A sterol of the molecular length of cholesterol 
proved to be optimal (Tavani et al., 1982). The amount of CE formed in the assays 
could be increased by the addition of cholesterol from a detergent, organic solvent 
or liposome vehicle (Balasubramaniam et al., 1978b; Erickson et al., 1980; Stange 
et al., 1983). The observation indicates that the microsomal pool of cholesterol 
does not saturate the enzyme. Further experiments showed that the enhancement of 
measured activity by cholesterol is not only due to the increase in the supply of 
substrate but cholesterol also acted as a nonsubstrate modulator of ACAT 
(Hashimoto et al., 1983). The relative increase induced in the ACAT activity by 
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cholesterol can be modified by treating the animal subjects with different diets, 
rich or deficient in cholesterol (Stange et al, 1983). 
25-Hydroxycholesterol activated ACAT in vitro (Erickson et al, 1980; 
Field and Mathur, 1983; Lichten-stein and Brecher, 1983), whereas other 
hydroxysterols were found to be inhibitory to ACAT (Erickson et al, 1980). 
Mevalonic acid (MVA), was also shown to activate ACAT (Drevon et al, 1980). 
The effect of 25-hydroxycholesterol and MVA on ACAT were additive, 
suggesting tiiat they act through different mechanism. These two treatments caused 
an inhibition of HMG-CoA reductase, but the characteristics of inhibition are 
different fi-om those of complementary activation of ACAT (Drevon et al, 1980). 
ACAT is activated by LDL in intact CHO cells, this activation is abolished in 
reconstituted en2yme (Doolitde and Chang, 1982). This is consistent with the idea 
that tiie effect of LDL cholesterol on ACAT activity requires the whole LDL 
receptor pathway for the internalization and utilization of the lipoprotein. 
In the adrenal gland, the activity of ACAT displays a diurnal rhythm with a 
tninimum at the onset of darkness coinciding with tiie peak of diurnal rhythm of 
corticosterone concentration (Beins et al, 1982), the rhythm was mirror image to 
that of HMG-CoA reductase. Acute administration of corticotropin led to about 
50% decrease in ACAT activity. These observations indicate that corticotropin 
plays an important role in generating the diurnal rhythm of ACAT. 
The short term regulation of ACAT activity has also been reported fi-om 
several laboratories (Basheeruddin et al, 1982; Gavey et al, 1983; Suckling 
et al, 1983b). Here ACAT activity was shown to increase by incubating the 
microsomes with ATP-Mg, NaF and a protein fraction from 100,000 x g 
supernatant of the liver cell. Some protein kinase activity was also present in the 
microsomes but the maximum activation effect was dependent on the presence of 
the supernatant fraction. ACAT activity could be inhibited by MgCh and a protein 
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fraction from 100,000 x g supernatant. The activation and inhibition was 
reversible. It was shown that the activation due to ATP and oflier components was 
independent of tibe effect of adding extra substrate cholesterol to microsomal 
vesicles (Suckling et al., 1983b) and also of the activity effect of 
25-hydroxycholesterol (Suckling et al, 1983a). ACAT has been found to be very 
sensitive to the environment. Several studies aimed at defining the optimal 
conditions for the assay of activity have shown that ACAT is readily inhibited by 
detergents such as Triton and organic solvents like acetone and ethanol 
(Balasubramaniam et al., 1978b; Spector et al., 1979; Suckling et al, 1983a). 
ACAT is inhibited by taurocholate (Norum et al, 1981) and this effect appears to 
be due to detergent effect of the bile acid rather than a more specific interaction. 
1.4. CHOLESTERYL ESTER HYDROLASE 
Cholesteryl ester hydrolase the principal enzyme responsible for the 
hydrolysis of endogenous C£ to free cholesterol, has been documented in many 
tissues and cell types using a wide range of in vitro and in vivo conditions. The 
following information is available for CEH in nonhepatic and hepatic tissues. 
1.4.1. CEH IN NONHEPATIC TISSUES 
1.4.1,1. CEH IN ADIPOSE TISSUE 
Hydrolysis of both TAG and CE is achieved by single en2yme known as 
hormone-sensitive Upase, which catalyses the rate limiting step in lypolysis. The 
enzyme has been purified from rat adipose tissue to a state approaching 
homogeniety and many of its molecular and catalytic properties have been 
investigated (Fredrickson et al, 1981a; Fredrickson et al, 1981b). Enzyme is 
activated by phosphorylation, mediated by cAMP-dependent protein kinase 
(Belfrage et al, 1977; Fredrickson et al, 1981a). 
Pittman and coworkers (1975) have also reported the presence in rat 
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adipose tissue of high levels of a CEH activity that shared many of the properties 
of honnone-sensitive lipase, including a comparable degree of activation by PKA. 
Some reports suggested the presence of multiple acyl-hydrolases in rat adipose 
tissue, including Upoprotein lipase, honnone-sensitive triacylglycerol lipase, 
diacylglycerol hydrolase, monoacylglycerol hydrolase (Kom and Quigley, 1955; 
Rizack, 1%1; Vaughan et al, 1964; Huttunen and Steinberg, 1971). Hormone-
sensitive lipase in adipocytes has also been studied in different species including 
chicken (Khoo et al, 1976) and human (Frayn et al, 1993). 
1.4.1.2. CEH IN ADRENAL CORTEX 
Adrenal cortex contain large amounts of cholesterol esterified to long chain 
fatty acids (Goodman, 1965). The CE are localized mainly in cytoplasmic droplets 
where they appear to function as a reservoir for the free cholesterol required for 
steroid biosyntiiesis. CEH catalyses one of die rate-limiting steps in 
steroidogenesis in the adrenal cortex (Boyd and Gorban, 1980). Following stress 
induced by either anesthesia, the cholesteryl ester stores are depleted and the 
activity of the CEH is elevated (Trzeciak and Boyd, 1973). CEH in adrenal cortex 
has been activated following incubation with cAMP and ATP-Mg (Trzeciak and 
Boyd, 1974; Wallat and Kunau, 1976; Beckett and Boyd, 1977; Naghsineh et al, 
1978), suggesting that activation results from phosphorylation of the enzyme. The 
actual number of neutral esterase species in the adrenal gland (Wallat and Kunau, 
1976; Pittman and Steinberg, 1977; Yeaman et al, 1980; Cook et al, 1981; 
Eiteljorge and Kunau, 1981), and the identification of their constituents 
polypeptides (Beckett and Boyd, 1977; Cook et al, 1981; Eiteljorge and Kunau, 
1981) remains controversial. The existence of two molecular forms of cholesteryl 
esterase in bovine (Wallat and Kunau, 1976; Eiteljorge and Kunau, 1981) and rat 
adrenals (Pittman and Steinberg, 1977) has been reported but not generally 
recognized (Beckett and Boyd, 1977; Naghsineh et al, 1978; Yeaman et al, 1980; 
Cook era/., 1981). 
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1.4.1.3. CEH IN TESTIS AND CORPUS LUTEUM 
CEH activity has shown properties of regulatory en2yme in testis 
(Rommerts et al., 1980; Duiham and Grogan, 1982; Durham and Grogan, 1984). 
Three CEH having molecular weights of 28 kDa, 72 kDa, and 420 kDa, have been 
found in rat testis (Durham and Grogan, 1982; Durham and Grogan, 1984). These 
enzymes are implicated in regulation of androgen synthesis and membrane 
cholesterol levels necessary for normal spermatogenesis (Rommerts et ai, 1980; 
Duiham and Grogan, 1982; Durham and Groan, 1984). The Mr 72 kDa and 
420 kDa forms are temperature-labile and completely inactivated by elevation of 
temperature from 32-37 **C (Durham and Grogan, 1982). In contrast, the 
temperature stable 28 kDa form retained activity at 37 °C. Both testicular en2ymes 
exhibit pH optima at about 7.3 and were activated by sodium cholate at 
concentration of 0.3-0.7%, but inhibited by higher concentrations (Durham and 
Grogan, 1984). The activation of both temperature-labile and temperature-stable 
enzymes are modulated by PKA involving phosphorylation (Baily and Grogan, 
1986). 
CEH in corpus luteum (CL) has been known to be activated by hormones 
which act through cAMP and phosphorylate the target proteins (Bisgaier et ai, 
1979). It is also known that purified CL, CEH is phosphorylated by PKA and 
amino acid analysis revealed that a single serine residue is phosphorylated 
(Colbrm etal., 1986). 
1.4.1.4. CEH m MAMMARY GLAND 
In mammary gland cholesterol derived from either de novo synthesis 
(20-40%) or plasma lipoproteins (60-80%) (Clarenburg and Chaikofif, 1966; 
Raphael et ai, 1975; Gibbons et al., 1983) may be esterified and stored as CE 
(Keenan and Patten, 1970; Ross and Rowe, 1984) which may in turn be 
hydrolyzed to free cholesterol when required, with the help of CE hydrolases 
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located in the microsomal and soluble cell fractions (Steinberg, 1976; Fernandez 
et al, 1987). Activities of the mammary gland acid, microsomal and cytosolic 
neutral CE hydrolases are greatly increased during lactation as compare to virgin 
rats (Botham, 1991). Botham et al. (1993) have investigated the activities of three 
cholesteryl ester hydrolases along widi ACAT during pregnancy, lactation, and 
involution of the rat mammary gland and studied the relationship between three 
CE hydrolases and ACAT during various stages of rat lactating mammary gjand to 
understand tiie mechanisms involved in cholesterylester synthesis and hydrolysis. 
Studies of microsomal and cytosolic enzymes provide evidence for the modulation 
of their activity by phosphorylation-dephosphoiylation (Martinez and Botham, 
1990) suggesting that these enzymes are under hormonal control and have a 
regulatory role in cholesterol ester cycle. 
1.4.1.5. PANCREATIC CEH 
Pancreatic CEH , also known as bile salt-stimulated lipase, carboxyl ester 
lipase or non specific Upase, catalyses the hydrolysis of CE to free cholesterol and 
fatty acids. The cholesteryl ester hydrolase is also capable of hydrolyzing other 
substrates such as phosphoUpids, lysophospholipids, retinyl esters and mono-, di-
and tri-acylglycerols (Rudel and Brockman, 1984). Some studies have shown that 
a serine residue and a histidine residue play a key role in the hydrolytic 
mechanism (Kissel et al, 1989; Di Persio et al, 1991). The enzyme synthesized 
primarily in the acinar cell of the pancreas and stored in zymogen granules, is 
secreted into the lumen of the intestine via the pancreatic duct (Guy and Figarella 
et al, 1981) in response to a dietary fat load. The pancreatic CEH is also found 
attached to the surface of intestinal mucosa and has been suggested to play a role 
in the re-esterification of cholesterol before secretion into the lymph (Gallo et al, 
1977). The role of the pancreatic CEH in these processes was demonstrated by 
observations that without pancreas or its secreted products, intestinal esterase 
activity and role of cholesterol and vitamin absorption were dramatically reduced 
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(Chaikofif and Kapalan, 1935; Borja et al, 1964; Gallo et al, 1977). Immuno-
logical comparison of the CEH has demonstrated the identity of the pancreatic 
CEH with the enzyme fovmd in the intestine, thus supporting the concept that tfiis 
protein may be involved in both the hydrolysis and re-esterification of dietary 
cholesteiyl ester for absorption and transport (Gallo et al, 1978). Pancreatic CEH 
stimulate not only the rate but also die extent of cholesterol uptake (Lopez-
Candales et al., 1993). This enhanced cholesterol uptake is accompained by die 
appearance of a significantly higher level (39-fold) of CE in the cell. In contrast, 
uptake in die absence of exogenous enzyme leads to the little subsequent 
metabolism. These findings, dierefore, suggest a specific, novel, and quantitatively 
important role for pancreatic CEH in regulating free cholesterol transport into die 
enterocyte. Purified pancreatic CEH has been obtained from several mammalian 
sources. Most of the preparations show similar specificity and enzyme kinetics 
(Rudel and Brockman, 1984). In all the species tested, the molecular weights of 
the protein moiety are similar, ranging from 69000 for the rat enzyme to 76000 for 
the human protein (Kissel et al, 1989). Kyger et al (1989) reported the first 
cDNA cloning of the pancreatic CEH and genomic pancreatic CEH followed soon 
thereafter (Fontaine et al, 1991). cDNA cloning of rat pancreatic CEH (Kissel 
et al, 1989) and human pancreatic CEH (Nilsson et al, 1990) has been reported. 
Kumar et al (1992) have reported the complete gene structure of human 
pancreatic CEH. Although normal cholesterol and fat absorption is important 
nutritionally, none the less excess cholesterol absorption may lead to 
hypercholesterolemia and premature atherosclerosis (Klemets and Lundburg, 
1984). Most of pancreatic digestive enzymes are regulated by the composition of 
the diet and gastric hormones, synthesized in die gut (Wicker et al, 1984; 
Steinhilber et al, 1985; Wicker et al, 1985; Scheele, 1986; Rodiman, 1989). The 
effect of gastric hormones, such as cholecystokinin and secretion, on the 
biosynthesis of pancreatic CEH has shown to increase CEH biosyntiiesis (Huang 
and Hui, 1991). This stimulation was mediated by a post-transcriptional 
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modification of CEH mRNA. Pancreatic enzyme is not modulated by PKA, 
instead its activity was found to be inhibited by cofactors of PKC (Ghosh and 
Grogan, 1991). 
1.4.1.6. LYSOSOMAL ACID CEH 
Lysosomal acid CEH (ACEH) is crucial for the hydrolysis of CE in either 
lipoprotein or other particles that enter the lysosomal system by endocytotic 
process. ACEH has been obtained in purified form fi^om the Uvers of rats (Brown 
and Sgoutas, 1980), humans (Warner et ai, 1981) and rabbits (Imanaka et ai, 
1982) and is well characterized. The enzyme is a hydrophobic glycoprotein which 
also possesses activity against triacylglycerols (Warner ei al, 1981; Klemets and 
Lundburg, 1984). A defect in ACEH results in various inborn disorders of 
metabolism, which are characterized by lipid accumulation in several organs, such 
as Wolmans disease (Klemets and Lundburg, 1984) and cholesteryl ester storage 
disease (CESD) (Sloan and Fredrikson, 1972). Both of these autosomal recessive 
conditions are characterized by severely depressed acid CE hydrolase activities, 
intralysosomal lipid accumulations, and derangement in die regulation of 
cholesterol production. cDNA (Anduson and Sando, 1991) as well as genomic 
DNA cloning (Anduson et al, 1994) for human ACEH have been done and it was 
found that mutations in both alleles of die gene firom a patient with Wolmans 
disease results in the complete disruption of catalytic function of the enzyme. 
ACEH has also been recognized as an important factor in the accumulation of CE 
in atiierosclerotic arteries (Goldstein et al, 1975; Subbiah and Dicke, 1976; Small 
and Engle, 1977) which is discussed later in arterial CEH. Although the 
importance of ACEH in lipoprotein metabolism and in the determination of the 
cell cholesterol levels has been recognized, very little is known about the enzymes 
catalytic mechanism or mode of regulation (Balasubramaniam et al, 1977; Hajjar 
et al, 1982; Loffler and Kunze, 1992). 
1.4.1.7. ARTERIAL CEH 
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The accumulation of cholesterol esters in the arterial wall is consistent 
feature of atherosclerotic lesions (Dayton and Hashimoto, 1968; St. Clair et ai, 
1970; Chobanian and Manzur, 1972; Proudlock and Day, 1972; Hashimoto et ai, 
1973). Both neutral and ACEH activities have been reported in arterial tissue and 
in cultured arterial smooth muscle cells (Sakurada et ai, 1976; Brecher et ai, 
1977; Riddle et ai, 1977; Kritchevsky and Kothari, 1978; Severson and Fletcher, 
1978; Shinomiya et ai, 1979; Subbiah, 1979). ACEH activity has been well 
characterized and even partially purified (Takano et ai, 1974; Kothari and 
Kritchevsky, 1975; Sakurada et ai, 1976; Brecher et ai, 1978; Haley et ai, 1980). 
Several investigators have reported neutral CEH activities in arteries of different 
mammalian species (Kritchevesky et ai, 1968; Kothari et ai, 1970; Brecher et ai, 
1973; Kothari et ai, 1973; Eisenberg and Levy, 1975; Sakurada et ai, 1976; 
Brecher et ai, 1977; Riddle et ai, 1977; Kritchevsky and Kothari, 1978; Severson 
and Fletcher, 1978; Shinomiya et ai, 1979; Subbiah, 1979). ACEH functions 
mainly in the lysosomal degradation of exogenous CE endocytized as component 
of the lipoproteins (Brown and Goldstein, 1976; Goldstein and Brown, 1977), 
whereas neutral CEH could hydrolyze endogenous extralysosomal CE. Some 
discrepancy in the property of arterial neutral CEH regarding pH optima, 
localization of the enzyme in particulate and/or soluble flection has been reported 
(Sakurada et ai, 1976; Brecher et ai, 1977; Riddle et ai, 1977; Kritchevsky and 
Kothari, 1978; Severson and Fletcher, 1978; Shinomiya et ai, 1979; Subbiah, 
1979). Later on Hajjar et ai (1983) reported two distinct form of esterases ACEH 
and neutral CEH in rabbit aorta, which could be distinguished by several criteria 
such as pH optimum, preference for forms of substrate dispersion, sensitivity to 
heat and storage, location within cells, and influence by hormones effectors. They 
have also reported the activation of neutral CEH involving PKA and suggested that 
the break down of cytosolic lipid droplets might be affected by glucagon or other 
hormones or by agents that enhance intracellular protein phosphorylation in a 
similar way as of hormone sensitive tissues. Some investigators have found 
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increased lysosomal CEH activity in a atherosclerotic lesions in several species 
including humans (Miller et ai, 1966; Bonner et al, 1972; Kwak et al, 1973). 
Brecher et al. (1977) have reported 2-5 fold increased lysosomal esterase activity 
in atiierosclerotic aortic tissue than the control one. In addition Goldstein et al. 
(1975) have suggested from their studies on cultured fibroblasts that die lysosomal 
CEH is not involved in the hydrolysis of endogenously formed cholesterol esters. 
De Duve (1974) has proposed that the accumulation of CE in atherosclerosis is 
due to a relative deficiency in a lysosomal cholesterol esterase, resulting in an 
inability of tibe smooth muscle cell to metabolize the increased influx of 
lipoprotein-associated CE. Thus regulation of arterial neutral CEH could be a 
determining factor in the retention of cholesteryl ester droplets and therefore, may 
contribute significantly to the Upid overloading of arterial cells in atherosclerosis. 
1.4.1.8. CEH IN MACROPHAGES 
In the macrophage, cytosolic CEH activity plays an important role in the 
cholesterol/CE cycle. The formation of macrophage derived foam cells is central 
in the development of fatty streaks within the arterial wall, and to the progression 
of atherosclerosis (Gerrity, 1981; Field and Mathur, 1983; Rianes and Ross, 1989). 
The unregulated deposition of CE, as lipid droplets within the cytosol of 
macrophage is responsible for the formation of these cells. The process, under 
normal condition is thought to be regulated by the proper balance between the 
esterification by ACAT and hydrolysis by CEH (Graham et al, 1996). It has been 
shown Aat removal of stored cholesterol by HDL, requires the activation of CEH 
(Khoo et al., 1981), which has been shown immunologically identical to hormone 
sensitive lipase (Small et al, 1989). This enzyme can be activated by PKA (Small 
and Engle, 1977; Khoo et al, 1981), and is reported to be inhibited by a cytosolic 
protein (Shand et al, 1993) found in a number of macrophage cell lines. 
Regulation of CEH activity, either by cAMP-mediated stimulation (Khoo 
et al, 1981; Goldberg and Khoo, 1990; Bernard et al, 1991) or by cytosolic 
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inhibitory protein activity appears central to the removal of stored cholesterol from 
macrophages. Modification of LDL by CEH, resulting in its reduced uptake by 
macrophages (Aviram et ai, 1991), may also be an additive factor in flie 
regression of arterial lipid laden foam cells. 
1.4.1.9. BRAIN CEH 
The physiological importance of CEH in brain is due to the fact that it is 
involved in the synthesis and maintenance of myeline (Eto and Suzuki, 1972; 
Ghosh and Grogan, 1990). Three distinct enzymes have been reported in brain. 
Unsterified cholesterol is a major constituent of myeline membrane in adult 
mammalian brain (Norton, 1977). Several investigators reported transient increase 
in CE in the immature CNS prior to the onset of myelination, followed by a 
decrease as myeline proceeded (Eto and Suzuki, 1972). Major lipid components of 
myeline undergo degradation in areas of active demyelination (Brante, 1949; 
Cumings, 1953; Lumsden, 1965). In contrast, CE, which are in very low 
concentration in normal brain, accumulate in demyelinating disorders such as 
multiple sclerosis (Wender ei al, 1974), Wallerian degeneration (Mezei, 1970) 
and experimental allergic encephalomyelitis (Maggio et al., 1972; Maggio and 
Cumar 1974; Roth et al, 1978). In multiple sclerosis, CE increase, not only in 
multiple sclerosis plaques, but also in apparently normal white matter (Wender 
et al, 1973), cerebrospinal fluid (Green et al, 1959; Pedersen, 1974) and serum 
(Tichy and Vymazal, 1973). Reports from several laboratories have suggested that 
CE accumulation in demyelinating disorders may be due to a decrease in CEH 
activity (Mezei, 1970; Eto and Suzuki, 1973; Shah and Johnson, 1980). Several 
investigators have reported decreased CEH activity in cerebrospinal fluid of 
multiple sclerosis patients and suggested that, this decrease reflects a similar 
change in brain tissue (Reiber and Vass, 1980; Johnson and Shah, 1981; Pitkanen 
et al, 1986). Shah and Johnson (1980) reported greatly decreased CE hydrolase 
and shghtly decreased cholesterol esterifying enzyme in plaques and periplaque 
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areas from brain of multiple sclerosis patients. CEH also decreases in the sciatic 
nerve during Wallerian degeneration (Mezei, 1970) and in the initial stage of 
experimental allergic encephalomyelitis (Ghosh and Grogan, 1991a). However, tiie 
mechanism(s) by which significant decline in CEH activity in above mentioned 
demyelinating disorders are not well known. 
1.4^. HEPATIC CEH 
Liver, the major site of cholesterol metabolism in the rat, have atleast three 
distinct CE hydrolases, with specific function and different subcellular location. 
Among these three enzymes, the best characterized being the lysosomal ACEH 
which hydrolyzes the CE internalized with the lipoprotein particles. The CE stored 
in cytosol and smooth endoplasmic reticulum (SER) are mobilized by cytosolic 
and microsomal CE hydrolases respectively (Deykin and Goodman, 1962; Stokke, 
1970; Nilsson, 1976; Cook et al, 1983; Fernandez et al, 1987). 
The existence of microsomal CEH remained controversial for a long time 
and thus fewer studies have been done on the fimction and regulation of this 
enzyme. It is su^ested to be involved in preventing the accumulation of CE in the 
SER membrane and controlling the fate of cell CE between the biliary and VLDL 
secretary pathways (Hernandez et al, 1993). Rat liver microsomal CEH has been 
partially solubilized (Crandarias et al, 1987), 75% of its activity has been found to 
be on the lumenal side of RER (Fernandez et al, 1987). This activity is different 
from the cytosolic CEH activity (Coleman and Haynes, 1983) and neutral retinyl 
ester hydrolase, located within the microsomes (Gad and Harrison, 1991). 
Microsomal CEH was found to be activated by Mg^ ^ and Ca^ ^ in a time 
dependent manner that could be reversed by EDTA and EGTA, respectively. 
Indirect evidence that rat liver microsomal CEH may be activated through cAMP 
and Ca ^/calmodulin-mediated mechanisms, whereas enzyme inactivation is 
dependent on phosphatase action, has been presented (Hoang et al, 1993; 
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Martinez et ai, 1994; Martinez et al, 1995; Botham et al., 1996; Hernandez 
et al., 1996). Moreover, Botham et al. (1996) have reported activation of the 
microsomal CEH activity by cAMP analogues, 8-chloro cAMP and 8-(4-chloro-
phenyl thiol) cAMP, in hamster hepatocytes, whereas, no effect could be detected 
on the CEH activity in rat hepatocytes. 
The microsomal CEH has high homology with cytosolic CEH as revealed 
by tiie studies on cDNAs (Robb et ai, 1990). Inspite of high sequence homology, 
the two enzymes show differences in (i) pH optima which is 6.1 for microsomal 
and 7.2 for cytosolic CEH (Robb et al., 1990). (ii) Substrate specificities with 
microsomal enzyme showing more affinity towards short chain fatty-acyl ester 
while the reverse is true for cytosoUc CEH. (iii) Diurnal rhythm and change in the 
rhythm under different conditions, (iv) These enzymes also show differential 
effect of divalent cations. Microsomal CEH activity is increased on preincubation 
with Mg^ ^ and Ca^ ^ while Mn^ ^ shows no effect (Hernandez et ai, 1993). 
Whereas cytosoHc CEH is positively modulated by Mg^ ^ and Mn^ ^ but remains 
unaffected by Ca^ .^ Moreover, most of the other divalent metal ions tend to inhibit 
cytosolic CEH activity (Natr^an et al., 1996a). 
Although rat Uver has acid lysosomal and microsomal CEH activities, the 
major regulatory activity is associated with a unique cytosolic CEH (Gallo, 1981; 
Ghosh and Grogan, 1989; Ghosh et al., 1990; Ghosh and Grogan, 1991b; Grogan 
et al., 1991). This enzyme is appropriately located, rationally regulated and able to 
rapidly mobilize cholesterol when required (Klauda et al., 1978; Ghosh and 
Grogan, 1989; Ghosh el al., 1990; Ghosh and Grogan, 1991b; Grogan et a/., 1991; 
Ghosh et al., 1995). Isolation, purification and characterization of rat liver 
cytosolic CEH has been reported by Ghosh and Grogan (199lb, 1992), and 
Natrajan et al. (1996a). The purified enzyme is 66 kDa protein (on SDS-PAGE), 
having pH optimum between 7.0-7.5 and isoelectric point of 5.5. It required 
0.25 mM taurocholate to prevent aggregation of enzyme into an inactive state. 
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However, optimum activity was observed at 5 mM taurocholate, whereas, activity 
inhibited at higher concentrations (10-20 mM) (Ghosh and Grogan, 1991b). CEH 
activity was inhibited by Zn^ ,^ Cu^^ , Cd^ ,^ Hg^ ^ and phenylmethyl-sulphonyl 
fluoride, whereas activated by N-ethyl maleimide and iodoacetamide. Moreover, 
hydrolytic activity of purified CEH for p-nitrophenyl fatty-acyl esters of varying 
carbon chain length (C2-C18) was observed, which showed lowest activity with 
p-nitrophenyl acetate, increasing with increase in chain length, peaked with 
p-nitrophenyl-octanoate (C8) and then decline gradually widi increasing chain 
length >C8. In contrast crude preparations of cytosolic and microsomal enzymes 
gave a maximum activity with p-nitrophenyl acetate (C2), suggesting the 
involvement of other esterases (Natrajan et al, 1996a). 
The studies regarding the bile salt dependent CEH activity in rat liver are 
controversial. The so called bile-salt dependent CEH activity varies widely among 
rat liver homogenates from 70-80% inhibition to no inhibition or stimulation up to 
ten-fold. (Harrison, 1988; Kissel et al, 1989). Some studies with rat hver 
homogenates have demonstrated the presence of CEH activity that requires 
millimolar concentrations of trihydroxy bile salts for optimal activity (Harrison 
et al, 1979). Camulli and coworkers have reported the purification of cytosoUc, 
bile salt-dependent CEH from rat liver (Camulli et al, 1989) and suggested that 
the pancreatic and hepatic CEH enzymes are very closely related, if not identical. 
In contrast, Ghosh and Grogan (1991b) have reported that purified hepatic CEH 
required very low concentration (0.25 mM) of bile salt to exhibit its activity, 
apparently by preventing the enzyme aggregation. 
Liver CE hydrolases have been shown to display a diumal rhythm 
(Martinez et al, 1991), similar to HMG-CoA reductase and C7aH (Shapiro and 
Rodwell, 1971; Danielsson, 1972; Edwards et al, 1977). Erickson et al (1995) 
have done similar studies on microsomal CEH. Natrajan et al (1996b, 1997) have 
demonstrated that the cytoslic CEH undergoes age-related changes in catalytic 
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activity involving gender-specific multivalent regulation of hepatic CEH. In male 
rats, age-related changes in mRNA, protein mass and enzyme activity suggested a 
transcriptional regulation of CEH (Natarajan et ai, 1996b). In contrast, during tiie 
development of female rats, specific activities of cytosolic and microsomal CEH, 
relative to CEH protein mass, exhibited changes consistent with post-translational 
regulation involving the modulation of eiLzyme activity by phosphorylation/ 
dephosphorylation (Natarajan et al, 1997). The age-related changes have also 
been observed in the other major cholesterol metabolizing enzymes, HMG-CoA 
reductase (Story et al, 1976; Choi et al, 1987; Stahlberg et al, 1991), C7aH 
(Stoiy et al, 1976; Choi et al, 1987; Stahlberg et al, 1991) and ACAT (Stahlberg 
et al, 1991; Little and Hahn, 1992). 
Regulation of liver cytosolic CEH activity in vivo by various dietary, 
hormonal and drug perturbations have been reported. Feeding of fat to rats caused 
an increase in CEH activity, whereas feeding of cholesterol alone and cholesterol 
plus fat was associated with down regulation of cytosolic CEH activity. 
Administration of progesterone caused increase in CEH activity (Grogan et al, 
1991). Feeding of coconut oil and cholesterol to hamster caused significant 
inhibition and activation of Uver cytosolic CEH, respectively. In contrast, both fat 
and cholesterol feeding caused a reduction in microsomal CEH activity (Ochoa 
et al, 1990). Feeding the bile acid sequestrant, cholestyramine, caused an increase 
in rat liver cytosolic CEH activity (Ghosh et al, 1990). In addition, feeding of 
cholestyramine increased both cytosolic and microsomal CEH activities in hamster 
liver (Ochoa et al, 1990). Feeding of cholestyramine, simvastatin and both drugs 
togetiier to male rats was associated with elevation of cytosolic CEH activity. The 
increase in CEH activity by the drug combination was additive (Shand and West, 
1995). Similar effects were observed on microsomal CEH activity, except Ae drug 
combination effect was not additive (Shand and West, 1995). The mechamsms(s) 
of liver cytosolic CEH regulation involving short-term and/or long-term control in 
35 
the above manipulations have not been reported. 
Several lines of research have demonstrated that cytosolic CEH can be 
activated by cAMP-dependent protein kinase-mediated phosphorylation in 
steroidogenic and other non-hepatic tissues (Pittman et ai, 1975; SmaU and Engle, 
1977; Bisgaier et ai, 1979; Khoo et al., 1981; Boyd et al., 1983; Hajjar et al, 
1983; Bailey and Grogan, 1986; Colbran et al, 1986). Regulation of en2ymatic 
activity of cytosolic CEH by reversible phosphorylation (activation) has not been 
fully resolved. Evidence for activation (phosphorylation) of cytosolic CEH activity 
by cAMP and Ca '^^ -mediated processes have been presented in vitro in cell-free rat 
liver preparations (Ghosh and Grogan, 1989; Natrajan et al., 1996b; Natrajan 
et al., 1997). The inactivation (dephosphory-lation) of enzyme was catalyzed by a 
cytoslic Mg'^ '^ -dependent phosphoprotein phosphatase (Ghosh and Grogan, 1989). 
Alkaline phosphatase treatment of cytosolic CEH resulted in the deactivation of 
CEH enzyme (Ghosh and Grogan, 1989). In contrast, evidence suggesting 
inactivation by phosphoiylation were presented in rat hepatocyte suspensions 
(Ruiz et al, 1988; Ruiz et al, 1990). However, Botham et al. (1996) have reported 
the activation of cytosolic CEH in rat hepatocytes by cAMP analogues, 8-chloro-
cAMP and 8-(4-chlorophenylthio) cAMP. In addition, CEH activity was found to 
be enhanced by both cAMP analogues (above) in cultured hamster hepatocytes, 
and this effect was mimicked by glucagon and theophylline (Hoang et al, 1993). 
To our knowledge, regulation of cytosolic CEH activity involving phosphorylation 
(activation) and dephosphorylation (inactivation) in intact rats imder different 
physiological perturbances has been lacking. 
Several reports have shown the presence of some proteins which act as 
inhibitors of CEH. These inhibitory proteins have been reported in rat liver (Shand 
and West, 1992a; Shand and West, 1992b), testis (Hines et al, 1996), macrophage 
cell lines (Shand et al, 1993) and gall bladder mucosa (Neiderhiser, 1982). Shand 
and West (1992a) have demonstrated the presence of a factor (or factors) in tiie 
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cytosol of male and female (Shand and West, 1992b) rat liver which inhibited the 
microsomal CEH from lactating rat mammary glands. These inhibitor proteins in 
several tissues may play an important role in the overall cholesterol/CE cycle by 
influencing the activity of CEH. 
1.5. CEH ASSAY 
Assay of CEH has been a problem due to its broad substrate specificities 
and insolubility of cholesteryl ester of long chain fatty acids in water. Radiometric, 
colorimetric and fluorimetric methods for CEH assay have been reported (Deykin 
and Goodman, 1962; Erlanson, 1970; Gallo, 1981; Lombardo, 1982; Hajjar et al, 
1983; Noel et al, 1983; Sale et al, 1984; Chen et al, 1986; Huang and Hui, 1991; 
Morgan et al, 1994; Yeaman et al, 1994). These methods utilize cholesteryl 
oleate (CO) as substrate for CEH, either dissolved in organic solvents like acetone 
or ethanol or in the form of mixed micelles with a phospholipid and sodium 
taurocholate (Deykin and Goodman, 1962; Khoo et al, 1976; Klemecke and 
Binkeley, 1980; Gallo, 1981; Hajjar et al, 1983; Sale et al, 1984; Hamada et al, 
1985; Chen et al, 1986). Aqueous emulsion of CO were used by Noel et al, 
(1983) for CEH assay. However, CEH specific activity from rat liver cytosol 
varies widely, from 0.25-333 pmole/min/mg, when CO was used as substrate 
(Chen et al, 1986; Camulli et al, 1989; Ghosh and Grogan, 1989; Ghosh and 
Grogan, 1991b; Grogan et al, 1991; Ghosh and Grogan, 1992; Camilo and 
Harrison, 1994). Some workers have also utilized water soluble, short chain 
synthetic substrate, p-nitrophenyl butyrate in the assay of CEH (Tsujita et al, 
1987; Huang and Hui, 1991). Assay of liver cytosolic CEH with short-chain 
substrates, p-nitrophenyl esters of acetate and capiylate can be done with purified 
enzyme only, as in crude preparations a high degree of non-specific hydrolysis 
was observed. However, activity of CEH in cytosol and partially purified fraction 
by employing long-chain fatty-acyl esters of p-nitrophenol has not been reported 
(Natrajan et al, 1996a). 
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1.6. SCOPE OF THE THESIS 
The mobilization of the stored esterified cholesterol in liver involves the 
supply of free cholesterol to be transformed into bile acids, secreted nascent 
lipoproteins or excreted in bile. Thus, the hydrolysis of cholesteryl esters, might 
be considered as an important process, whose activity needs to be regulated. 
Imbalances between the abihty of the cell to maintain cytosolic CEH activation 
(phosphorylation) and to prevent enzyme deactivation (dephosphorylation) by 
protein phosphatases or inhibition by diet-induced lipidemia may be a contributory 
factor in the regulation of cholesteryl ester cycle and has important implications 
for die maintenance of overall cholesterol homeostasis. Therefore, the following 
detailed in vitro and in vivo investigations pertaining to regulation of CEH 
enzymic activity involving phosphorylation (activation) and dephosphorylation 
(inactivation) have been carried out. 
An appropriate and sensitive method for CEH assay has been developed by 
modifying and improving the existing methods in order to detect even small 
change in CEH activity under different in vitro and in vivo modulations. 
A detailed in vitro investigation of activation and inactivation of rat liver 
cytosolic and partially purified CEH involving phosphorylation-dephosphorylation 
reaction sequence has been carried out. hi the first part, reversible phosphorylation 
of CEH has been investigated by utilizing endogenous cAMP-dependent protein 
kinase (PKA) and phosphoprotein phosphatases. This aim was achieved by adding 
different cofactors for cAMP-dependent protein kinase, and inhibitiors/activators 
of phosphoprotein phosphatases to the enzyme flection. The second part deals 
with the assay of CEH activity in the presence of exogenous cAMP-dependent 
protein kinase and its cofactors including inhibitors/ activators of phosphatases or 
in the presence of alkaline phosphatase. 
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In vivo study of phosphorylation (activation) and dephosphorylation 
(inactivation) of CEH in rats and its potential modulation by variety of dietary, 
honnonal and drug treatments known to influence die cholesterol homeostasis has 
been done. In these experiments, modulation of m vivo phosphorylation and 
dephosphoiylation of CEH was investigated in vitro by employing PKA and its 
activators including inhibitors/activators of endogenous phosphatases and alkaline 
phosphatase. 
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^Ex^erimentaC 
MATERIALS 
2.1.1. Chemicals 
Chemicals and biochemicals used for the present study were obtained from 
the following sources. 
Chemicals 
Adenosine 
Adenosine, 5'- Monophosphate 
Adenosine, 5'- Diphosphate 
Adenosine, 5'- Triphosphate 
Alkaline phosphatase. Type I 
(Calf Intestinal Mucosa) 
Alkaline phosphatase. Type HI (E. Coli) 
Alkaline phosphatase. Type V 
(Chicken Intestine) 
Alkaline phosphatase. Type VIINL 
(Bovine Intestinal Mucosa) 
Bovine Serum Albumin (Fraction IV) 
Benzamidine 
Beta-mercaptoethanol 
Calyculin A 
Coomassie Briliant Blue-G 250 
Cholestyramine Resin 
Dithiothreitol 
Dimethyl Sulphoxide 
N',2'-o-dibutyryl cAMP 
EDTA (Disodium Salt:Dihydrate) 
EGTA 
Source 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Miles Laboratories Inc., USA 
Sigma Chem. Co., USA 
Loba Cheme. India 
GIBCOBRLUSA 
Polysciences, Inc., USA 
Sigma Chem. Co., USA 
Bethesda Research Laboratories, 
USA 
SISCO Research Laboratories, 
India 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
USB 
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Guanosine 
Glycerophosphate 
Lovastatin Tablets USP 
Leupeptin 
Magnesium Acetate 
Magnese Chloride 
p-Nitrophenol 
p-Nitrophenyl Palmitate 
p-Nitrophenyl Phosphate 
(Disodium Hexahydrate) 
Okadaic Acid 
Pelleted Rat Chow 
Protein Kinase A (Bovine Heart) 
Protein Kinase Inhibitor 
(Synthetic: Rabbit Sequence) 
Pyrophosphate (Disodium Salt) 
PMSF 
Sephadex G-25 M- P.D. 10 Column 
Sodium Taurocholate 
Streptozotocin 
Sodium Orthovanadate 
TPCK 
TLCK 
Tris 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Woldiardt Limited 
Bachem California 
Sigma Chem. Co., USA 
Loba Cheme. India. 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
GIBCO BRL USA 
Hindustan Lever Ltd., India 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Pharmacia, Sweden 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
All other chemicals and reagents used were of analytical grade. 
2.1.2. Animak 
Male albino rats, weighing about 175-200g were purchased from Central 
Animal House, J.N. Medical College, A.M.U., Aligarh. Rats were conditioned to 
the animal house environment prior to use, and were given pelleted rat chow and 
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water ad libitum. The rats were maintained with alternating 12 h periods of light 
(L, 0700-1900) and dark (D, 1900-0700) for two weeks. The rats were routinely 
killed at L3 except the rats in starved groups, which were killed at L9. For the 
routine preparations of cytosol for various in vitro studies, rats were decapitated 
and livers were removed. For in vivo experiments, rats were anesthetized and 
livers were removed. 
2.1.2.1. Design for in vivo experiments 
Each experimental group contained five rats. The daily dosage was given 
orally twice a day, half dose in the morning and second half in the evening, unless 
stated otherwise. 
2.1.2.1.1. Dietary stress experiment 
Following dietary manipulations were done to rats in each group: 
(i) Cholestyramine-treated group was given 300 mg cholestyramine suspension 
in 2 ml saline/day/rat for one week, 
(ii) Lovastatin-treated group was given 7.5 mg lovastatin solution in 2 ml 
saline/day/rat for one week, 
(iii) Cholestyramine and lovastatin-treated group was given 300 mg 
cholestyramine and 7.5 mg lovastatin simultaneously in 2 ml saline/day/rat 
for one week, 
(iv) Rats in control group were given 2 ml saline/day for one week. 
2.1.2.1.2. Starvation experiment 
Rats were starved for 21 and 36 hours but given free excess to water, 
whereas, rats in control group were given chow and water ad libitum. 
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2.1.2.13. Mevalonolactone (MVL) treatment 
(i) Rats were given single oral dose of 100 mg MVL solution in 1 ml 
saline/rat, 30 min before killing, 
(ii) Rats were given single oral dose of 100 mg MVL solution in 1 ml 
saline/rat, 4 h before killing. 
Rats in control group were given 1 ml saline, 30 min before killing. 
2.1.2.1.4. Cyclic-AMP (cAMP) treatment 
Rats were injected 300(xg dibutyryl cAMP solution in 1 ml saUne/rat, 
intravenously (i.v.) or intraperitonially (i.p.) as indicated: 
(i) Injected dibutyryl cAMP (i.v.), 15 min before killing. 
(ii) Injected dibutyryl cAMP (i.v. and i.p. simultaniously), 2 h prior to killing. 
(iii) Rats in control group were injected 1 ml saline (i.v.), 15 min prior to 
killing. 
2.1.2.1.5. Sodium orthovanadate treatment to normal and diabetic rats 
Rats were made diabetic with a single injection (i.p.) of 65 mg/kg body 
weight streptozotocin, dissolved in 100 mM citrate buffer (pH 4.5) 
containing 150 mM NaCl. Control rats were injected with buffer containing 
150 mM NaCl. The rats were checked for diabetes by monitoring the 
presence of sugar in urine using Uristix strips. After three days all the 
streptozotocin-injected rats were found diabetic. The rats were divided into 
four groups and following manipulations were carried out: 
(i) Normal control group, injected (i.p.) 0.5% NaCl for four weeks. 
(ii) Normal, vanadate-treated group. Vanadate treatment (i.p.) was initiated at 
0.1 mg/ml sodium ordiovanadate, increased to 0.8 mg/ml over a period of 
one week, and continued for a further three weeks. Vanadate solutions 
contained 0.5% NaCl and were made fresh every three days. 
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(iii) Streptozotocin-induced diabetic control group, injected (i.p.) 0.5% NaCl 
for four weeks, 
(iv) Diabetic, vanadate-treated group. Vanadate treatment was initiated and 
continued for four weeks exactly as described for group (ii). 
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METHODS 
2.2.1. PREPARATION OF RAT LIVER CYTOSOL 
Rats were sacrificed, livers removed and kept in chilled saline on ice. The 
pooled livers in each group were homogenized in a varying blender in buffer A 
(2 ml/g liver) containing 20 mM Tris-HCl pH 7.0, 80 mM KCl, 200mM sucrose, 
0.5 mM PMSF, 0.1 mM TPCK, 0.1 mM TLCK, 0.1 mM benzamidine and 
0.02 mM leupeptin. The homogenate was centrifuged at 15,000 x g for 20 min and 
post-mitochondrial supernatant was centrifuged at 104,000 x g for 60 min in order 
to obtain cytosol. The cytosol was aliquoted and stored fi-ozen at -20 °C. A portion 
of cytosol was fi'actionated with ammonium sulfate to 40% saturation. After 
centrifugation at 15,000 x g for 20 min at 4 °C the pellet was saved by storing at 
-20 °C. The pellet was utilized when needed by dissolving in buffer B containing 
20 mM Tris-HCl pH 7.0, 80 mM KCl and 200 mM sucrose. 
In certain experiments cytosol was desalted on Sephadex G-25 M- P.D.IO 
column. The column was equilibriated with 2-3 volumes of buffer B, 2.5 ml 
cytosol was applied on the column and eluted with 3.75 ml of buffer B. 
2.2.2. PREPARATION OF SUBSTRATES FOR CEH ASSAY 
PNP-acetate, PNP-butyrate, PNP-caprylate, PNP-pahnitate and PNP-
stearate or CO (cold or radiolabelled) was dissolved in acetone at the 
concentration of 4 mM (40 X) and was used as droplet dispersion. Emulsion of 
CO was prepared as previously reported by Noel et al. (1983). 10 jimole of CO 
was dissolved in 25 |il of benzene to which 175 |il of Triton-X-100 was added and 
the contents were mixed. 40 ^1 of this emulsion was added dropwise by a hamilton 
syringe to one ml of a rapidly vortexing saline. 
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2.2 J. CEH ASSAY 
CEH assay was done by an improved and sensitive colorimetric mediod 
developed in our laboratory which utilizes PNP-palmitate as substrate. In pilot 
experiments, assay conditions for CEH activity were optimized for pH, protein 
amount, substrate concentration, time dependency, and temperature. Assay 
mixture contained 100 mM Tris-HCl buffer, pH 7.0 and 100-300 \i% of cytosolic 
protein or 50-100 ^ protein of 0-40% ASF in a total volume of 250 jal, unless 
stated otherwise. The reaction mixture was preincubated for 2 min or 20 min when 
ligands were added, at 37 °C and reacion was initiated by the addition of PNPP 
(100 mM) and incubation was continued for 10 min. At the end of incubation 
reaction was terminated by placing the tubes in ice bath. The tubes were 
centrifiiged at 10,000 rpm for 2 min at 4 °C and the absorbance of the hydrolytic 
product, p-nitrophenol in clear supernatant was measured at 405 nm in a Beckman 
DU 640 spectrophotometer. The CEH activity was calculated by utilizing 
p-nitrophenol as a standard. One unit of enzyme activity was defined as the 
amount of CEH required to hydrolyze one nmole of PNP-palmitate to 
p-nitrophenol per min. 
In some experiments CEH activity with PNP-palmitate was compared with 
CO emulsion. CEH activity was determined by estimating fi^ee cholesterol 
generated by CO hydrolysis, by employing oxidase/peroxidase coupled assay as 
described by Deacon and Dawson (1979). The absorbance was measured at 
520 nm. CEH activity was calculated by utilizing cholesterol as a standard. One 
unit of enzyme activity was defined as Ae amount of CEH required to hydrolyze 
one rmiole of CO to cholesterol per min. 
2.2.4. ASSAY OF p-NITROPHENYL PHOSPHATE (PNP-PHOSPHATE) 
SENSITIVE PHOSPHATASES 
The activity of PNP-phosphate-sensitive phosphatases in 0-40% ASF was 
determined essentially as described by Li et al. (1979) with following 
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modifications. The assay mixture contained 0.1 M Tris-HCl, pH 7.0 (unless stated 
otherwise) and 50 jxg of 0-40% ASF as a source of enzyme in a final volume of 
100 ^1. The reaction mixture was preincubated at 37 °C for 20 min. The reaction 
was started by the addition of aqueous solution of PNP-phosphate (100 mM) and 
incubated for 10 min at 37 °C. The reaction was terminated by the addition of 
200 ^1 of 0.1 N NaOH. The tubes were centrifiiged at 10,000 rpm for 2 min and 
the absorbance of clear supernatant was meaured in a Beckman DU 640 
^>ectophotometer at 405 mn. The activity of phosphatases were calculated by 
utilizing p-nitrophenol as a standard. 
One unit of enzyme activity was defined as the amount of phosphatases 
required to hydrolyze one nmole of p-nitrophenyl phosphate to p-nitrophenol per 
min. 
2.2.5. PROTEIN ESTIMATION 
The protein was determined by the method of Bradford (1976), using 
bovine serum albumin as standard. Aliquots of cytosol and ammonium sulpfate 
fi-actions (ASF) of cytosol were precipitated by adding 500 i^l of 20% TCA. After 
30 min, the samples were centrifiiged at 10,000 rpm for 10 min at room 
temperature. The pelletes were dissolved in 500 }xl of IN NaOH by heating at 
80 °C. Suitable aliquots were used for the determination of protein. 
2J2.6. STATISTICAL ANALYSIS 
Statical analysis of data was done by employing two tailed Student t-test 
(Bennet and Franklin, 1967), P values less than 0.05 were considered significant. 
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^suCts 
3.1. IN VITRO MODULATION OF ENZYMATIC ACTIVITY OF 
CYTOSOLIC CEH BY ACTIVATION (PHOSPHORYLATION) AND 
INACTIVATION (DEPHOSPHORYLATION) 
3.1.1. Characterization of rat liver cytosolic and partially purified (0-40% ASF) 
CEH 
In the present investigation, we have utilized a modified and sensitive 
colorimetric method developed in our laboratory, for the assay of CEH activity in 
cytosol and 0-40% ammonium sulfate fraction. The assay is based on the CEH-
mediated hydrolysis of substrate, p-nitropheriyl esters of long-chain fatty acids 
such as palmitate and stearate, to generate the product p-nitrophenol with an 
absorption maxima at 405 nm. This assay method has been compared with other 
previously published colorimetric and radiometric procedures, which utilize 
cholesteryl oleate (CO) as a substrate. Comparison of substrate specificities of CE 
hydrolases in cytosol and 0-40% ASF were made with PNP-fatty acid esters of 
various chain lengths and CO. Highest specific activity with PNP-acetate was 
obtained in cytosol and 0-40% ASF, followed by PNP-butyrate, PNP-caprylate, 
PNP-palmitate and PNP-stearate. In comparison to PNP-palmitate, the CEH 
specific activity with PNP-acetate was 3.55 and 2.50 fold higher in cytosol and 
0-40% ASF, respectively. When PNP-caprylate was used as a substrate the fold 
increase in CEH activity for the two enzyme fractions was 1.97 and 1.65, 
respectively. PNP-stearate hydrolysis generated a CEH specific activity slightly 
lower than PNP-palmitate. These results surest that high enzyme activities of 
cytosol and 0-40% ASF toward short chain PNP-fatty acid esters may be due to 
the presence of additional esterase(s), in cytosol, with greater specificities for 
these substrates. Water solubility of PNP-acetate and PNP-butyrate appears to be 
an additional factor for substantially enhanced CEH-mediated hydrolysis of these 
substrates. These results also indicate that PNP-palmitate and PNP-stearate, like 
CO, appear to be specific substrates for CEH in cytosol and 0-40% ASF. 
However, the rate of hydrolysis with PNP-palmitate was significantly higher than 
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CO, when these substrate were added to en2yme fractions as acetone droplet 
dispersion (Siddiqui, 1999). 
In order to rule out Ae possibility that PNP-palmitate may also be 
hydrolyzed by the presence, in cytosol, of additional esterase(s), CEH enzymatic 
activities were measured in 1 nmi gel slices after non-SDS-PAGE of cytosolic 
protein, by utilizing PNP-palmitate and highly specific substrate, CO. Measure-
ment of CEH enzymatic activities in gel slices with either of the substrates 
revealed that Ae peak enzyme activity of CEH protein was associated with the 
same gel slice. However, CEH activity obtained with PNP-palmitate was 
approximately 2.5-3.0 fold higher in comparison to CO. Throughout the gel no 
other enzyme activity peak was detected when PNP-palmitate or CO was 
employed. In anotiier experiment, 0-40% ASF of cytosol was subjected to gel 
permeation HPLC and enzymatic activities were determined in 100 jxl fractions by 
employing both PNP-palmitate and CO substrates. Analysis of all the HPLC 
fractions for enzyme activity revealed that single peak activity for CEH was 
associated witih the same fraction, when assayed with PNP-palmitate or CO. 
Again, the rate of hydrolysis of PNP-palmitate, in comparison to CO, was 3 fold 
higher. The combined results indicate that all the activity was associated with CEH 
after non-SDS-PAGE and gel permeation HPLC, when assayed either with PNP-
palmitate or CO. Consistent with earlier results, PNP-palmitate appears to be 
hydrolyzed more efficiently than CO, indicating that accessibility of the CEH 
enzyme toward PNP-palmitate is significantly greater than CO due to lower 
hydrophobicity of PNP-palmitate. 
Next, the hydrolysis of PNP-palmitate and CO was compared with four 
commercially procured CE hydrolases. With purified CE hydrolases from rabbit 
liver and porcine liver the efficiency of PNP-palmitate hydrolysis was 13-14 fold 
higher in comparison to CO. The rate of hydrolysis for PNP-palmitate was only 
slightly (1.23-1.25 fold) higher than CO, when CE hydrolases from bovine 
pancreas and pseudomonas were used. These results confirm the earlier 
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observations that PNP-palmitate is a specific substrate for CE hydrolases and 
preferentially hydrolyzed in comparison to CO, when they are presented as 
acetone droplet dispersion (Siddiqui, 1999). 
It was first necessary to define the assay conditions for cholesteryl ester 
hydrolase (CEH) in cytosol and 0-40% ASF. The results depicted in Fig. 3.1, 
demonstrate the optimal assay conditions for cytosolic CEH activity for time 
(panel A), protein concentrations (panel B) and substrate concentrations (panel C). 
When 100 ng of cytosol was assayed in the presence of 100 i^M PNP-palmitate, 
added as droplet dispersion, at indicated time intervals as described in the 
experimental procedures, the linearity of the reaction was maintained upto 20 min, 
after which the increase in the rate of PNP-palmitate hydrolysis was slowed and 
platued at 60 min (Fig. 3.1, A). Figure 3.1, panel B shows the protein depen-
dency at indicated concentrations (10-1000 jig). CEH activity was assayed for 
10 min in tilie presence of 100 jiM PNP-palmitate as described in experimental 
procedures. The reaction was linear upto 450 )ig of cytosolic protein. Figure 3.1, 
panel C depicts the results of CEH assay conducted at increasing concentration of 
PNP-palmitate at 100 ng protein, assayed for 10 min. The reaction showed a rapid 
linear increase with increasing concentration of PNP-palmitate fi^om 10-50 |iM. A 
littie non-linear increment in the hydrolysis rate between 50 ^M and 100 jiM was 
seen, which remained constant beyond 100 |iM (Fig. 3.1, C). Figure 3.2 shows the 
results of CEH assay optimized for incubation time (A), protein concentrations (B) 
and substrate concentrations (C) for partially purified CEH associated with 0-40% 
ASF. Linearity with time was 17.5 min at 50 p.g protein of 0-40% ASF and 
100 )xM of PNP-pahnitate. As seen in Fig. 3.2, panel B, PNP-pahnitate (100 ^M) 
hydrolysis was found to be linear upto 350 |ig protein of 0-40% ASF, when the 
incubation was 10 min. Figure 3.2, panel C shows a linear increase in CEH 
activity with increasing concentration of PNP-palmitate upto 50 |iM. There was 
small non-linear increase in the hydrolysis rate between 50 i^M and 100 L^M of 
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FIG. 3.1 CHARACTEIZATION OF RAT LIVER CYTOSOLIC CEH ACTIVITY ASSAYED 
WITH PNP-PALMITATE (PNPP). 
[A] TIME CURVE: substrate concentration, 0.1 mM; protein, 100 l^g/assay. 
[B] PROTEIN DEPENDENCE: substrate concentration, 0.1 mM; incubation time, 10 min. 
[C] DEPENDENCE ON SUBSTRATE CONCENTRATION: protein, 100^g/assay; incu-
bation time, 10 min. 
Values represent the mean of duplicate detenminations from two seperate experiments. 
The average error in the data points in these assays were mean ± 8.2%, 9.4% and 
7.5%, for A, B and C, respectively. 
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FIG. 3.2 CHARACTERIZATION OF RAT LIVER CYTOSOLIC 69 kDa CEH ACTIVITY 
(IN (M0% ASF) ASSAYED WITH PNP-PALMITATE (PNPP). 
[A] TIME CURVE: substrate concentration, 0.1 mM; protein, 50^g/assay. 
[Bl PROTEIN DEPENDENCE: substrate concentration, 0.1 mM; incubation time, 10 min. 
[C] DEPENDENCE ON SUBSTRATE CONCENTRATION: protein, 50ng/assay; incu-
bation time, 10 min. 
Values represent the mean of duplicate determinations from two separate experiments. 
The average enror in the data points in these assays were mean ± 7.4%, 8.6% and 
6.5%, for A, 8 and C, respectively. 
substrate. Assays were done for 10 min at 50 jxg protein of 0-40% ASF (Fig. 3.2, 
C). The combined results demonstrate that pattern of substrate dependency with 
respect to CEH present in cytosol and 0-40% ASF was found to be similar. 
3.1.2. Activation ofcytosolic CEH by phosphorylating agents 
Cytosol was treated with cAMP-dependent protein kinase (PKA) or with 
compounds which selectively activate the PKA associated with the cytosolic 
preparation. As seen in Table 1, treatment of cytosol with ATP or Mg resulted in 
a concentration-dependent activation of CEH. The maximal activation of CEH was 
achieved at 3 mM ATP (109%) or 5 mM Mg^ ^ (75%). However, incubation of 
cytosol with complexed ATP-Mg also resulted in a concentration-dependent 
activation of CEH, with a maximum effect at 2.5 mM. In comparison to control 
value, CEH activation in tiie presence of 2.5 mM ATP-Mg was 104%, which was 
further increased to 137% when cAMP was added in the incubation mixture 
(Table 1). 
Consistent wiA above results, addition of 100 \i% PKA alone and 100 ^ iM 
cAMP produced an increase of 52% and 39%, respectively, in CEH activity. 
Addition of 2.5 mM ATP-Mg along with 100 ^ iM cAMP caused CEH activation of 
98%, which was further enhanced to 157% when 100 ng of exogenous PKA was 
added to the incubation mixture (Table 2). These results indicate that cytosolic 
CEH activity was significantly increased apparently by the enhanced phosphory-
lation of CEH, mediated by an endogenous cAMP-dependent protein kinase, 
which was activated in the presence of various activators (Table 1). Furthermore, 
addition of exogenous PKA along with cAMP and ATP-Mg, fully activated 
cytosolic CEH via increased phosphorylation (Table 2). 
In order to test the specificity of ATP-mediated stimulation of CEH 
activity, ADP and AMP were employed. As evident fi-om the data presented in 
Table 3, addition of adenosine and AMP alone or in presence of Mg^ ^ with and 
without cAMP caused low (5-17%) activation in CEH activity. Addition of ADP 
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TABLE 1 
IN VITRO MODULATION OF CYTOSOLIC CEH BY ATP, Mg^\ ATP-Mg, 
cAMP AND ATP-Mg PLUS cAMP 
Additions CEH activity 
(units/mg) 
1.45 
1.57 
2.23 
3.03 
0.86 
N D 
1.93 
1.96 
2.07 
2.12 
2.54 
2.48 
1.51 
1.43 
1.90 
2.04 
2.68 
2.92 
1.68 
1.18 
N.D. 
3.39 
2.57 
1.19 
N D 
Activation 
(% of control) 
100 
108 
154* 
209* 
59^ 
-
133^ 
135^ 
143* 
146* 
175* 
171* 
104 
100 
133^ 
143* 
187* 
204* 
117^ 
82.5' 
-
237* 
180* 
83 
-
None 
ATP, ImM 
ATP, 2mM 
ATP, 3mM 
ATP,4mM 
ATP,5mM 
Mg 
Mg' 
Mg 
Mg' 
Mg' 
Mg' 
Mg' 
ImM 
2inM 
3niM 
4mM 
5mM 
6mM 
10 mM 
None 
cAMP, 100 nM 
ATP-Mg, ImM 
ATP-Mg, 2 mM 
ATP-Mg, 2.5 mM 
ATP-Mg, 3 mM 
ATP-Mg, 3.5 mM 
ATP-Mg, 4.0 mM 
ATP-Mg, 2.5 mM + cAMP, 100 nM 
ATP-Mg, 3.0 mM + cAMP, 100 i^M 
ATP-Mg, 3.5 mM + cAMP, 100 l^M 
ATP-Mg, 4.0 mM + cAMP, 100 nM 
300 |ig protein of cytosol was preincubated without and with indicated cofactors for 
20 min at 37 °C in a reaction volume of 500 jil before assaying CEH activity. Values 
shown are the mean of duplicate determinations of three representative experiments. The 
average error in CEH assay performed with and without ligands were ± 9.2% and ± 3%, 
respectively. N.D., not detectable.Significantly different fi-om control at ^p<0.001, ^p<0.01 
and V<0.05. 
TABLE 2 
IN VITRO MODULATION OF CYTOSOLIC CEH BY cAMP-DEPENDENT 
PROTEIN KINASE 
Additions 
None 
PKA, 50 ng 
PKA, 100 ng 
cAMP, 100 \M 
ATP-Mg, 2.5 mM 
cAMP, 100 ^M + PKA, 100 [ig 
ATP-Mg, 2.5 mM + cAMP, 100 \xM 
ATP-Mg, 2.5 mM + PKA, 100 ^g 
ATP-Mg, 2.5 mM + cAMP, 100 ^M + 
PKA, 100 ^g 
CEH activity 
(units/mg) 
2.37 
2.90 
3.60 
3.30 
4.50 
4.99 
4.70 
5.00 
6.10 
Activation 
(% of control) 
100 
122^ 
152* 
139^ 
190* 
211* 
198* 
211* 
257* 
300 (ig protein of cytosol was preincubated without and with indicated cofactors for 
20 min at 37 °C in reaction volume of 500 \i\ prior to CEH assay. Values shown are the 
mean of duplicate determinations of two representative experiments. The average error in 
CEH assay performed with and without ligands were ± 8% and ± 4%, respectively. 
SigniJHcantly diflFerent from control at ^p<0.001 and ^p<0.0]. 
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TABLE 3 
IN VITRO MODULATION OF CYTOSOLIC CEH ACTIVITY BY ADENOSINE, 
AMP, ADP, ATP ALONE OR IN COMBINATION WITH Mg*^  AND cAMP 
Additions 
None 
Adenosine, 2 mM 
Adenosine, 2.5 mM 
Adenosine, 3 mM 
Adenosine + Mg^* 2 mM 
Adenosine + Mg^\ 2.5 mM 
Adenosine + Mg^*,3.0 mM 
Adenosine + Mg^\2.5 mM +cAMP, 100 jiM 
AMP,2mM 
AMP, 2.5 mM 
AMP, 3mM 
AMP + Mg^\2mM 
AMP + Mg^^,2.5mM 
AMP + Mg^^3mM 
AMP + Mg^'. 2.5 mM + cAMP, 
ADP, 2 mM 
ADP, 2.5 mM 
ADP, 3mM 
ADP + Mg^',2mM 
ADP + Mg^^2.5mM 
ADP + Mg^\3mM 
ADP + Mg^^ 2.5 mM + cAMP, 
ATP,2mM 
ATP, 2.5 mM 
ATP,3mM 
ATP + Mg^*,2mM 
ATP + Mg^^,2.5mM 
ATP + Mg^ ,^ 2.5 mM + cAMP, 
100 nM 
100 |iM 
100 nM 
CEH activity 
(units/mg) 
1.46 
1.46 
1.41 
1.66 
1.49 
1.66 
1.46 
1.46 
1.46 
1.54 
1.63 
1.66 
1.71 
1.54 
1.46 
1.57 
2.59 
2.59 
2.48 
2.53 
2.09 
2.26 
2.51 
2.73 
2.87 
2.59 
3.00 
3.20 
Activation 
(% of control) 
100 
100 
97 
114' 
102 
114' 
100 
100 
100 
105 
112 
114 
117^ 
105 
100 
108 
177* 
177* 
170* 
173* 
143^ 
155^ 
172* 
187* 
197* 
177* 
205* 
219* 
300 lag protein of cytosol was preincubated without and with indicated cofactors for 
20 min at 37 °C in a reaction volume of 500 (il prior to CEH assay. Values shov^ are the 
mean of duplicate determinations of two representative experiments. The average error in 
CEH assay performed with and without ligands were ± 9% and ± 2.8%, respectively. 
Significantly different fi-om control at *p<0.001, ^ p<0.01 and V<0 05. 
(2.5 mM) alone or with Mg caused a significant increase of approximately 75% 
in CEH activity. Addition of cAMP did not fiirther enhanced the CEH activity 
(Table 3). Addition of 2.5 mM ATP-Mg produced a marked increase in CEH 
activity (105%), which was furflier enhanced (119%) by the addition of cAMP 
(Table 3). These results indicate that endogenous PKA-dependent activation of 
cytosolic CEH is specific to ATP, followed by some activation by ADP 
(Table 3). 
3.1.3. Inadivation ofcytosoUc CEH by dephosphorylaAng agents 
Treatment of cytosol with nonspecific alkaline phosphatase fi^om calf 
intestinal mucosa resulted in a marked concentration-dependent decrease in the 
activity (Fig. 3.3). Addition of 0.6 units of alkaline phosphatase caused inactiva-
tion of CEH by 96% (Fig. 3.3). These results demonstrate that dephosphorylation 
and inactivation of phosphorylated and active CEH is mediated by alkaline 
phosphatase. 
A correlation between enzymatic activity of CEH and the inhibition of 
endogenous phosphatases was investigated in cytosol, treated with nonspecific 
phosphoprotein phosphatase inhibitor, pyrophosphate (PP). A 16% stimulation in 
CEH activity was seen in presence of 25 mM PP, which was fiuther enhanced by 
77% and 82% when PP concentration was increased to 40 mM and 60 mM, 
respectively, in comparison to control. It is interesting to note that high levels of 
Mg^ ^ (6 and 10 mM) blocked the activation of cytosoUc CEH (Table 1). A 
concentration of ATP (5 mM) alone or complexed ATP-Mg (4.0 mM), not only 
blocked the CEH activation but completely inhibited the basal CEH activity 
(Table 1). These results suggest that inactivating effects of high levels of ATP or 
ATP-Mg on CEH might depend on an endogenous phosphatase (ATP-Mg-
dependent) related dephosphorylation. 
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Fig. 3.3 CONCENTRATION-DEPENDENT DEPHOSPHO-
RYLATION (INACTIVATION) OF CYTOSOLIC CEH. 300 
^g cytosolic protein was preincubated for 20 min at 37 ^C 
with increasing amounts of calf intestinal mucosa 
alkaline phosphatase prior to CEH assay. Assays were 
done in triplicate. The mean ± S.D. averaged 9.4%. 
The absolute value of 100% CEH activity was 1.80 ± 0.08 
units/mg. 
3.2. IN VITRO MODULATION OF ENZYMATIC ACTIVITY OF 
PARTIALLY PURIFIED CYTOSOLIC CEH BY ACTIVATION 
(PHOSPHORYLATION) AND INACTIVATION (DEPHOSPHORY-
LATION) 
3.2.1. Activation of partially purified cytosolic CEH in 0-40% ASF by phospho-
rylating agents 
Based on the results that CEH activity in cytosol is apparently modulated 
by pho^hoiylation and dephosphorylation, a detailed characterization of factors 
involved in the phosphorylation (activation) and dephosphorylation (inactivation) 
systems of partially purified hepatic CEH in 0-40% ASF was undertaken. 
Fractionation of rat liver cytosol to 40% ammonium sulphate saturation resulted in 
the enrichment and purification of CEH specific activity by 2.5 fold in comparison 
to CEH activity in cytosol. Based on the results obtained for the activation 
(phosphorylation) of CEH in cytosol by various phosphorylating agents, we first 
tested the capacity of 0-40% ASF in the activation of CEH by utilizing the 
ATP-Mg, cAMP and exogenous PKA. The results are sunmiarised in Table 4. 
Cyclic AMP alone or PKA alone were able to activate the CEH activity by 45% 
and 47%, respectively. The CEH activation was further enhanced (95%) when 
both cAMP and PKA were added. Addition of ATP-Mg caused an activation of 
70% which was increased to 129% when exogenous PKA was added. Maximum 
activation (167%) of partially purified CEH in 0-40% ASF was associated with the 
complete system, containing 2 mM ATP-Mg, 100 jiM cAMP and 100 \x% PKA. 
Incubation of ATP with partially purified fi"action of CEH was associated 
with a concentration-dependent increase in CEH activity, with an optimal 
activation of 90% at 3 mM ATP (Fig. 3.4). Addition of 4 mM ATP not only 
completely blocked this activation of CEH but inhibited the basal enzyme activity 
by 22%. At 5 mM ATP, basal CEH activity was inhibited by 82%. The level of 
inhibition was not increased at 10 mM ATP (Fig. 3.4). Treatment of 0-40% ASF 
witii Mg also resulted in cencentration-dependent activation of CEH, with a 
maximal activation of 71% at 5 mM. At 10 mM Mg^ ^ this activation of CEH was 
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TABLE 4 
IN VITRO MODULATION OF PARTIALLY PURIFIED CEH INVOLVING 
cAMP-DEPENDENT PROTEIN KINASE 
Additions CEH activity Activation 
(units/mg) (% of control) 
None 2.88 ±0.08 100 
cAMP, lOOuM 4.17 ±0.10 145* 
PKA,100ng 4.24±0.13 147* 
cAMP, 100 nM + PKA, 100 ng 5.62 ±0.23 195* 
ATP-Mg, 2 mM 4.90 ± 0.28 170* 
ATP-Mg, 2 mM + PKA, 100 [ig 6.60 ± 0.36 229* 
ATP-Mg, 2 mM + cAMP, 100 pM 5.98 ± 0.26 208* 
ATP-Mg, 2 mM +cAMP, 100 ^M + 7.68 ± 0.27 267* 
PKA 100 ng 
100 |ig protein of 0-40% ASF of cytosol was preincubated without and with indicated 
cofactors for 20 min at 37 °C and CEH activity was determined. Each value represents the 
mean ± S.D. of triplicate determinations. 
Significantly different fi^om control at ^p<0.001. 
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FIG. 3.4 EFFECT OF ATP ON CEH ACTIVITY. 100 ^ g 
protein of 0-40% ASF of cytosol was preincubated 
with increasing concentration of ATP for 20 min at 
37 °C prior to CEH assay. Assays were done in 
triplicate. The mean ± S.D. averaged 7%. The abso-
lute value of 100% CEH activity was 3.0 ±0.10 
units/mg. 
completely blocked and the enzymatic activity was reduced to a level similar to 
control value (Fig. 3.5). The enzymatic activity of CEH in 0-40% ASF was 
significantly enhanced when ATP-Mg was added together. The maximal CEH 
activation of 89% was obtained at 2 mM ATP-Mg, which was concentration-
dependent. Higher levels of ATP-Mg (2.5-5.0 mM) consistently reduced this 
activation and at 5 mM ATP-Mg, 90% of the basal activity was inhibited 
(Fig. 3.6). It is interesting to note that in cytosol 2.5 mM ATP-Mg was associated 
with maximal activation of CEH, whereas in 0-40% ASF optimal activation was 
obtained at 2 mM ATP-Mg. 
The effects of cAMP alone and ATP-Mg plus cAMP on endogenous PKA-
mediated activation (phosphorylation) of partially purified CEH in 0-40% ASF 
was studied next. As seen in Fig. 3.7, cAMP increased CEH activities in a 
concentration-dependent manner with an optimal activation of 56% at 10 ^M, 
which was maintained upto 100 jjiM cAMP. A significantly higher enhancement of 
activity was achieved by the addition of 2 mM ATP-Mg and increasing 
concentration of cAMP, when compared to control value of 84% containing only 
ATP-Mg. At 10 nM cAMP an optimal CEH activation of 120% was obtained, 
which remained unchanged upto 100 |iM cAMP (Fig. 3.8). The combined results 
demonstrate that preincubation of 0-40% ASF containing partially purified CEH 
with ATP (3 mM) alone, Mg^ * (5 mM) alone, ATP-Mg (2 mM), cAMP 
(10-100 nM) alone and combination of ATP-Mg (2 mM) and cAMP (100 nM) 
was associated with a significant and maximal increase (phosphorylation) in 
enzyme activity mediated by endogenous cAMP-dependent protein kinase and 
other phosphorylating agents. Like other phosphorylating agents, the effect of 
exogenous PKA on CEH activation was concentration-dependent. Incubation of 
exogenous PKA alone with 0-40% ASF increased CEH activity io a concentration-
dependent manner (Fig. 3.9). An activation of 53% was achieved at 100 ng of 
PKA, which was slightly increased (65%) at 200 [ig PKA. Full activation of CEH 
was achieved by the addition of increasing concentration of exogenous PKA to the 
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FIG. 3.5 EFFECT OF Mg2* ON CEH ACTIVITY. 100 ^g 
protein of 0-40 % ASF of cytosol was preincubated 
with increasing concentration of Mg2+ for 20 min at 
37 °C prior to CEH assay. Assays were done in tripli-
cate. The mean ± S.D. averaged 5.5%. The absolute 
value of 100% CEH activity was 3.12 ± 0.09 units/mg. 
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FIG. 3.6 EFFECT OF ATP-Mg ON CEH ACTIVITY. 
100 ng protein of 0-40 % ASF was preincubated 
with increasing concentration of ATP-Mg for 20 min 
at 37 °C prior to CEH assay. Assays were done in 
triplicate. The mean ± S.D. averaged 8.5%. The 
absolute value of 100% CEH activity was 3.06 ± 
0.10 units/mg. 
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FIG. 3.7 CONCENTRATION-DEPENDENT ACTIVATION 
OF CEH BY CAMP. 100 ^g protein of 0-40 % ASF of 
cytosol was preincubated with increasing concentra-
tion of cAMP for 20 min at 37 °C prior to CEH assay. 
Assays were done in triplicate. The mean ± S.D. averaged 
7%. The absolute value of 100% CEH activity was 3.30 
±0.11 units/mg. 
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FIG. 3.8 CONCENTRATION-DEPENDENT ACTIVATION OF 
CEH BY cAMP IN PRESENCE OF 2 mM ATP-Mg. 100 ^g 
protein of 0-40 % ASF of cytosol was preincubated with 
increasing concentration of cAMP in presence of 2 mM 
ATP-Mg for 20 min at 37 oC prior to CEH assay. Assays 
were done in triplicate. The mean ± S.D. averaged 9%. 
The absolute value of 100% CEH activity was 3.25 ± 0.08 
units/mg. The value of CEH activity in presence of 2 mM 
ATP-Mg was 5.99 ± 0.40 units/mg. 
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FIG. 3.9 CX)NCENTRAT10N-DEPENDENT ACTIVATION 
OF CEH BY BOVINE HEART PKA. 100 ^g protein of 
0-40 % ASF of cytosol was preincubated with increasing 
concentration of PKA for 20 min at 37 oQ prior to CEH 
assay. Assays were done in triplicate. The mean i S.D. 
averaged 6.5%. The absolute value of 100% CEH activity 
was 3.00 ± 0.07 units/mg. 
incubation mixture containing 2 mM ATP-Mg and 100 pM cAMP (Fig. 3.10). A 
maximal CEH activation (165%) was obtained at 100 i^g PKA in comparison to an 
activation level of 112% achieved by 2 mM ATP-Mg and 100 nM cAMP. A PKA 
concentration of 200 |ig in a complete system was associated with a slight increase 
(176%) in the en2ymatic activity of CEH (Fig. 3.10). These results demonstrate 
that phosphorylation and activation of partially purified CEH in 0-40% ASF of 
cytosol is mediated by a cAMP-dependent protein kinase and a maximal CEH 
activation was observed in a complete system containing an exogenous PKA, 
ATP-Mg and cAMP. The PKA-mediated activation of partially purified CEH was 
partially blocked by a synthetic protein kinase inhibitor (Table 5). 
To determine whether the activating effect of Mg alone and complexed 
with ATP on CEH can be duplicated with another divalent cation, Mn^ "^ . As seen 
in Fig. 3.11, Mn^\ like Mg^ ^ also mediated the activation of CEH in 0-40% ASF 
in a concentration-dependent manner with an optimal activation of 165% at 5 mM 
Mn^ .^ However, degree of CEH activation by 5 mM Mn^ ^ was significantly higher 
than the activation observed by 5 mM Mg^ "^  (71%). In addition, only at 1 mM 
Mn^ ^ an activation of 82% was achieved. At 10 mM Mn^ *, similar to Mg^^ , the 
CEH activation was completely blocked (Fig. 3.11). Since activating effect of 
Mn * on CEH was considerably higher than Mg^ ,^ we investigated the possibility 
of direct effect of Mn^ ^ on CEH activity, independent of the cAMP signal 
transduction system. Data presented in Table 6 demonstrate that a 20 min 
preincubation of partially purified CEH with 5 mM Mn^ ^ followed by a 10 min 
incubation resulted in 162% activation in comparison to control values. This Mn^ -^
mediated activating effect on CEH was reduced to 98% when Mn "^ was present 
during 10 min incubation only. Furthermore, when 0-40% ASF was preincubated 
with 5 mM Mn^ ^ for 20 min, followed by addition of 20 mM EDTA (for Mn^ ^ 
chelation) and incubation for 10 min, the activating effect of Mn^ ^ was reduced to 
33%, which is similar to conti-ol value of 40% when 20 mM EDTA was added 
along with 5 mM Mn^ * at the start of preincubation (Table 6). These results 
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FIG. 3.10 CONCENTRATION-DEPENDENT ACTIVATION 
OF CEH BY PKA IN PRESENCE OF ATP-Mg AND cAMP. 
100 ^g protein of 0-40 % ASF of cytosol was preincubated 
with increasing concentration of PKA in presence of 2 mM 
ATP-Mg and 100 \iM cAMP for 20 min at 37 oC prior to CEH 
assay. Assays were done in triplicate. The mean ± S.D. 
averaged 8.8%. The absolute value of 100% CEH activity 
vras 3.00 ± 0.10 units/mg. The value of CEH activity in 
presence of 2 mM ATP-Mg and 100 ^M cAMP was 6.36 
± 0.44 units/mg. 
TABLES 
ACTIVATION OF PARTIALLY PURIFIED CEH BY cAMP-DEPENDENT 
PROTEIN KINASE: EFFECT OF PROTEIN KINASE INHIBITOR (PKI> 
Additions 
None 
PKI, 300 nM 
ATP-Mg, 2 mM + cAMP, 100 ^M" 
ATP-Mg, 2 mM + cAMP, 100 |iM + 
PKI, 300 nM 
PKA, 100 ^g* 
PKA, 100 ng + PKI, 300 nM 
ATP-Mg, 2 mM + cAMP, 100 i^M + 
PKA, 100 ng' 
ATP-Mg, 2 mM + cAMP, 100 ^M + 
PKA, 100 ng + PKI, 500 nM 
CEH activity 
(units/mg) 
• 2.94 ± 0.07 
2.64 ±0.10 
6.27 ±0.32 
3.81 ±0.26 
4.63 ±0.18 
4.35 ± 0.20 
7.74 ±0.44 
5.32 ±0.29 
Relative activity 
(% of control) 
100 
90^ 
213* 
129^ (39)'* 
157* 
148* (06)'' 
263* 
181* (31)'* 
100 |ig protein of 0-40% ASF of cytosol was preincubated without and with indicated 
cefaclors for 20 min at 37 °C prior to CEH assay. Each value represents the mean ± S.D. 
of triplicate determinantions. Values shown in parenthesis are percent inactivation in 
presence of protein kinase inhibitors in comparison to respective controls. 
Significantly different fi-om respective controls at ^p<0.001 and ^ p<0.01. 
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FIG. 3.11 EFFECT OF Mn2* ON CEH ACTIVITY. 100 ^g 
protein of 0-40% ASF of cytosol was preincubated with 
increasing concentration of Mn2+ for 20 min at 37 oC 
prior to CEH assay. Assays were done in triplicate. 
The mean ± S.D. averaged 7.4%. The absolute value of 
100% CEH activity was 3.14 ± 0.12. 
TABLE 6 
MAGNESE-DEPENDENT IN VITRO MODULATION OF CEH ACTIVITY 
Additions 
None 
Mn^\ 5 mM 
Mn^\ 5 mM 
Mn^', 5mM 
Mn^\ 5 mM 
None 
Mn^\ 5 mM 
Mn^\ 5 mM 
Preincubation 
(min) 
20 
20 
20 
.* 
.** 
30 
30 
30 
Incubation 
(min) 
10 
10 
_» 
_* 
10 
10 
10 
_* 
CEH activity 
(units/mg) 
2.76 ± 0.09 
7.24 ± 0.28 
3.67 ±0.33 
3.86 ±0.10 
5.48 ±0.17 
2.69 ± 0.08 
7.17 ±0.30 
3.50 ±0.26 
Activation 
(*/• of control) 
100 
262^ 
133^  
140* 
198* 
100 
267* 
130^  
100 ng protein of 0-40% ASF of cytosol was preincubated for 20 min or 30 min at 37 °C 
without and wth indicated ligands and CEH activity was detemined. Each value 
represents the mean ± S.D. of triplicate determinations. 
-• Signifies that Mn^ "^  was chelated by the addition of 20 mM EDTA during preincubation 
and/or incubation. 
-** Signifies that Mn^ "^  was not present during preincubation. 
Significantly different fi-om respective controls at ^p<0.001 and ^p<0.01. 
demonstrate that bulk of activating effect of Mn^ ^ in CEH is time independent, 
does not require preincubation (20 min) in order to modify CEH involving 
endogenous PKA and appears to directly affect tiie hydrolysis of substrate during 
10 min incubation. Similar results were obtained when preincubation time was 
increased to 30 min (Table 6). Based on these results, the Mg^*-mediated 
activation of CEH, which appears to involve endogenous ATP and PKA (Fig. 3.5) 
was reinvestigated. The data summarised in Table 7 revealed that treatment of 
CEH in 0-40% ASF with 5 mM Mg^ * during preincubation (20 min) and 
incubation (10 min) or during preincubation (20 min) only resulted in a 68% and 
62% activation of CEH, respectively, in comparison to control CEH value of 34% 
when 20 mM EDTA was added along with 5 mM Mg^ ^ at the start of 
preincubation. Preincubation of 0-40% ASF with 5 mM Mg^ ^ for 30 min with and 
without incubation of 10 min caused a similar CEH activation of 72% and 69%, 
respectively. Addition of 5 mM Mg^ ^ with 20 mM EDTA during 10 min 
incubation only, increased CEH activity by 26%, (Table 7). The results indicate 
that unlike Mn^ ,^ the activating effect of Mg^ ^ on CEH activity is time dependent, 
require 20 min preincubation to fully activate the enzyme, which is mediated by 
endogenous phosphorylating agents including PKA, involving activation 
(phosphorylation) of partially purified CEH. The differential effect of Mn^ ^ and 
Mg^ "^  on CEH activity was consistent with the Va^ x and K^ values obtained in the 
presence of each cation. A V a^x value of 0.18 and 0.24 nmole/min was obtained 
for CEH in the presence of Mg^ ^ and Mn^ *, respectively, when compared to a 
control value of 0.13 nmole/min obtained in absence of Mg^ ^ or Mn^^ . Similarly, a 
Kn, value of 13.3 and 22.0 jiM was obtained for CEH enzyme in the presence of 
Mg and Mn , respectively. A K^ value of 24.5 jiM was obtained when enzyme 
was assayed in absence of Mg^ * or Mn^ "^ . 
Next, effect of ATP-Mn on the activation of CEH was investigated. The 
stimulation in CEH activity was concentration-dependent and an optimal 
activation of 75% was achieved at 2 mM ATP-Mn (Fig. 3.12). At concentrations 
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TABLE? 
MAGNESIUM-DEPENDENT IN VITRO MODULATION OF CEH 
Additions 
None 
Mg^\ 5 mM 
Mg^\ 5 mM 
Mg^\ 5 mM 
Mg^\ 5 mM 
None 
Mg^\ 5 mM 
Mg^\ 5 mM 
Preincubation 
(min) 
20 
20 
20 
.* 
_** 
30 
30 
30 
Incubation 
(min) 
10 
10 
_* 
_* 
10 
10 
10 
_* 
CEH activity 
(units/mg) 
2.82 ±0.10 
4.75 ± 0.25 
4.56 ±0.13 
3.78 ±0.15 
3.55 ±0.26 
2.76 ±0.12 
4.74 ± 0.29 
4.67 ± 0.30 
Activation 
(% of control) 
100 
168* 
162* 
134* 
126^  
100 
172* 
169* 
100 fig protein of 0-40% ASF of cytosol was preincubated for 20 min or 30 min at 37 °C 
without and with indicated ligands and CEH activity was detemined. Each value 
represents the mean ± S.D. of triplicate determinations. 
-* Signifies that Mg^ ^ was chelated by the addition of 20 mM EDTA during preincubation 
and/or incubation. 
-** Signifies that Mg^ ^ was not present during preincubation. 
Significantly (tiflferent fi-om respective controls at *p<0.001 and ^ p<0.01. 
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FIG. 3.12 EFFECT OF ATP AND ATP-Mn ON GEH ACTIVITY. 
100 ng protein of 0-40% ASF of cytosol was preincubated 
with increasing concentration of ATP in presence of 5 mM 
Mn2+ (—•—) or increasing concentration of equimolar 
ATP-Mn (—o—) for 20 min at 37 oC prior to CEH assay. 
Assays were done in triplicate. The mean ± S.D. averaged 
7.5% and 9% for ATP series and ATP-Mn series respectively. 
The absolute value of 100% CEH activities (units/mg) were 
2.7 ± 0.08 and 3.1 ± 0.10 for ATP series and ATP-Mn series, 
respectively. The value of CEH activity with 5 mM Mn2+ 
alone was 6.94 ± 0.50 units/mg. 
of ATP-Mn higher than 2 mM, inactivation of CEH occured. At 5 and 10 mM 
ATP-Mn, 27% and 61% of basal CEH activity was inhibited (Fig. 3.12). The rate 
of inactivation of activated CEH and inhibition of basal activity at higher levels of 
ATP-Mn was significantly lower than with ATP-Mg, where 5 mM ATP-Mg 
caused 90% inhibition of basal CEH activity (Fig. 3.6). These results indicate that 
activating effect of ATP-Mg (1:1) on CEH is more specific than ATP-Mn (1:1). 
Modulation of en2ymatic activity of partially purified cytosolic CEH was also 
investigated at 5 mM of Mn^ ^ or Mg^ "^  and varying concentrations of ATP. The 
data presented in Fig. 3.12 and Fig. 3.13, revealed that maximal CEH activation in 
presence of either Mn^ ^ or Mg^ ^ was achieved at 2 mM ATP. However, degree of 
CEH activation mediated by ATP-Mn was significantly higher (176%, Fig. 3.12) 
when compared to ATP-Mg (87%, Fig. 3.13). Consistent with earlier results, 
concentrations of ATP higher than 2 mM in presence of either 5 mM Mn 
(Fig. 3.12) or Mg^ * (Fig. 3.13) blocked the CEH activation. The CEH activation at 
3 mM ATP in Mg series was reduced from 87% to 25%, whereas, for Mn 
series CEH activation was reduced from 176% to 19% at a much higher ATP 
concentrartion of 5 mM. Similarly, 5 and 10 mM ATP in Mg^ ^ series resulted in 
the inhibition of basal CEH activity to a level of 82% and 91%, respectively. The 
degree of inhibition in Mn^ ^ series was 22% and 53% at 10 mM and 20 mM ATP, 
respectively, which is significantly less than Mg^ "^  series (Fig. 3.12 and 3.13). 
These results are consistent with the data presented above that unlike Mg^^ , bulk 
of increase in CEH activity is due to direct effect of free Mn^ ^ on enzyme and is 
independent of PKA-mediated phosphorylation (activation) of CEH. 
In order to test the hypothesis that inactivating effects of higher levels of 
ATP-Mg will be counteracted by the presence of PKA/cAMP, 0-40% ASF was 
incubated at increasing concentration of ATP-Mg (2-20 mM) and a fixed level of 
PKA (100 ng) and cAMP (100 i^M). Figure 3.14 depicted the results of such an 
experiment. As expected, maximal CEH activation of 167% was obtained at 
2 mM ATP-Mg. The inactivating effects of high levels of ATP-Mg on CEH 
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FIG. 3.13 EFFECT OF ATP AND ATP-Mg ON GEH ACTIVITY. 
100 ng protein of 0-40% ASF of cytosol was preincubated 
with increasing concentration of ATP in presence of 5 mM 
Mg2* (—•—) or increasing concentration of equimolar 
ATP-Mg (—o—) for 20 min at 37 °C prior to CEH assay. 
Assays were done in triplicate. The mean ± S.D. averaged 
8% and 8.5% for ATP series and ATP-Mg series, respecti-
vely. The absolute value of 100% CEH activities (units/mg) 
were 3.06 ± 0.09 and 3.0 ± 0.07 for ATP series and ATP-Mg 
series, respectively. The value of CEH activity v^ rith 5 mM 
Mg2+ alone was 5.00 ± 0.42 units/mg. 
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FIG. 3.14 EFFECT OF cAMP AND PKA ON CEH ACTIVITY 
WITH INCREASING CONCENTRATION OF ATP-Mg. 100 ^g 
protein of 0-40 % ASF of cytosol was prelncubated with 100 |ig 
of PKA and 100 i^M cAMP along with increasing concentration 
of ATP-Mg for 20 min at 37 °C prior to CEH assay. Assays were 
done in triplicate. The mean ± S.D. averaged 8.4%. The absolute 
value of 100% CEH activity was 2.88 ± 0.11 units/mg. The value 
for CEH activity in presence of 2 mM ATP-Mg + 100 ^M cAMP 
and 100 jig PKA was 7.68 ± 0.45 units/mg. 
activity were significantly counteracted by the PKA/cAMP-promoted activation of 
CEH. In the presence of PKA/cAMP, 5 mM ATP-Mg was able to inactivate and 
reduce CEH activity fi-om 167% activation to 40%, whereas, 10 mM and 20 mM 
ATP-Mg caused approximately 50% reduction of basal acitivity (Fig. 3.14). When 
compared to results obtained widi ATP-Mg in the absence of PKA/cAMP 
(Fig. 3.6), 3 mM ATP-Mg reduced the CEH activation from 89% to an inhibition 
of 8% (Fig. 3.6). Whereas, 5 mM ATP-Mg was associated with a 90% inactivation 
of basal CEH activity. 
These results indicate that inactivating effects of high levels of ATP 
(Fig. 3.4) and ATP-Mg on CEH activation, and almost complete inhibition of basal 
CEH activity at 5 mM and 10 mM of ATP and ATP-Mg might be associated with 
an endogenous ATP-Mg-dependent phosphatase-mediated dephosphorylation 
(inactivation) of CEH enzyme. Activation of such type of phosphatase at high 
levels of ATP and ATP-Mg will counteract the cAMP-dependent protein 
kinase/cAMP and ATP-Mg-promoted activations in a similar order of potency, 
reducing CEH acitvity to the control value or even inactivating the basal CEH 
activity by more than 90%. 
3.2.2, Inactivation of partially purified cytosolic CEH in 0-40% ASF by 
dephosphorylating events 
Treatment of partially purified CEH in 0-40% ASF with nonspecific 
alkaline phosphoprotein phosphatases fi"om bovine and chicken intestinal mucosa 
resulted in a marked concentration-dependent decrease in activity, though the 
extent of inhibition varied (Fig. 3.15). Addition of 0.5 unit of phosphatase fi^om 
chicken intestinal mucosa inhibited CEH activity by 50%, whereas 1.0 unit of 
bovine intestinal mucosa phosphatase was required to inactivate enzyme by 50% 
(Fig. 3.15). These results demonstrate that like cytosoUc CEH, enzyme activity of 
partially purified CEH can also be dephosphorylated and inactivated by alkaline 
phosphatases. 
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Fig. 3.15 CONCENTRATION-DEPENDENT DEPHOSPHO-
RYLATION (INACTIVATION) OF CEH. 100 ^g protein of 
0-40% ASF of cytosol was preincubated for 20 min at 
37 oC with increasing amounts of chicken (—•—) and 
bovine ( - •—) intestinal mucosa alkaline phosphatase, 
prior to CEH assay. Assays were done in triplicate. 
The mean ± S.D. averaged 9% and 9.5% for CEH assay 
in presence of chicken and bovine phosphatase, respec-
tively. The absolute value of 100% CEH activities (units/mg) 
were 3.1 ± 0.11 and 2.92 ± 0.09 with chicken and bovine 
phosphatase, respectively. 
>.*. 
^ 
A correlation between enzyme activity and the inhibition of endogenous 
phosphatases was demonstrated in 0-40% ASF treated with phosphatase inhibitors 
pyrophosphate, glycerophosphate and orthovanadate (Table 8). At 50 mM of 
pyrophosphate and glycerophosphate an increase of 131% and 114% in CEH 
activity was observed in comparison to untreated control. Treatment of 0-40% 
ASF with 1-100 nM orthovanadate, a tyrosine phosphatase inhibitor, did not 
modify CEH activity (Table 8). However, at 5 mM and 10 mM of orthovanadate, 
CEH activity was increased by 110% and 150% (Table 8). These findings suggest 
a role of endogenous serine/threonine phosphatases in the inactivation of CEH. 
As shown in Table 9, the pyrophosphate-induced activation of CEH was 
optimal (113%) at 50 mM, which was reduced to 76% at 75 mM. In case of 
glycerophosphate the increase in CEH activity was maximal (83%) at 75 mM, 
whereas 100 mM glycerophosphate was associated with a decline in CEH 
activation to 23%. The orthovanadate-induced activating efifect on CEH was 
optimal (116%) at 10 mM, whereas at 20 mM orthovanadate the CEH activation 
was reduced to 80% (Table 9). Since okadaic acid and calyculin A are particularly 
useful for distinguishing phosphatases, as diey have high affinity for the catalytic 
subunits of type I and 2 A phosphatases, CEH activity was measured by incubating 
0-40% ASF wiA these specific phosphatase inhibitors. The data presented in 
Table 9, demonstrate that both okadaic acid and calyculin A at 10 nM increased 
CEH activity by 73% and 53%, respectively, in comparison to untreated control. 
Both the phosphatase inhibitors at much higher concentration of 5 i^M, induced 
CEH activation of 23% and 60%, respectively (Table 9). Since level of CEH 
activation at 10 nM and 5 |JM of okadaic acid and calyculin A is similar, 
apparently activity of endogenous phosphatase 2A is inhibited by these two 
inhibitors. Treatment of 0-40% ASF with 50 mM pyrophosphate and 10 mM 
orthovanadate did not further increase the CEH activation when compared to level 
of CEH activation achieved by individual inhibitors of endogenous phosphatases 
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TABLES 
EFFECT OF PYROPHOSPHATE, GLYCEROPHOSPHATE AND 
ORTHOVANADATE ON CEH ACTIVITY 
Additions 
None 
Pyrophosphate, 25 mM 
Pyrophosphate, 50 mM 
Glycerophosphate, 25 mM 
Glycerophosphate, 50 mM 
Orthovanadate (10 nM) 
Orthovanadate (100 nM) 
Orthovanadate, 5 mM 
Orthovanadate, 10 mM 
CEH activity 
(units/mg) 
2.80 
3.72 
6.48 
2.90 
6.00 
2.80 
2.89 
5.88 
7.00 
Activation 
(% of control) 
100 
133^ 
231* 
104 
214* 
100 
103 
210* 
250* 
50 ng protein of 0-40% ASF of cytosol was preincubated in presence of increasing 
concentration of indicated phophatse inhibitors for 20 min at 37 °C prior to CEH assay. 
Values shown are the mean of duplicate determinations of two representative experiments. 
The average error in CEH assay performed with and without ligands were ± 7.5% and 
± 3.3%, respectively. 
Significantly different fi-om control at ^p<0.001 and ^ p<0.01. 
TABLE 9 
IN VITRO MODULATION OF ENZYMATIC ACTIVITY OF CEH BY 
PYROPHOSPHATE, GLYCEROPHOSPHATE, ORTHO VANADATE, OKADAIC 
ACID AND CALYCULIN A 
Additons 
None 
Pyrophosphate, 50 mM 
Pyrophosphate, 75 mM 
Pyrophosphate, 100 mM 
Glycerophosphate, 50 mM 
Glycerophosphate, 75 mM 
Glycerophosphate, 100 mM 
Orthovanadate, 10 mM 
Orthovanadate, 20 mM 
Okadaic acid, 10 nM 
Okadaic acid, 5 ^ M 
Calyculin A, 10 nM 
Calyculin A, 5 |iM 
CEH activity 
(units/mg) 
3.60 
7.68 
6.36 
3.48 
6.24 
6.60 
4.44 
7.80 
6.48 
6.24 
4.44 
5.52 
5.76 
Activation 
(% of control) 
100 
213* 
176* 
97 
173* 
183* 
123^ 
216* 
180* 
173* 
123^  
153* 
160* 
100 ng protein of 0-40% ASF of cytosol was preincubated without and with specified 
amounts of indicated phosphatse inhibitors for 20 min at 37 °C prior to CEH assay. Values 
shown are the mean of duplicate determinations of three representative experiments. The 
average error in CEH assay performed with and without ligands were ± 5.5% and ± 3.5%, 
respectively. 
Significantly different fi-om control at ^p<0.001 and ^p<0.01. 
(data not shown). These results suggest that both pyrophosphate and ordiovanadate 
mediate the inhibition of common serine/threonine phosphatases. 
Since nonspecific and specific inhibitors of endogenous phosphatases 
significantly modify (activate) CEH activity, experiments were performed in 
which partially purified CEH was first preincubated with low (10 jiM and 
100 nM) and high (5 mM and 10 mM) levels of orthovanadate, 25 mM and 
50 mM of pyrophosphate, 25 mM and 50 mM of glycerophosphate and 0.05 nM 
and 0.2 nM of okadaic acid, and the activities of CEH and p-nitrophenyl 
phosphate-sensitive phosphatases were determined. The results are summarised in 
Table 10. At 10 ^M and 100 i^M of orthovanadate, 30-39% activity of 
phosphatases were inhibited, whereas no effect was seen on CEH activity. These 
results are consistent with the fact that low micromolar concentrations of 
ordiovanadate inhibit tyrosine phosphatases. Since tyrosine phosphatases are not 
involved in the dephosphorylation of CEH, no activation in CEH enzyme activity 
was observed (Table 10). Incubation of 0-40% ASF with 5 mM and 10 mM 
orthovanadate produced a marked inhibition (53% and 81%) of phosphatases 
activity and concomitant activation of 85% and 120% of CEH enzyme 
(Table 10). These results represent the initial demonstration of inactivation of 
cytosolic phosphatases at millimolar concentrations of orthovanadate, and the 
inhibitory effects appear to be analogous to pyrophosphate-mediated inhibition of 
phosphatases. As expected, 25 mM and 50 mM of pyrophosphate and glycero-
phosphate caused a significant inhibition (31-67%) of enzymatic activities of 
phosphatases and an increase of 26-98% in CEH activity. Consistent with earlier 
results, glycerophosphate was less effective in inhibiting phosphatases and 
activating CEH than pyrophosphate (Table 10). Okadaic acid sensitive to type I 
and 2A phosphatases only, inhibited phosphatases by 23% and 51% at 0.05 nM 
and 0.2 nM, respectively, whereas activation level of CEH was 22% and 51% 
(Table 10). These results demonstrate that specific and non-specific inhibitors of 
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TABLE 10 
MODULATION OF ENZYMATIC ACTIVITIES OF CEH AND PHOSPHATASES 
(Ptases) BY VARIOUS INHIBITORS OF PHOSPHATASES 
Treatments 
None 
Orthovanadate (10 nM) 
Orthovanadate (100 l^M) 
Orthovanadate (5 mM) 
Orthovanadate (10 mM) 
Pyrophosphate (25 mM) 
Pyrophosphate (50 mM) 
(Hycerophosphate (25 mM) 
Glycerophosphate (50 mM) 
Okadaic acid (0.05 nM) 
Okadaic acid (0.2 nM) 
Enzyme activity 
(units/me) 
CEH 
2.82 ±0.11 
2.80 ±0.17 
2.89 ±0.16 
5.22 ±0.20 
6.21 ± 0.25 
4.10 ±0.30 
5.58 ±0.33 
3.55 ±0.22 
4.98 ±0.36 
3.45 ±0.30 
4.26 ±0.33 
Ptases 
14.90 ±0.30 
10.40 ±0.40 
9.10±0.37 
7.00 ± 0.22 
2.80 ±0.25 
9.40 ± 0.40 
4.90 ±0.30 
10.30 ±0.28 
5.80 ±0.30 
11.40 ±0.45 
7.30 ±0.32 
Relative changes 
(% of control) 
CEH 
100 
99 
102 
185* 
220* 
145^ 
198* 
126^ 
177* 
122' 
151* 
Ptases 
-
30* 
39* 
53* 
81* 
37* 
67* 
31* 
61* 
23* 
51* 
11 tubes containing 820 [ig protein of 0-40% ASF of cytosol were first preincubated with 
the indicated ligands for 20 min at 37 °C in a reaction volume of 2 ml. Aliquots of 244 1^ 
and 50 |il fi-om each tube were assayed for activities of CEH and phosphatases, 
respectively, as described in experimental procedures except the pH, which was 8.0 for 
assay of phosphatases in presence of 10 mM Mg^ "^ . Each value represents the mean ± S.D. 
of triplicate determinations. 
Significantly different fi-om respective controls at ^p<0.001, ^ p<0.01 and 'p<0.05. 
phosphatases mediate the activation of CEH by inhibiting the activities of 
phosphatases and in turn blocking the dephosphorylation (inactivation ) of CEH. 
Since earlier results have demonstrated that low levels of ATP, Mg and 
ATP-Mg activated CEH enzyme, and high levels of ATP, Mg^ ^ and ATP-Mg were 
associated with significant inhibition of CEH activity, it was interesting to 
determine whether inactivating effects of higher levels of ATP, Mg and ATP-Mg 
might depend on activation of endogenous phosphatases. 0-40% ASF was 
incubated with increasing concentration of above ligands and activities of 
phosphatases were measured. As seen in Table 11, 2 mM of ATP, Mg '^ and 
ATP-Mg increased the activities of phosphatases by 7%, 12% and 25%, 
respectively. At 5 mM, 10 mM and 20 mM of ATP, activities of phosphatases 
were increased to 36%, 66% and 122%, respectively. The increase in activities of 
phosphatases in presence of 5 mM, 10 mM and 20 mM Mg^ ^ was 28%, 34% and 
62%, respectively. The level of Mg -mediated activation of phosphatases was 
significantly lower than obtained by ATP. Treatment of partially purified CEH 
fi"action with increasing concentration (2-20 mM) of ATP-Mg was associated with 
stimulating effect on activities of phosphatases in a dose-dependent manner. At 
5 mM, 10 mM and 20 mM ATP-Mg the increase in phosphatases activities were 
91%, 138% and 270%, respectively. These results suggest that low levels of ATP, 
Mg and ATP-Mg responsible for CEH activation do not significantly influence 
the activities of endogenous phosphatases. At 10 mM and 20 mM Mg^ ^ the 
activities of phosphatases were moderately enhanced, which may be responsible 
for complete inactivation of activated CEH mediated by 5 mM of Mg^ .^ Since high 
levels of ATP (5-20 mM) and ATP-Mg (5-20 mM) were associated with high 
degree of activation of phosphatases, which may be responsible for nearly 
complete inactivation (dephosphorylation) of basal CEH activity. The data 
presented in Table 12 confirmed tiie above observation that the activation of 
endogenous phosphatases, mediated by high concentrations of Mg^^ , ATP and 
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TABLE 11 
IN VITRO MODULATION OF ENZYMATIC ACTrVITIES OF PHOSPHATASES 
BY ATP, Mg^ *, AND ATP-Mg 
Additions 
None 
ATP,2mM 
ATP,5mM 
ATP, 10 mM 
ATP, 20 mM 
Mg^\ 2 mM 
Mg^', 5 mM 
Mg^\ lOmM 
Ug^\ 20 mM 
ATP-Mg, 2 mM 
ATP-Mg, 3 mM 
ATP-Mg, 4 mM 
ATP-Mg, 5 mM 
ATP-Mg, 7.5 mM 
ATP-Mg, 10 mM 
ATP-Mg, 15 mM 
ATP-Mg, 20 mM 
Activity of phosphatases 
(units/mg) 
6.00 ±0.18 
6.40 ± 0.20 
8.13 ±0.33 
9.98 ± 0.45 
13.30 ±0.52 
6.70 ±0.25 
7.66 ±0.30 
8.07 ±0.38 
9.70 ±0.45 
7.50 ±0.33 
9.14 ±0.42 
10.30 ±0.44 
11.45 ±0.56 
12.20 ±0.52 
14.30 ±0.65 
17.80 ±0.55 
22.20 ±0.75 
Activation 
(% of control) 
100 
107^ 
136* 
166* 
222* 
112^ 
128* 
134* 
162* 
125^ 
152* 
172* 
191* 
204* 
238* 
296* 
370* 
50 ng protein of 0-40% ASF of cytosol was preincubated without and with indicated 
ligands for 20 min at 37 °C prior to assay of p-nitrophenyl phosphate-sensitive 
phosphatases. Each value represents the mean ± S.D. of triplicate determinations. 
Significantly different fi-om control at ^p<0.001, V<0.01 and V<0 05. 
TABLE 12 
IN VITRO MODULATION OF ENZYMATIC ACTTVITIES OF CEH AND 
PHOSPHATASES BY ATP, Mg^ *, AND ATP-Mg 
Additions 
None 
ATP,2niM 
ATP, 10 mM 
Mg^^ 5 mM 
Ui\ 10 mM 
ATP-Mg, 2 mM 
ATP-Mg, 10 mM 
Enzyme activity 
(units/me) 
CEH 
2.70 ±0.08 
4.44 ±0.18 
0.36 ±0.05 
4.26 ± 0.20 
3.48 ±0.15 
4.86 ±0.25 
0.30 ± 0.04 
Ptases 
5.85 ±0.15 
6.44 ± 0.22 
9.36 ±0.35 
7.14 ±0.28 
7.90 ± 0.40 
7.40 ± 0.36 
12.30 ±0.65 
Relative 
r%of< 
CEH 
100 
164^ 
13^ 
158^ 
129^ 
180^ 
11^ 
changes 
:ontrol) 
Ptases 
100 
110^ 
160^ 
122^ 
135^ 
126^ 
211^ 
100 ng protein of 0-40% ASF of cytosol for CEH activity and 50 ixg protein of 0-40% 
ASF of cytosol for Ptases activities, were preincubated without and with indicated ligands 
for 20 min at 37 °C followed by assay of CEH and Ptases activities. Each value represents 
the mean ± S.D. of triplicate determinations. 
Significantly different fi^om respective controls at ^p<0.001 and ^ p<0.01. 
ATP-Mg, was responsible for the partial inactivation or almost complete inhibition 
of basal CEH activity involving dephosphorylation (Table 12). 
To determine whether the activating effects of ATP-Mg and cAMP might 
depend on the activities of endogenous PKA and phosphatases, 0-40% ASF was 
first pretreated with okadaic acid (0.2 nM), ortfaovanadate (10 mM) and 
pyrophosphate (50 mM), followed by second preincubation with 2 mM ATP-Mg 
and 100 jiM cAMP with and without cAMP-dependent protein kinase (100 ng) 
and activities of CEH and phosphatases were determined. The results are 
summarized in Table 13. As diown in (A), untreated control in the presence of 
ATP-Mg and cAMP caused 102% activation in CEH activity whereas activities of 
phosphatases remained unaffected. When PKA was added wifli ATP-Mg and 
cAMP to the incubation mixture, full activation (161%) of CEH was obtained, 
whereas activities of pho^hatases remained unchanged. In (B), ASF pretreated 
with okadaic acid, resulted in an inactivation of 47% in the activities of 
phosphatases with a concomitant increase of 54% in CEH activity. When ATP-Mg 
and cAMP without and with PKA was added to the incubation mixture, the level 
of CEH activation was increased to 167% and 218%, respectively. The inhibition 
(52-56%) of activities of phosphatases were similar to control. In (C), treatment of 
ASF with orthovanadate (10 mM) caused substantial (88%) inhibition of activities 
of phosphatases, with an increase of 115% in CEH activity. Addition of ATP-Mg 
and cAMP without and with PKA to the orthovanadate-treated en2yme was 
associated with increased activation of CEH to 196% and 229%, respectively. 
Inhibition of activities of phosphatases remained same (87%), similar to 
orthovanadate-treated control. When CEH fi-action was treated with pyrophosphate 
(D), an inhibition of 63% in activities of phosphatases, and an activation of 108% 
in CEH activity was obtained. Addition of ATP-Mg and cAMP without and with 
PKA to the pyrophosphate-treated samples caused an activation of 221% and 
226%, respectively. The level of inactivation (65-67%) in phosphatases were 
similar to pyrophosphate-treated control (Table 13). These results demonstrate that 
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TABLE 13 
ACTIVATION OF PARTIALLY PURIFIED CYTOSOLIC CEH BY cAMP-
DEPENDENT PROTEIN KINASE IN OKADAIC ACID, ORTHOVANADATE 
AND PYROPHOSPHATE-TREATED 0-40% ASF 
Treatments 
A. None 
B. Okadaic acid 
(0.2 nM) 
Additions Enzyme activity 
(units/ms) 
CEH 
None 2.76 ± 0.06 
ATP-Mg,2mM+ 5.58 ±0.31 
cAMP.O.lpM 
ATP-Mg, 2 mM + 7.21 ± 0.44 
cAMP, 0.1 |iM + 
PKA, 100 i^g 
None 4.26 ±0.15 
ATP-Mg, 2 mM+ 7.38 ±0.38 
cAMP,0.1nM 
ATP-Mg, 2 mM+ 8.77 ±0.52 
cAMP,0.1 |iM + 
PKA, 100 |ig 
C. Orthovanadate None 5.94 ± 0.25 
(10 mM) ATP-Mg, 2 mM+ 8.16 ±0.38 
cAMP, O.luM 
ATP-Mg, 2 mM+ 9.08 ±0.55 
cAMP, 0.1 l^M + 
PKA, 100 ng 
D. Pyrophosphate None 5.76 ± 0.24 
(50 mM) ATP-Mg, 2 mM+ 8.86 ±0.50 
cAMP, 0.1}iM 
ATP-Mg, 2 mM+ 9.00 ±0.48 
cAMP, 0.1 ^M + 
PKA, 100 [ig 
Ptases 
12.00 ±0.29 
11.96 ±0.33 
12.00 ±0.35 
6.30 ±0.25 
5.70 ±0.20 
5.30 ±0.27 
1.38 ±0.08 
1.56±0.12 
1.41 ±0.15 
4.41 ±0.20 
3.95 ±0.24 
4.18 ±0.27 
Relative changes 
( % COI 
CEH 
100 
202* 
261* 
154* 
267* 
318* 
215* 
296* 
329* 
208* 
321* 
326* 
itroH . 
Ptases 
-
3 
47* 
52* 
56* 
88* 
87* 
88* 
63* 
67* 
65* 
4 tubes containing 2.52 mg protein of 0-40% ASF of cytosol were preincubated in 
absence or presence of okadaic acid (0.2 nM), orthovanadate (10 mM), and pyrophos-
phate (50 mM), respectively for 20 min at 37 °C in a total volume of 5 ml. Aliquots of 
1.627 ml from each tube containing 820 ^g protein was preincubated with ATP-Mg-
cAMP with and without PKA for 20 min at 37 °C in a reaction volume of 2 ml. Finally, 
aliquots of 244 \i] and 50 |il were assayed for activities of CEH and phosphatases, 
respectively. Each value represents the mean ± S.D of triplicate determinations. 
Significantly different from respective controls at ^p<0.001. 
in complete system, full activation of CEH is achieved, which is mediated by 
PKA. This activation was further enhanced, when endogenous phosphatases were 
inactivated by inhibitors. 
3.2.3. Reversibility of the changes induced by phosphorylation of partially 
purified CEH in 0^0% ASF 
The existence of an activation/deactivation (phosphorylation/dephospho-
lylation) cycle for CEH was investigated in 0-40% ASF by utilizing cAMP-
dependent protein kinase/cAMP/ATP-Mg as activators, and the alkaline 
phosphatase from bovine intestinal mucosa as an inactivator. In another series, 
enzyme fractions were first pretreated with specific and nonspecific 
phosphoprotein phosphatase inhibitors, okadaic acid (0.2 nM), pyrophosphate 
(50 mM) and orthovanadate (10 mM) followed by treatments with activators alone 
or first with activators and then inactivator. As shown in Table 14, alkaline 
phosphatase (3 units) treatment in B, caused an inhibition of CEH activity by 85% 
when compared to untreated control value in A. Addition of ATP/Mg/'cAMP/PKA 
in C caused a CEH activation of 123% in comparison to untreated control (A). In 
D, activated enzyme as in C (123%) was treated with phosphatase which 
completely counteracted the increase in CEH and caused a deactivation of 84%. 
Similar results were obtained for the enzyme fractions treated with phosphatase 
inhibitors, okadaic acid (E), pyrophosphate (G) and orthovanadate (I), except 
PKA-mediated CEH activation (phosphorylation) levels were higher, 130%, 149% 
and 141%, respectively, than shown in C. In F, H, and J series, treatment of 
activated CEH with phosphatase was associated with deactivation (dephospho-
rylation), reducing CEH activity by 83%, 79% and 77%, respectively, which is 
lower than control CEH activity as shown in A (Table 14). These results 
demonstrate that partially purified CEH activity can be modulated in vitro by acti-
vation/deactivation cycle involving phosphorylation/dephosphorylation reactions. 
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TABLE 14 
IN VITRO MODULATION OF ENZYMATIC ACTIYTTY OF PARTIALLY 
PURIFIED CYTOSOLIC CEH INVOLVING ACTIVATION 
(PHOSPHORYLATION) AND INACTIVATION (DEPHOSPHORYLATION) 
Additions CEH activity Relative-
Preincubation I Preincubation H Preincubation HI (units/mg) changes (%) 
1.98 ±0.28 
Phosphatase 0.30 ± 0.04 
ATP/Mg/cAMP/PK - 4.42 ± 0.44 
ATP/Mg/cAMP/PK Phosphatase 0.71 ± 0.10 
ATP/Mg/cAMP/PK - 4.56 ± 0.38 
ATP/Mg/cAMP/PK Phosphatase 0.78 ±0.09 
G. Pyrophosphate ATP/Mg/cAMP/PK - 4.92 ±0.38 
H. Pyrophosphate ATP/Mg/cAMP/PK Phosphatase 1.04 ±0.10 
L Orthovanadate ATP/Mg/cAMP/PK - 4.78 ±0.42 
J. Orhovanadate ATP/Mg/cAMP/PK Phosphatase 1.10 ±0.08 
A. 
B. 
C. 
D. 
E. Okadaic acid 
F. Okadaic acid 
BVsA{-S5)^ 
CVsAi+\23f 
DVsC (-84)* 
EVsA(:^nof 
FVsE{-%3f 
GVsA{+U%f 
HVsG (-79)* 
/F5^(+141)* 
JVsIi-llf 
10 mg protein of 0-40% ASF was preincubated at 37 °C for 20 min in four separate tubes 
in a total volume of 5 ml, with no ligand, okdaic acid (0.2 nM), pyrophosphate (50 mM), 
and ortho vanadate (10 mM) respectively. At the end of preincubation I, aliquots of 
(3.74 mg) from each tube were preincubated at 37 "C for 20 min with or without ATP-Mg 
(2 mM), cAMP (100 \M) and PKA (50 ng) in a reaction volume of 3.22 ml. The molarity 
of phosphatasse inhibitors were maintained as indicated in preincubation I. At the end of 
preincubation II, 20 mM EDTA was added and samples were desalted on a sephadex G 15 
column. Aliquots from desalted samples (174 |il, 100 |ig protein) were preincubated for 
20 min at 37 °C with (3 units) or without alkaline phosphatase and CEH activity was 
determined. Each value represents the mean ± S.D. of triplicate determinations. 
Significantly different from respective controls at ^p<0.001. 
3J. IN VIVO REGULATION OF PHOSPHORYLATION (ACTIVA-
TION) AND DEPHOSPHORYLATION (INACTIVATION) OF RAT 
LIVER CYTOSOLIC CEH UNDER DIFFERENT PHYSIOLO-
GICAL PERTURBATIONS IN RATS 
3.3.1. Short-ierm regulation of enzymatic activity of cytosoUc CEH in rats 
treated with cAMP 
Based on in vitro results related to cAMP-dependent protein kinase-
mediated activation (phosphorylation) of cytosolic CEH, short-term (15 min) and 
long-term (2 h) effect of cAMP administration on tiie activity of CEH was 
investigated. As shown in Table 15, 15 min after the injection of cAMP 
(300 ng/rat) to rats, a significant increase of 27% was achieved in the basal CEH 
activity in comparison to values from untreated control rats. 120 min after the 
administration of cAMP, the activation effect on CEH was reversed. To evaluate 
the contribution of protein phosphorylation to the observed changes in hepatic 
CEH activity in the cAMP-treated rats, the enzyme activity was assayed in the 
presence of cofactors for endogenous cAMP-dependent protein kinase including 
exogenous PKA and phosphatase inhibitor, pyrophosphate (PP). Activators of 
endogenous PKA increased CEH activity in the presence of PP in control and 
cAMP-treated groups. The maximum activation was obtained in complete system 
containing exogenous PKA, cAMP, ATP-Mg and PP (Table 15). In comparison to 
untreated control, the magnitude of CEH activation in 15 min cAMP-treated rats 
was significantly (27-32%) higher in each category, assayed in the presence of 
different combinations of cofactors. After 120 min of cAMP treatment to rats (C), 
both in vivo and in vitro activation levels of CEH, mediated by PKA, were similar 
to control values as shown in (A) (Table 15). As depicted in Fig. 3.16, treatment 
with increasing concentration of alkaline phosphatase decreased CEH activity in a 
dose-dependent manner. However, the initial rate of CEH dephosphorylation from 
15 min cAMP-treated rats was significantly higher than CEH from control rats, 
and at one unit of alkaline phosphatase the level of CEH inactivation in both the 
groups were similar, indicating a complete reversal of CEH activation (Fig. 3.16). 
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TABLE 15 
J7V VIVO MODULATION OF PHOSPHORYLATION (ACTIVATION) AND 
DEPHOSPHORYLATION (BSACTIVATION) OF CEH IN cAMP-TREATED 
RATS 
Group Additions CEH activity Activation 
(units/mg) (% of control) 
A. Control None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOOng) + cAMP (lOOuM) + 
PP(50mM) 
PK (lOOng) + cAMP (lOO^M) + 
ATP-Mg (2mM) + PP (50mM) 
B. cAMP, IS min None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOO i^g) + cAMP (lOOpM) + 
PP (50mM) 
PK (lOOng) + cAMP (lOOuM) + 
ATP-Mg (2mM) + PP (50mM) 
C. cAMP, 120 min None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOOng) + cAMP (lOOuM) + 
PP (50mM) 
PK (lOO^g) + cAMP (lOO^M) + 
ATP-Mg (2mM) + PP (50mM) 
2.46 ± 0.07 
4.50 ±0.18 
4.74 ± 0.20 
6.18 ±0.39 
3.12±0.12 
5.94 ± 0.40 
6.06 ± 0.38 
8.10 ±0.45 
2.52 ±0.10 
4.60 ±0.21 
4.74 ± 0.26 
6.24 ±0.37 
100 (100) 
183*(100) 
193*(100) 
251H100) 
7.14 ±0.45 290* (100) 
100 (127)* 
190*(132)^ 
194*(128)^ 
260*(131)^ 
9.36 ±0.54 300* (131)^ 
100 (102) 
183*(102) 
188*(100) 
248*(101) 
7.20 ±0.48 286* (101) 
100 jig protein of 0-40% ASF of cytosol was preincubated without and with indicated 
cofactors for 20 min at 37 °C and CEH activity was determined. Each value represents the 
mean ± S.D. of triplicate determinations. The values given in parenthesis are % change 
relative to A. 
SigniJBcantly different from respective controls at ^p<0.001 and V<0 01. 
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Fig. 3.16 CONCENTRATION-DEPENDENT DEPHOS-
PHORYLATION (INACTIVATION) OF CEH FROM RATS 
TREATED WITH cAMP. 100 ^g protein of 0-40% ASF 
of cytosol from control (—•—), 15 min cAMP-treated, 
(—•- ) and 120 min cAMP-treated (—A—) rats were 
preincubated for 20 min at 37 oC with increasing 
amounts of bovine intestinal mucosa alkaline phos-
phatase prior to CEH assay. Assays were done in 
triplicate. The mean ± S.D. averaged 8.5%, 8.7%, 
and 7.9% for control, 15 min cAMP-treated and 120 
min cAMP-treated rats, respectively. 
In 120 min cAMP-treated rats, due to lack of/« vivo phosphorylation (activation) 
of CEH, the rate and magnitude of in vitro dephosphorylation and inactivation was 
almost identical to CEH fi-om untreated control rats (Fig. 3.16). The level of 
in vitro activation of endogenous ATP-Mg-dependent phosphatase at high levels of 
ATP-Mg in the three groups (A, B and C) were almost identical. In addition, due 
to lack of phosphatase activation, the activated levels of CEH in 15 min cAMP-
treated rats were maintained (Table 16). The combined results represent the initial 
demonstration of an in vivo cAMP-dependent protein kinase-mediated activation 
(phosphorylation) of cytosolic CEH in cAMP-treated rats, which apparently 
activated tiie endogenous PKA. The magnitude of in vitro alkaline phosphatase-
mediated dephosphorylation (inactivation) of in vivo modified (activated) CEH 
was consistent with the in vitro data suggesting that the level of phosphorylation 
may play an important role in the regulation of CEH activity in vivo. These results 
also demonstrate that after 2 h of cAMP administration, the short-term effect of 
PKA-mediated activation of CEH was reversed. 
3.3.2. Regulation by mevalonolacione (MVL) 
Mevalonate is synthesized in Uver from HMG-CoA by the action of rate 
controlling enzyme, HMG-CoA reductase (Fig. 1.1). It has been previously 
established tiiat administration of mevalonolactone to rats was associated with the 
inhibition of HMG-CoA reductase activity involving both short-term (reversible 
phosphorylation) and long-term (changes in protein synthesis and/or degradation) 
control. Based on these reports, impact of MVL on liver cytosolic CEH activity 
after 30 min and 4 h of administration to rats was investigated. As seen in Table 
17, 30 min after the administration of a single dose (100 mg/rat) of MVL caused 
no efifect on basal CEH activity in comparison to untreated control (A). However, 
4 h after tiie administration of MVL, basal CEH activity was significantly 
enhanced by 21% (C). In vitro activation of CEH by the addition of different 
combination of phosphorylating agents, including exogenous PKA and 
phosphatase inhibitor, PP, revealed that in 4 h MVL-treated rats (C) the levels of 
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TABLE 16 
REGULATION OF ENZYMATIC ACnVITIES OF CEH AND PHOSPHATASES 
(Ptases) FROM cAMP-TREATED RATS 
Group ATP-Mg 
(mM) 
Enzyme activity 
(units/mg) 
CEH Ptases 
Relative changes 
r% of control) 
CEH Ptases 
A. Control 
3 
4 
5 
B. cAMP, 15 min -
3 
4 
5 
C. cAMP, 120 min 
3 
4 
5 
2.88 ±0.110 
2.58 ±0.130 
1.68 ±0.100 
0.42 ± 0.030 
3.60 ±0.170 
3.42 ±0.150 
2.04 ±0.110 
0.36 ± 0.050 
3.00 ±0.100 
2.76 ±0.190 
1.68 ±0.190 
0.36 ± 0.030 
6.50 ±0.17 
10.20 ±0.39 
11.55 ±0.45 
12.56 ±0.65 
6.75 ±0.12 
10.80 ±0.22 
11.86 ±0.55 
13.30 ±0.72 
6.16±0.11 
9.11 ±0.45 
10.90 ±0.52 
11.98 ±0.75 
100 (100) 
90^100) 
58*(100) 
15^(100) 
100 (104) 
92 (107) 
56*(100) 
12*(86)' 
100 
157* 
178* 
193* 
100 (125)^ 100 
95 (133)* 160* 
57* (121)^ 176* 
10* (86) 197* 
100 
148* 
177* 
195* 
100 ng protein of 0-40% ASF of cytosol for CEH activity and 50 ^g protein of 0-40% 
ASF of cytosol for Ptases activities, were preincubated without and with increasing 
concentration of ATP-Mg for 20 min at 37 "C followed by assay of CEH and Ptases 
activities. Each value represents the mean ± S.D. of triplicate determinations. The values 
given in parenthesis are % change relative to A. 
Significantly different fi-om respective controls at *p<0.001, V<0.01 and V<0.05. 
TABLE 17 
IN VIVO MODULATION OF PHOSPHORYLATION (ACTIVATION) AND 
DEPHOSPHORYLATION (BSACTIVATION) OF CEH BY 
MEVALONOLACTONE 
Group 
A. Control 
B. Mevalono-
lactone, 0.5 h 
C. MevaJono-
lactone, 4 h 
Additions 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOO^g) + cAMP (lOOuM) + 
PP (50mM) 
PK (lOOng) + cAMP (lOOuM) + 
ATP-Mg (2mM) + PP (50mM) 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOOng) + cAMP (lOOpM) + 
PP(50mM) 
PK (lOO^g) + cAMP (lOO^iM) + 
ATP-Mg (2mM) + PP (50mM) 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOO i^g) + cAMP (lOOuM) + 
PP(50niM) 
PK (lOOng) + cAMP (lOO i^M) + 
ATP-Mg (2niM) + PP (50mM) 
CEH activity 
(units/mg) 
2.52 ±0.05 
4.44 ± 0.22 
4.86 ±0.25 
6.78 ± 0.48 
7.20 ± 0.40 
2.46 ± 0.09 
4.44 ±0.36 
4.68 ± 0.27 
6.60 ±0.36 
7.08 ±0.55 
3.06 ±0.11 
5.94 ± 0.40 
6.12 ±0.29 
8.46 ±0.34 
9.18 ±0.62 
Activation 
(% of control) 
100 (100) 
176* (100) 
193^(100) 
269*(100) 
286*(100) 
100 (98) 
180*(100) 
190* (96) 
268* (97) 
288* (98) 
100 (121)* 
194* (134^ 
200* (126)^ 
276* (125)^ 
300* (128)^ 
100 \ig protein of 0-40% ASF of cytosol was preincubated without and with indicated 
cofactors for 20 min at 37 °C and CEH activity was determined. Each value represents the 
mean ± S.D. of triplicate determinations. The values given in parenthesis are % change 
relative to A. 
Significantly different fi-om respective controls at ^p<0.001 and V<0.01. 
CEH activation were higher than values in control (A). After 30 min feeding of 
MVL (B) no difference in magnitude of CEH activation was seen in comparison to 
control values (A). These results indicate that after 4 h administration of MVL, the 
basal CEH activity was increased partially due to in vivo phosphorylation. 
Treatment of CEH witii alkaline phosphatase confirmed this observation 
(Fig. 3.17). At one unit of alkaline phosphatase-mediated dephosphoiylation, the 
inhibition levels of CEH activity of control (A) and 4 h MVL-treated rats (C) were 
close. These results indicate a partial and significant reversal of initial increased 
activation (phosphorylation) of CEH in 4 h MVL-treated rats (C). The dephospho-
rylation and inactivation profile of CEH from 30 min MVL-treated rats (B) was 
substantiaUy similar to control rats (A) (Fig. 3.17). No significant difference in the 
activation levels of ATP-Mg-dependent phosphatase and subsequent inactivation 
of basal CEH activities in the presence of high ATP-Mg levels were seen in 
control (A) and 30 min MVL-treated rats (B). However, in 4 h MVL-treated rats, 
ATP-Mg-dependent phosphatase-mediated dephosphorylation of CEH at 3 and 
4 mM ATP-Mg was considerably lower than control values in A. (Table 18). The 
combined results demonstrate that 4 h feeding of MVL to rats triggered an increase 
in CEH activity, which was substantially due to phosphorylation. The in vitro 
dephosphorylation data was consistent with this observation. 
3.3.3. Regulation of enzymatic activity of cytosolic CEH in rats fed 
cholestyramine, lovastatin and cholestyramine plus lovastatin for one 
week 
It is well known that feeding of cholestyramine binds to bile acids and 
prevents their absorption in small intestine. Elimination of resin-bound cholesterol 
in tiie faeces forces the liver to convert more cholesterol to bile acids than normal. 
The consequent decrease in the serum cholesterol concentration induces synthesis 
of LDL receptors and HMG-CoA reductase, the later increase the rate of 
cholesterol biosynthesis. Lovastatin (mevinolin) has been shown to be a potent 
anticholesterol drug in hyperUpidemic patients. Lovastatin exerts its hypoUpidemic 
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Fig. 3.17 CONCENTRATION-DEPENDENT DEPHOS-
PHORYLATION (INACTIVATION) OF CEH FROM RATS 
AFTER THE ADMINISTRATION OF A SINGLE DOSE OF 
MEVALONOLACTONE. 100 ^g protein of 0-40% ASF 
of cytosol from control ( • ), 0.5 h MVL-treated ( o~), 
4 h MVL-treated (—°—) rats were preincubated for 20 min 
at 37 oC with increasing amounts of bovine intestinal 
mucosa alkaline phosphatase prior to CEH assay. 
Assays were done in triplicate. The mean ± S.D. averaged 
7%, 6.9% and 7.6% for control, 0.5 h MVL-treated'and 4 h 
MVL-treated groups, respectively. 
TABLE 18 
REGULATION OF ENZYMATIC ACnVITIES OF CEH AND PHOSPHATASES 
(Ptases) FROM RATS AFTER THE ADMINISTRATION OF A SINGLE DOSE 
OF MEVALONOLACTONE 
Group i 
A. Control 
B. Mevalono-
lactone, 0.5 h 
C. Mevalono-
lactone, 4 h 
^TP-Mg 
(mM) 
3 
4 
5 
3 
4 
5 
3 
4 
5 
Enzyme activity 
(units/me) 
CEH Ptases 
2.82 ±0.130 
2.58 ±0.160 
1.44 ±0.080 
0.42 ± 0.068 
2.70 ±0.110 
2.52 ±0.210 
1.50±0.130 
0.30 ±0.039 
3.84 ±0.130 
3.60 ±0.260 
1.76 ±0.130 
0.40 ± 0.060 
7.00 ±0.21 
10.84 ±0.42 
12.22 ±0.53 
13.60 ±0.82 
6.25 ±0.13 
9.30 ± 0.40 
10.87 ±0.57 
11.92 ±0.67 
7.70 ±0.22 
11.73 ±0.38 
13.09 ±0.59 
15.40 ±0.86 
Relative changes 
r% of control) 
CEH Ptases 
100 (100) 100 
91 (100) 155* 
51*(100) 175* 
15* (100) 195* 
100 (96) 100 
93 (98) 149* 
56* (104) 174* 
11* (71)^ 190* 
100 (136)* 100 
94 (140)^ 152* 
46*(122)' 170* 
10* (95) 200* 
100 ng protein of 0-40% ASF of cytosol for CEH activity and 50 \\.% protein of 0-40% 
ASF of cytosol for PNP-phosphatse sensitive Ptases activities, were preincubated without 
and with increasing concentration of ATP-Mg for 20 min at 37 °C followed by assay of 
CEH and Ptases activities. Each value represents the mean ± S.D. of triplicate 
determinations. The values given in parenthesis are % change relative to A. 
Significantly different from respective controls at ^p<0.00l/p<0.01 and V<0 05. 
action by competitively inhibiting the activity of HMG-CoA reductase- the rate 
limiting enzyme in the biosynthetic pathway of cholesterol. Based on these 
reports, we investigated their role in the short-term regulation of cytosolic CEH. 
One week feeding of cholestyramine (300 mg/rat/day) to rats (B) was 
associated with a significant increase of 28% in the CEH activity in comparison to 
control value (A) (Table 19). Assay of CEH activity in the presence of cofactors 
for PKA including phosphatase inhibitor, PP, revealed that CEH activation in vitro 
was consistently higher, by approximately 30%, in cholestyramine fed rats when 
compared to activated levels of CEH from untreated control rats. The maximally 
dephosphoiylated level of CEH in cholestyramine-treated rats was close to but not 
identical to control values, suggesting dephosphorylation (inactivation) of partially 
activated CEH enzyme (Fig. 3.18). Assay of PNP-sensitive phosphatases activities 
revealed a 20% decline in cholestyramine-fed rats (B) when compared to control 
rats in A. (Table 20). Activation of phosphatases by high levels of ATP-Mg caused 
increase in activities, which were consistently lower by approximately 20% in 
cholestyramine-fed rats (B) than corresponding control values in A. In addition, 
due to lower activation level of phosphatases at 3 and 4 mM ATP-Mg, in 
cholestyramine-fed rats (B), the inactivation levels of CEH was significantly lower 
in comparison to corresponding control values in A (Table 20). These results 
demonstrate that cholestyramine feeding to rats for one week caused 28-33% 
activation of CEH, substantial part of which was due to in vivo phosphorylation. 
In vitro dephosphorylation of CEH was consistent with this observation. The 
combined results indicate that cholestyramine feeding to rats triggers both PKA-
mediated phosphorylation and activation of CEH, and inactivation of phospha-
tases, thus reducing the dephosphorylation (inactivation) of CEH and favouring an 
overall activation status of CEH, (Table 19 and 20). 
Feeding of lovastatin (7.5 mg/rat/day) to rats for one week resulted in an 
increase of 86% in the activity of cytosolic CEH, assayed in 0-40% ASF 
(Table 19). Addition of cofactors for PKA along with exogenous PKA and 
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TABLE 19 
REGULATION OF CEH PHOSPHORYLATION (ACTIVATION) AND 
DEPHOSPHORYLATION (INACTIVATION) IN RATS TREATED WITH 
CHOLESTYRAMINE, LOVASTATDS, AND CHOLESTYRAMINE PLUS 
LOVASTATIN FOR ONE WEEK 
Group 
A. Control 
B. Cholestyramine-
treated 
C. Lovastatin-
treated 
D. Cholestyramine 
Lovastatin-treated 
Additions 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOO^g) + cAMP (100^lM) + 
PP(50mM) 
PK (lOOng) + cAMP (100^lM) + 
ATP-Mg (2mM) + PP (50mM) 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOOng) + cAMP (100^lM) + 
PP (50mM) 
PK (100^lg) + cAMP (lOO^M) + 
ATP-Mg (2mM) + PP (50mM) 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOOng) + cAMP (lOO i^M) + 
PP(50mM) 
PK (lOO i^g) + cAMP (lOO^M) + 
ATP-Mg (2mM) + PP (50mM) 
+ None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOOng) + cAMP (100^lM) + 
PP (50niM) 
PK (lOOng) + cAMP (lOO i^M) + 
ATP-Mg (2mM) + PP (50mM) 
CEH activity 
(units/mg) 
2.58 ±0.08 
4.38 ± 0.24 
4.92 ± 0.35 
6.36 ± 0.27 
7.56 ±0.48 
3.30 ±0.12 
6.24 ± 0.33 
6.42 ± 0.45 
8.46 ± 0.44 
9.90 ± 0.66 
4.80 ±0.25 
5.10 ±0.33 
5.22 ±0.38 
7.50 ±0.35 
7.62 ± 0.62 
6.48 ± 0.28 
6.36 ±0.32 
6.54 ± 0.44 
7.50 ± 0.46 
8.70 ±0.55 
Activation 
(% of control) 
100 (100) 
170* (100) 
191*000) 
247* (100) 
293*(100) 
100 (128)* 
189* (142)* 
195* (130)^ 
256* (133)* 
300*(131)^ 
100 (186)* 
106 (116)^ 
109 (106) 
156*(118)^ 
159*(101) 
100 (251)* 
98 (145)* 
101 (133)^ 
116'(118)^ 
134^(115)' 
100 ng protein of 0-40% ASF of cytosol was preincubated without and with indicated 
cofectors for 20 min at 37 °C and CEH activity was determined. Each value represents the 
mean ± S.D. of triplicate determinations. The values given in parenthesis are % change 
relative to A. Significantly different fi-om respective controls at ^p<0.001, V<0 01 and 
V0.05. 
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Fig. 3.18 CONCENTRATION-DEPENDENT DEPHOS-
PHORYLATION (INACTIVATION) OF CEH FROM RATS 
ADMINISTERED CHOLESTYRAMINE, LOVASTATIN, 
CHOLESTYRAMINE PLUS LOVASTATIN FOR ONE WEEK. 
100 i^ g protein of 0-40% ASF of cytosol from control (—•—), 
cholestyramine-treated ( • ), lovastatin-treated (—•—), and 
cholestyramine plus lovastatin-treated ( • ) rats were pre-
incubated for 20 min at 37 °C with increasing amounts of 
bovine intestinal mucosa alkaline phosphatase prior to CEH 
assay. Assays were done in triplicate. The mean ± S.D. 
averaged 6.5%, 7.7%, 7.2% and 8.5% for control, cholestyramine-
treated, lovastatin-treated and cholestyramine plus lovastatin-
treated groups, respectively. 
TABLE 20 
MODULATION OF ENZYMATIC ACnvmES OF CEH AND PHOSPHATASES 
(Puses) FROM RATS TREATED WITH CHOLESTYRAMINE, LOVASTATIN, 
AND CHOLESTYRAMINE PLUS LOVASTATIN FOR ONE WEEK 
Group 
A. Control 
ATP-Mg 
(mM) 
3 
4 
5 
B. Cholestyramine- -
treated 3 
4 
5 
C. Lovastatin-
treated 3 
4 
5 
D. Cholestyraniine+ -
Lovastatin-treated 3 
4 
5 
Enzyme activity 
(units/m2) 
CEH Ptases 
2.70 ±0.090 
2.40 ±0.120 
1.20 ±0.090 
0.48 ± 0.048 
3.60 ±0.200 
3.24 ± 0.280 
1.80 ±0.080 
0.42 ± 0.050 
5.16 ±0.270 
5.10 ±0.200 
4.38 ±0.380 
2.58 ± 0.280 
7.00 ±0.330 
7.14±0.150 
7.00 ± 0 .590 
5.22 ± 0 .460 
8.80 ±0.25 
14.16 ±0.48 
16.47 ±0.64 
17.30 ±0.89 
7.00 ±0.29 
11.00 ±0.58 
12.97 ±0.57 
14.35 ±0.68 
7.70 ±0.30 
9.64 ±0.39 
11.55 ±0.65 
12.16 ±0.54 
7.98 ±0.37 
9.17 ±0.48 
11.60 ±0.62 
12.32 ±0.75 
Relative changes 
f % of control) . 
CEH Ptases 
100 
89' 
44* 
18* 
100 
90 
50* 
12* 
100 
99 
85^ 
50* 
100 
102 
100 
75^ 
100 (100) 
161*(100) 
187* (100) 
197* (100) 
100 (80)* 
158* (78)* 
185* (79)* 
205* (83)^ 
100 (87)^ 
125^ (68)* 
150* (70)* 
158* (70)* 
100 (91)^ 
115^(65)* 
146* (70)* 
154* (71)* 
100 i^g protein of 0-40% ASF of cytosol for CEH activity and 50 [ig protein of 0-40% 
ASF of cytosol for Ptases activities, were preincubated without and with increasing 
concentration of ATP-Mg for 20 min at 37 °C followed by assay of CEH and Ptases 
activities. Each value represents the mean ± S.D. of triplicate determinations. The values 
given in parenthesis are % change relative to A. 
Significantly different fi-om respective controls at *p<0.001,^ p<0.01 and 'p<0.05. 
phosphatase inhibitor, PP, to the assay meduim caused a slight activation of CEH 
in lovastatin-fed rats (C), when compared to activation levels of CEH assayed 
under similar conditions from untreated control rats (A). These results suggest that 
phosphorylation was not involved in the activation of CEH in lovastatin-fed rats 
(Table 19). Consistent with the above results, Ae substantial activation of CEH in 
lovastatin-fed rats was minimally reversed by preincubation of 0-40% ASF with 
alkaline phosphatase. Only 35% inactivation of CEH was observed following 
incubation with 2 units of alkaline pho^hatase when compared to an inhibition of 
74% in control rats (Fig. 3.18). 
These results surest that unlike cholestyramine, feeding of lovastatin was 
minimally associated with increased phosphorylation and activation of CEH. 
Dephosphorylation of activated CEH with 0.25 and 0.5 units of alkaline 
phosphatase resulted in the inhibition of CEH activity only by 1% and 16%, 
respectively. On the other hand, same units of phosphatase caused 18% and 41% 
inhibition of activated CEH from cholestyramine-fed rats, which is comparable to 
CEH inhibition of 20% and 46% in control rats (Fig. 3.18). Basal activities of 
phosphatases in 0-40% ASF of lovastatin-fed rats (C) were 13% lower than Ae 
values of phosphatases in control A (Table 20). Treatment of CEH fraction of 
control (A) with 3 mM, 4 mM and 5 mM of ATP-Mg was associated with 
activation of phosphatases by 61%, 87% and 97%, respectively, whereas CEH 
activity was inhibited by 11%, 56% and 82% in comparison to control value 
lacking ATP-Mg (Table 20). In comparison to activation of phosphatases at 
3 mM, 4 mM and 5 mM ATP-Mg in control rats (A), the level of phosphatases 
activation in lovastatin-fed rats were approximately 30% lower (C). Consistent 
with the activation levels of ATP-Mg-dependent phosphatase in C, CEH inhibition 
levels were 1%, 15% and 50% of control value lacking ATP-Mg, which were 
significantly lower Aan CEH inhibition exhibited in control rats (A) 
(Table 20). These results indicate that low activation of phosphatase at high 
concentrations of ATP-Mg with a concomitant low inhibition of CEH activity will 
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favour the overall activation status of CEH following lovastatin feeding to rats 
(Table 20). 
Feeding of cholestyramine (300 mg/day) in combination with lovastatin 
(7.5 mg/rat/day) for one week enhanced the CEH activity by 151% (D) in 
comparison to control (A) (Table 19). A further CEH activation of only 34% was 
observed in complete system in D, whereas in control rats (A), the CEH activation 
level was 193% when all the phosphorylating agents including pyrophosphate 
were present during the assay (Table 19). After dephosphorylation, the 
reversibility in terms of inhibition of CEH activity was minimal (Fig. 3.18). No 
inhibition of CEH activity was observed at 0.25 and 0.5 units of alkaline 
phosphatase, whereas, the CEH activation was reversed only by 18% and 32% at 
1.0 and 2.0 units of phosphatase, respectively. These results suggest that very httle 
phosphoiylated species of CEH existed in rats treated witii combination of 
cholestyramine and lovastatin (D), almost all the high activation of CEH was 
independent of phosphorylation (Fig. 3.18). Treatment of cholestyramine plus 
lovastatin (D) to rats caused a decline of 9% in the phosphatase activity of 0-40% 
ASF of cytosol, when compared to basal value from control rats (A) (Table 20). 
Activation levels of phosphatases at 3 mM, 4 mM and 5 mM of ATP-Mg in 
cholestyramine plus lovastatin-fed rats (D) were comparable to activation levels in 
lovastatin-fed rats (C). CEH activity was minimally (25%) inhibited at 5 mM of 
ATP-Mg in D when compared to control rats (A) or cholestyramine-treated rats 
(B) (Table 20). These results demonstrate that counter effect of dephosphorylation 
(inactivation) mediated by phosphatases were minimized in order to maintain a 
high CEH activation level of 151-159% in rats treated with combination of 
cholestyramine and lovastatin. 
3.3.4. In vivo modulation ofernymatic activity of liver cytosoUc CEH infused 
rats 
It is well known that fasting in rats is associated with severe inhibition of 
hepatic HMG-CoA reductase activity, which is accompanied by decrease in 
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cellular cholesterol levels. Rats were fasted either for 21 h (B) or 36 h (C) and 
impact of fasting on CEH regulation was investigated. As seen in Table 21, 21 h 
and 36 h fasting of rats caused an increase of 88% and 100%, respectively, in the 
basal CEH activity in comparison to control rats (A). Maximum CEH activation of 
194% was observed in control rats when enzyme activity was assayed in the 
presence of ATP-Mg, PKA, cAMP and PP. Following in vitro activation of CEH 
in a complete system, significantly less increase in CEH activity of 65% and 64%, 
respectively, was obtained in 21 h and 36 h fasted rats, when compared to control 
rats in A (Table 21). The magnitude and rate of dephosphorylation of CEH fi-om 
fasted rats revealed little reversibility of activation, when compared to 
dephosphorylation of CEH fi-om control rats. One unit of alkaline phosphatase 
caused an inhibition of CEH activity by 70%, 25% and 21% in control, 21 h and 
36 h fasted rats, respectively (Fig. 3.19). Addition of 3 mM, 4 mM and 5 mM of 
ATP-Mg during the preincubation caused an activation of phosphatases by 50%, 
71% and 100%, respectively, with a concomitant decrease of 14%, 48% and 86%, 
respectively, in CEH activity in control rats (A). After 21 h of fasting, phosphatase 
activity was enhanced by the addition of 3 mM, 4 mM and 5 mM ATP-Mg to 
20%, 45% and 65%, respectively, whereas level of activation in 36 h fasted rats 
was 8%, 41% and 58%, respectively. The inhibition of CEH activities assayed in 
presence of high concentrations of ATP-Mg was 0%, 23% and 51% in 21 h fasted 
rats, whereas a decline of 0%, 12% and 45% was seen in 36 h fasted rats 
(Table 22). The combined results demonstrate that high level of CEH activation 
seen after fasting was not associated with phosphorylation of the enzyme. In vitro 
dephosphorylation of CEH was consistent with the observation that little or no 
phosphorylation of CEH had occured in vivo during fasting. These results are 
consistent with low degree of in vitro activation of CEH with phosphorylating 
agents. Furthermore, fasting was associated with significantly reduced in vitro 
activation of phosphatases and substantially low inhibition of CEH activities when 
compared to values firom control rats (Table 22). 
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TABLE 21 
REGULATION OF CEH PHOSPHORYLATION (ACTIVATION) AND 
DEPHOSPHORYLATION (INACTIVATION) IN FASTED RATS 
Group 
A. Control 
B. Fasted, 21 h 
C. Fasted, 36 h 
Additions 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (100^ig) + cAMP (lOO i^M) + 
PP (50mM) 
PK (lOO i^g) + cAMP (lOOuM) + 
ATP-Mg (2mM) + PP (50mM) 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOO i^g) + cAMP (lOOpM) + 
PP (50mM) 
PK (lOO^g) + cAMP (lOOuM) + 
ATP-Mg (2mM) + PP (50mM) 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (100^lg) + cAMP (lOOuM) + 
PP (50mM) 
PK (lOOng) + cAMP (lOOuM) + 
ATP-Mg (2mM) + PP (50mM) 
CEH activity 
(units/mg) 
2.88 ± 0.09 
5.04 ± 0.28 
5.34 ±0.34 
7.56 ±0.41 
8.46 ±0.58 
5.40 ± 0.20 
5.94 ±0.37 
6.00 ±0.33 
7.92 ± 0.58 
8.90 ± 0.62 
5.76 ±0.19 
6.12 ±0.29 
6.00 ± 0.25 
8.22 ± 0.43 
9.42 ± 0.40 
Activation 
(% of control) 
100 (100) 
175*(100) 
185^(100) 
263*(100) 
294*(100) 
100 (188)* 
110 (118)' 
111^(112)' 
147* (105) 
165*(105) 
100 (200)* 
106 (121)^ 
104 (112)' 
143*(109) 
164* (111)' 
100 ng protein of 0-40% ASF of cytosol was preincubated without and with indicated 
cofactors for 20 min at 37 °C and CEH activity was determined. Each value represents the 
mean ± S.D. of triplicate determinations. The values given in parenthesis are % change 
relative to A. 
Significantly different fi-om respective controls at *p<0.001, V<0.01 and V<0.05. 
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Fig. 3.19 CONCENTRATION-DEPENDENT DEPHOSPHO-
RYLATION (INACTIVATION) OF CEH IN FASTED RATS. 
100 i^ g protein of 0-40% ASF of cytosol from control ( •—), 
21 h fasted (—•—) and 36 h fasted (—*—) rats were pre-
incubated for 20 min at 37 oC with increasing amounts of 
bovine intestinal mucosa alkaline phosphatase prior to 
CEH assay. Assays were done in triplicate. The mean ± 
S.D. averaged 6%, 6.4%, and 7.5% for control, 21 h 
fasted and 36 h fasted rats, respectively. 
TABLE 22 
IN VIVO MODULATION OF ENZYMATIC ACTIYITIES OF CEH AND 
PHOSPHATASES (Ptases) IN FASTED RATS 
Group 
A. Control 
B. Fasted, 21 h 
C. Fasted, 36 h 
ATP-Mg 
(mM) 
3 
4 
5 
-
3 
4 
5 
-
3 
4 
5 
Enzyme activity 
(unit 
CEH 
3.00 ±0.08 
2.58 ±0.13 
1.56±0.11 
0.42 ±0.04 
5.88 ±0.17 
5.88 ±0.18 
4.50 ±0.26 
2.88 ± 0.25 
6.18 ±0.22 
6.42 ± 0.32 
5.46 ±0.35 
3.42 ±0.18 
ts/me) 
Ptases 
8.00 ±0.16 
12.00 ± 0.48 
13.70 ±0.59 
16.00 ± 0.73 
7.50 ±0.20 
8.99 ± 0.35 
10.90 ± 0.63 
12.38 ± 0.74 
7.82 ± 0.27 
8.43 ± 0.40 
11.00 ±0.44 
12.32 ±0.62 
Relative changes 
(%< 
CEH 
100 
86^ 
52* 
14* 
100 
100 
77* 
49* 
100 
104 
88' 
55* 
9f control) 
Ptases 
100 
150* 
171* 
200* 
100 
120^ 
145* 
165* 
100 
108 
141* 
158* 
100 ng protein of 0-40% ASF of cytosol for CEH activity and 50 ng protein of 0-40% 
ASF of cytosol for Ptases activities, were preincubated without and with increasing 
concentration of ATP-Mg for 20 min at 37 °C followed by assay of CEH and Ptases 
activities. Each value represents the mean ± S.D. of triplicate determinations. 
Significantly different fi-om respective controls at *p<0.001, ^ pO.Ol and V<0.05. 
3.3.5. Effect of orthovanadaie administration on CEH activity in normal and 
diabetic rats 
Ortitiovanadate has been shown to influence certain in vivo kinase/ 
phosphatase systems in rats, hi many cases, sodium oithovanadate has been 
observed to alleviate Ae effects of diabetes both in vivo and in vitro (Pugazhenfhi 
and Khandelwal, 1990; King et al, 1993; Ramasanna, 1996). In addition, we have 
demonstrated that 5 mM and 10 mM of oithovanadate inhibited the activities of 
cytosoUc phosphoprotein phosphatases which in turn caused an increase in CEH 
activity (Table 12). Based on the above information the in vivo impact of 
orthovanadate on CEH activity in normal and diabetic rats was investigated. As 
seen in Table 23, no significant effect of 4 week orthovanadate administration on 
CEH activity was seen. Streptozotocin-induced diabetes in rats failed to tri^er 
any change in CEH activity. Furthermore, diabetic rats treated wifli orthovanadate 
did not influence the activation/inactivation system of cytosohc CEH (Table 24). 
Addition of cofactors known to promote in vitro activation (phosphorylation) of 
CEH failed to diow any significant difference in the CEH activation levels of 
orthovanadate-treated rats (B and D) in comparison to corresponding controls 
(A and C, Table 23). 
Some difference in the magnitude and rate of dephosphoiylation and 
inhibition of cytosoUc CEH activity in vanadate-treated rats was observed in 
comparison to normal rats, but it was not significant (Fig. 3.20). Addition of high 
levels of ATP-Mg (3-5 mM) during the preincubation caused an activation of 
phosphatases and a concomitant inhibition of basal activity of CEH in all groups 
(A-D), but the difference in treated versus untreated control was insignificant 
(Table 24). The combined results indicate that 4-week administration of 
orthovanadate to normal and diabetic rats failed to modulate the enzymatic activity 
of CEH. 
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TABLE 24 
REGULATION OF ENZYMATIC ACTIYITIES OF GEH AND PHOSPHATASES 
(Ptases) IN NORMAL AND DIABETIC RATS TREATED WITH 
ORTHOVANADAE FOR FOUR WEEKS 
Group ATP-Mg 
(mM) 
A. Control 
3 
4 
5 
B. Orthovanadate- -
treated 3 
4 
5 
C. Diabetic control 
3 
4 
5 
D. Diabetic, treated -
with orthovanadate 3 
4 
5 
Enzyme: activity 
(units/me) 
CEH 
2.52 ±0.04 
2.22 ± 0.08 
1.26 ±0.08 
0.36 ± 0.04 
2.40 ±0.10 
2.16±0.11 
1.26 ± 0 09 
0.24 ± 0.02 
2.52 ±0.09 
2.28 ± 0.08 
1.32 ±0.10 
0.30 ±0.03 
2.46 ±0.10 
2.28 ±0.16 
1.38±0.10 
0.24 ± 0.05 
Ptases 
7.51 ±0.25 
11.85 ±0.32 
12.84 ±0.43 
14.78 ±0.63 
7.80 ±0.18 
11.88 ±0.51 
13.89 ±0.53 
15.12 ±0.77 
8.50 ±0.24 
13.18 ±0.34 
14.84 ± 0.48 
17.00 ±0.67 
8.25 ± 0 .29 
12.41 ±0.46 
14.63 ±0.51 
15.70 ±0.75 
Relative changes 
(% of 
CEH 
100 
88^ 
50* 
14* 
100 
90^ 
53* 
10* 
100 
90' 
52* 
12* 
100 
93 
56* 
10* 
control) 
Ptases 
100 
158* 
171* 
197* 
100 
152* 
178* 
194* 
100 
155* 
175* 
200* 
100 
150* 
177* 
190* 
100 ng protein of 0-40% ASF of cytosol for CEH activity and 50 ng protein of 0-40% 
ASF of cytosol for Ptases activities, were preincubated without and with increasing 
concentration of ATP-Mg for 20 min at 37 °C followed by assay of CEH and Ptases 
activities. Each value represents the mean ± S.D. of triplicate determinations. 
Significantly different fi-om respective controls at ^p<0.00l/p<0.01 and ^p<0.05. 
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Fig. 3.20 CONCENTRATION-DEPENDENT DEPHOSPHO-
RYLATION (INACTIVATION) OF CEH FROM NORMAL 
AND DIABETIC RATS TRATED WITH ORTHOVANADATE 
FOR FOUR WEEKS. 100 i^ g protein of 0-40% ASF of cytosol 
from control (—•—), vanadate-treated (—•—), diabetic control 
(—A- )^  and diabetic rats treated with vanadate( v ) were 
preincubated for 20 min at 37 °C with increasing amounts of 
bovine intestinal mucosa alkaline phosphatase prior to CEH 
assay. Assays were done in triplicate. The mean ± S.D. 
averaged 6.9%, 6.3%, 7.2% and 8% for control, vanadate-
treated, diabetic control and diabetic-treated with vanadate, 
respectively. 
TABLE 23 
IN VIVO MODULATION OF CEH PHOSPHORYLATION (ACTIVATION) AND 
DEPHOSPHORYLATION (INACTIVATION) IN NORMAL AND DIABEIC 
RATS TREATED WITH ORTHO VANADATE FOR FOUR WEEKS 
Group 
A. Control 
B. Orthovanadate-
treated 
C. Diabetic control 
D. Diabetic, treated 
with orthovanadate 
Additions 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOOng) + cAMP (lOO i^M) + 
PP(50mM) 
PK (lOOjig) + cAMP (lOOuM) + 
ATP-Mg (2mM) + PP (SOmM) 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (100^lg) + cAMP (lOOuM) + 
PP(50mM) 
PK (lOO i^g) + cAMP (lOOuM) + 
ATP-Mg (2mM) + PP (50mM) 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOO^g) + cAMP (100^lM) + 
PP (50mM) 
PK (lOOng) + cAMP (lOOuM) + 
ATP-Mg (2mM) + PP (50mM) 
None 
EDTA (10 mM) + PP (50 mM) 
ATP-Mg (2 mM) + PP (50 mM) 
PK (lOO i^g) + cAMP (lOOuM) + 
PP (50mM) 
PK (lOOng) + cAMP (lOOuM) + 
ATP-Mg (2mM) + PP (SOmM) 
CEH activity 
(units/mg) 
1.52 ±0.07 
2.72 ±0.16 
2.84 ±0.12 
3.76 ±0.25 
4.20 ±0.30 
1.48 ±0.05 
2.68 ±0.12 
2.76 ±0.18 
3.56 ±0.22 
4.24 ± 0.28 
1.56 ±0.06 
2.76 ±0.15 
2.96 ±0.21 
3.72 ±0.30 
4.28 ±0.33 
1.48 ±0.07 
2.76 ±0.11 
2.84 ±0.19 
3.76 ±0.21 
4.28 ± 0.28 
Activation 
(% of control) 
100 (100) 
180* (100) 
187*(100) 
247* (100) 
276*(100) 
100 (97) 
181* (99) 
186* (97) 
241* (95) 
286*(101) 
100 (103) 
177* (101) 
190*(104) 
238* (99) 
274*(102) 
100 (97) 
186*(101) 
192*(100) 
254*(100) 
289*(102) 
100 ng protein of 0-40% ASF of cytosol was preincubated without and with indicated 
cofactors for 20 min at 37 °C and CEH activity was determined. Each value represents the 
mean ± S.D. of triplicate determinations. The values given in parenthesis are % change 
relative to A. 
Significantly different fi-om respective controls at *p<0.001. 
discussion 
The results presented in the thesis provide sufficient evidence that rat liver 
cytosolic cholesteryl ester hydrolase (CEH) might belong to the group of 
interconvertible enzymes, whose activities are controlled by phosphorylation and 
dephosphorylation. In particular, we provide detailed evidence that in vitro 
conditions favouring phosphorylation in cytosolic and partially purified (0-40% 
ASF of cytosol) fi-action enhance the rate of cholesteryl ester hydrolysis, whereas, 
marked decreases in CEH are correlated with tiiie presence of phosphatase activity. 
Liver cytosol is known to contain cAMP-dependent protein kinase and 
phosphoprotein phosphatases (Kuo and Greengard, 1969; Cohen, 1989). Our 
findings are consistent with the view that when cytosolic or exogenous cAMP-
dependent protein kinase cascade is triggered, CEH activity is enhanced due to 
increased phosphorylation. CEH activity in cytosol and 0-40% ASF of cytosol was 
increased to 137% and 108% by tiie addition of ATP-Mg and cAMP indicating the 
involvement of endogenous cAMP-dependent protein kinase. Addition of bovine 
heart cAMP-dependent protein kinase along with ATP-Mg and cAMP to cytosol 
and partially purified fi-action (0-40% ASF) of CEH was associated with maximal 
activation (157-167%) of CEH en2yme. Moreover, the activation of CEH was 
partially abolished by synthetic: rabbbit sequence protein kinase inhibitor, 
indicating the involvement of a cAMP-dependent protein kinase. These results are 
consistent with the previously published reports, where activation of rat liver 
cytosolic and microsomal CEH by ATP-Mg and cAMP has been demonstrated 
(Ghosh and Grogan, 1989; Martinez et al., 1994; Natrajan et al., 1996b; Natrajan 
et al., 1997). The results also demonstrate that preincubation of cytosolic and 
partially purified CEH with 3 mM ATP or 5 mM Mg^ "^  significantly activated the 
CEH, which is apparently mediated by endogenous PKA and other cofactors 
required for phosphorylation (activation). Mg^^-mediated activation of CEH is 
inconsistent with tiie findings reported by Ghosh and Grogan (1989), where 4 mM 
Mg ^ resulted in dephosphorylation and inactivation of cytosolic CEH, involving a 
Mg -dependent phosphatase. 
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It is interesting to note that increasing concentration of Mg^ ^ (6-10 mM) 
abolished the activation of cytosolic and partially purified CEH caused by 5 mM 
Mg^^ . Similarly, high concentrations of ATP (above 3 mM) and ATP-Mg (above 
2 mM) consistently reduced the optimal CEH activation caused by 3 mM ATP or 
2 mM ATP-Mg. In addition, 5 mM ATP and ATP-Mg not only completely 
abolished the CEH activation but inhibited the basal enzyme activity by 90%. The 
inhibitory effects of high levels of ATP-Mg on CEH activity were significantly 
counteracted by the PKA/cAMP-promoted activation of CEH. Consistent with the 
above results, high concentrations of ATP and ATP-Mg was associated with the 
activation of p-nitrophenyl phosphate-sensitive phosphatases with a concomitant 
inactivation of CEH in 0-40% ASF of cytosol. The combined results strongly 
suggest the involvement of endogenous ATP-Mg-dependent phosphatase-mediated 
dephosphorylation and inactivation of CEH enzyme. Furthermore, activation of 
such type of phosphatases at high levels of ATP and ATP-Mg counteracts the 
PKA/cAMP and ATP-Mg-promoted activations, reducing CEH activity to the 
control value or even inhibiting the basal CEH activity by more than 90%. A 
similar mechanism of dephosphorylation mediated by ATP-Mg-dependent 
phosphatase has been reported for rabbit muscle phosphoryase a, phosphorylase 
kinase, glycogen synthase, inhibitor 1 and troponin I, mammary gland acetyl-CoA 
carboxylase and ATP citrate lyase, and rabbit reticulocyte initiation factor eIF-2 
(Yang et al., 1980b; Stewart et al., 1981). This enzyme dephosphorylated and 
inactivated phosphorylase kinase and inhibitor 1, and dephosphorylated and 
activated glycogen synthase and acetyl-CoA carboxylase (Stewart et al., 1981). 
Involvement of cytosolic ATP-Mg-dependent phosphatase-mediated dephosphory-
lation and inactivation of CEH represents an initial demonstration. Since in our 
studies Mn^ ^ and ATP-Mn also activated cytosolic CEH, we investigated in detail 
the role and specificity of firee Mn^ ^ and ATP-Mn on the activation of partially 
purified CEH associated with 0-40% ASF of cytosol. 5 mM of Mn^ ^ stimulated 
CEH activity to a significantly higher degree than 5 mM Mg^ .^ This activation was 
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completely blocked at 10 mM Mn^'. Our results demonstrate that unlike Mg^, 
high increase in CEH activity is substantially due to direct effect of free Mn^ ^ 
(5 mM) on enzyme and is independent of PKA-mediated phosphorylation 
(activation) of CEH. However, 2 mM of ATP-Mn was associated with the 
activation of CEH analogous to ATP-Mg-dependent CEH activation. High 
concentrations of ATP-Mn (above 2 mM) completely blocked the CEH activation 
and also inhibited the basal activity of CEH. The degree of CEH activation by 
2 mM ATP-Mn and inactivation of activated CEH at higher levels of ATP-Mn was 
significantly lower than obtained with ATP-Mg. These results support the view 
that ATP-Mg is specific and preferred cofactor for a PKA-dependent activation of 
CEH and ATP-Mg-dependent phosphatase-mediated dephosphorylation and 
inactivation of CEH. 
If CEH were regulated by phosphorylation/dephosphorylation mechanism 
as suggested by these studies, the endogenous phosphatases should inhibit CEH 
activity. Infact, CEH was activated and its dephosphorylation and inactivation 
prevented by the nonspecific serine/threonine phosphatase inhibitors, pyro-
phosphate and glycerophosphate. Serine/threonine phosphatases are classified by 
their Mg^ ,^ Ca^ "^  and Mn^ ^ dependence and their sensitivity to various inhibitors. 
(Cohen, 1989; Cohen et al, 1990). Type I, 2A, 2B and 2C phosphatases, which 
account for virtually all detectable phosphatase activities in liver, are directed 
toward many phosphoproteins including HMG-CoA reductase and acetyl-CoA 
carboxylase (Cohen, 1989; Cohen et al., 1990; Ingebritsen et a/., 1983b; 
Ingebritsen et al, 1983c; Asins et al, 1991). Since tyrosine phosphatases are not 
involved in the dephosphorylation of CEH, no activation of CEH enzyme activity 
observed at 10-100 jiM orthovanadate. We report here a novel finding that high 
concentrations (5-10 mM) of orthovanadate was associated with CEH activation 
apparently by inhibiting serine/threonine phosphatases in a manner analogous to 
pyrophosphate and glycerophosphate. Okadaic acid/calyculin A as a specific 
inhibitor is usefiil for distinguishing phosphatases, as it has a high affinity for the 
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catalytic subimit of Type 1 and 2A phosphatases (Biolajan and Takai, 1988; Cohen 
et al., 1990). Because the endogenous phosphatases acting on CEH is sensitive to 
both low (10 nM) and high (5 i^M) concentrations of okadaic acid/calyculin A and 
partially inactivated the phosphatase activity, it is likely that 2A phosphatase is 
involved in the dephosphorylation and inactivation of CEH. Like cytosolic CEH, 
microsomal CEH has also been shown to be activated by the nonspecific 
serine/threonine phosphatase inhibitors, pyrophosphate and glycerophosphate. 
However, no effect of okadaic acid in terms of microsomal CEH activation was 
observed (Martinez et al., 1994). The mechanism by which phosphatase inhibitors, 
pyrophosphate, orthovanadate and okadaic acid mediated the activation of CEH 
apparently by inactivating serine/threonie phosphatases. Addition of ATPMg/ 
cAMP/PKA to the samples treated with above three phosphatase inhibitors caused 
an additional 1.5-2 fold activation of CEH indicating a PKA-mediated enhanced 
phosphorylation. This is the first evidence for the involvement of endogenous 
phosphatases in the inactivation of partially purified cytosohc CEH. 
Inhibition of CEH activity by endogenous phosphatases involving 
dephosphorylation was confirmed by utilizing conmiercial nonspecific alkaline 
phosphatases. Inhibition of CEH by alkaline phosphatase suggests that cytosolic 
CEH is deactivated under conditions at which other proteins are dephosphorylated. 
The existence of an activation/deactivation cycle for CEH involving phosphory-
lation/dephosphorylation was established by using cAMP-dependent protein 
kinase/cAMP/ATP-Mg as activators, and the nonspecific alkaline phosphatase 
fi-om bovine intestinal mucosa as an inhibitor. PKA-mediated phosphorylation and 
activation of CEH was reversed by alkaline phosphatase involving dephos-
phorylation and inactivation. The combined results confirm and extend the idea 
that cytosolic CEH activity can be modulated in vitro involving a cAMP-
dependent protein kinase. Dephosphorylation and inactivation of CEH is mediated 
by endogenous cytosolic ATP-Mg-dependent phosphatase, and okadaic acid 
sensitive 2A phosphatase. The regulation of CEH by reversible covalent 
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phosphorylation can not be comfirmed without the demonstration of specific 
phosphorylation of purified cytosolic CEH enzyme, which remains to be 
investigated. 
The regulation of rat liver cytosohc CEH involving phosphorylation 
(activation)/dephosphorylation (inactivation) was investigated in in vivo. Results 
presented in this thesis show that short-term (15 min) administration of cAMP was 
associated with a significant activation of CEH activity. This in vivo CEH 
activation was completely reversed following dephosphorylation with alkaline 
phosphatase. These results represent an initial demonstration of an in vivo cAMP-
dependent protein Idnase-mediated phosphorylation and activation of cytosolic 
CEH in cAMP-treated rats. The magnitude of in vitro alkaline phosphatase-
mediated dephosphorylation and inactivation of in vivo activated CEH is 
consistent with the in vitro data suggesting that the level of phosphorylation may 
play an important role in the regulation of CEH activity in vivo. These results are 
consistent with published reports where incubation of cAMP analogues to hamster 
and rat hepatocytes caused activation (31-37%) of cytosohc CEH (Hoang et al, 
1993; Botham et al, 1996). However, our results are inconsistent with two 
previously pubhshed reports indicating a dibutyryl cAMP and glucagon-induced 
inhibition of cytosolic CEH in rat hepatocytes (Ruiz et al, 1988; Ruiz et al, 
1990). 
Our experiments confirmed the idea that a short-term regulatory mechanism 
involving protein phosphorylation operates on intracellular cholesterol 
homeostasis though different mediators. Under conditions of increased cholesterol 
need, there is ativation of adenylate cyclase to increase the intracellular levels of 
cAMP. This activation could be hormone-mediated, analogous to regulation of 
carbohydrate metabolism in liver, by hormones acting via cAMP. Cyclic AMP 
would then activate cAMP-dependent protein kinase. The active protein kinase 
would, in turn, phosphorylate and activate the inactive or less active CEH to an 
active form. The active CEH would then hydrolyse cholesteryl ester stores to 
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maintain free cholesterol for bile acid and maintenance of membrane cholesterol. 
In contrast, under conditions of decreased cholesterol need, activation of protein 
phosphatases would be operative. The active protein phosphatases would in turn, 
dephosphoiylate and inactivate tiie active CEH to inctive form. The inactive CEH 
would Aen prevent the hydrolysis of cholesteryl esters (Fig. 4.1). 
Thirty minutes after the administration of mevalonolactone to rats failed to 
elicit any effect on liver cytosolic CEH. In contrast, short-term (20-30 min) 
administration of MVL to rats has been shown to cause inhibition of HMG-CoA 
redutase involving reversible phosphorylation (Erickson et al., 1980; Beg e/ ai, 
1987). In 4 h MVL-treated rats, the basal CEH activity was increased partially due 
to in vivo phosphorylation. Dephosphorylation of CEH with alkaline phosphatase 
partially reversed the initial activation of CEH, which is consistent with MVL-
mediated reversible phosphorylation of CEH. The observation that bulk of CEH 
activation in MVL-treated rats is due to interconversion of inactive to active 
(phosphorylation) form of CEH is supported by the fact that only 11% increase in 
CEH protein mass was obtained (Siddiqui, 1999). It has been established that 1-4 h 
administration of MVL to rats was associated with long-term regulation of HMG-
CoA reductase activity, by alteration in protein synthesis (Erickson et al., 1980; 
Beg et al., 1987). In contrast to HMG-CoA reductase, delayed effect of MVL on 
CEH activity involving reversible phosphorylation is apparently due to secondary 
response, because increased CEH-mediated hydrolysis of cholesteryl esters to free 
cholesterol is dependent on increased cellular free cholesterol demand, which is 
due to decreased free cholesterol pool caused by MVL-mediated inhibition of 
HMG-CoA reductase. These results represent an initial demonstration of MVL-
mediated in vivo modulation of cytosolic CEH activity by reversible 
phosphorylation. 
One week feeding of cholestyramine to rats was associated with a 
significant increase in CEH activity, substantial part of which was due to in vivo 
activation (phosphorylation). In vitro dephosphorylation of CEH was consistent 
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with this observation. The combined results demonstrate that cholestyramine 
feeding to rats triggers both PKA-mediated phosphorylation and activation of 
CEH, and inactivation of phosphatases, thus reducing the dephosphorylation 
(inactivation) of CEH and favouring an overall activation status of CEH. Similar to 
CEH, in cholestyramine-fed rats, HMG-CoA reductase was also partially 
inactivated involving reversible phosphorylation (Mitropoulos, 1983). The 
activation of CEH in cholestyramine-fed rats is consistent with other published 
reports. However, the mechanism of activation of CEH was not investigated 
(Ghosh et al., 1990; Shand and West, 1995). Feeding of lovastatin (mevinolin) 
alone or in combination with cholestyramine for one week enhanced the CEH 
activity by 86% and 151%, respectively. In both the groups, after dephosphory-
lation, the reversibility in terms of inhibition of activated CEH was minimal. These 
results demonstrate that unlike cholestyramine, feeding of lovastatin or 
combination of lovastatin plus cholestyramine was not associated with increased 
phosphorylation and activation of CEH. The results also demonstrate that counter 
effect of dephosphorylation (inactivation) mediated by phosphatases were 
minimized in order to maintain a high CEH activation levels in rats treated with 
lovastatin or cholestyramine in combination v^th lovastatin. Our results are 
consistent with an earlier finding where feeding of simvastatin (an analogue of 
lovastatin) alone or in combination with cholestyramine to rats caused a 
substantial increase in CEH activity (Shand and West, 1995). 
Liver cytosolic CEH activity in 21 h and 36 h fasted rats was increased by 
approximately 2-fold. The magnitude of dephosphorylation of CEH from fasted 
rats revealed little reversibility of activation, when compared to dephosphory-
lation of CEH from control rats. The combined results demonstrate tiiat high levels 
of CEH activation seen after fasting was not associated with phosphorylation of 
the enzyme. The results are consistent with low degree of in vitro activation of 
CEH with phosphorylating agents. Furthermore, fasting was associated with 
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significantly reduced in vitro activation of phosphatases and substantially low 
inhibition of CEH activities, thus favouring an overall activation of CEH. 
Four week admnistration of orthovanadate to normal and diabetic rats failed 
to affect partially purified CEH activity via phosphorylation/dephosphorylation. 
However, orthovanadate has been shown to influence certain in vivo 
kinase/phosphatase systems after prolonged treatment (42-120 days) to normal and 
streptozotocin-induced diabetic rats. Therefore, it is likely that in our studies, only 
four weeks of or&ovanadate administration to normal and diabetic rats ^parently 
failed to produce any effect on CEH activity (Pugazhenthi and Khandelwal 1990; 
King et al., 1993; Ramasarma, 1996). 
The results presented here offer considerable evidence that neutral cytosolic 
and partially purified CEH is activated by cAMP-dependent protein kinase 
involving activation (phosphorylation). The dephosphorylation and inactivation of 
CEH is catalyzed predominantly by endogenous ATP-Mg-dependent phosphatase 
and partially by okadaic acid-sensitive 2A phosphatase. We also present initial 
evidence that in vivo modulation of cytosolic CEH activity involving reversible 
phosphorylation is regulated by cAMP. The present work provides evidence that 
modulation of CEH enzyme activity involving activation (phosphorylation) and 
inactivation (dephosphorylation) is also partially modulated in MVL and 
cholestyramine-treated rats. The in vitro and in vovo results imply that CEH is 
regulated by reversible phosphorylation and the phosphorylated form is the active 
species, whereas the dephosphorylated form is the inactive form. Based on 
previously published reports and above results indicating the involvement of 
reversible phosphorylation in the regulation of enzymatic activities of HMG-CoA 
reductase (Beg et al., 1987), cholesterol 7 a-hydroxylase (Goodwin et al., 1982; 
Sanghvi et al., 1983; Sanghvi, 1985; Berglund et al., 1986), acyl CoA: cholesterol 
acyltransferase (Basheeruddin et al., 1982; Gavey et al., 1983; Suckhng et al, 
1983b) and CEH, it appears that coordinate control of these enzymes by 
phosphorylation/dephosphorylation may play an important role in maintaining 
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appropriate levels of unesterified cholesterol (Fig. 4.2). Stimuli shifting phospho-
rylation though the cAMP-dependent protein kinase cascade would enhance 
cholesteryl ester mobilization to supply cholesterol and fatty acids, the former 
being used for bile acid synthesis (Goodwin et al., 1982; Scallen and Sanghvi, 
1983; Sanghvi, 1985; Berglund et al., 1986). In contrast, the availability of 
substrates for cholesteryl ester synthesis is reduced by the phosphorylation 
(inactivation) of HMG-CoA reductase and activation (phosphorylation) of 
cholesterol 7 a-hydoxylase and ACAT enzymes. In addition, fatty acid levels will 
be reduced due to AMP-activated protein kinase, which inactivates acetyl-CoA 
carboxylase and antagonizes the activation of the hormone-sensitive lipase by 
PKA (Garton et al., 1989; Hardie et al., 1989). CEH, which is more active in the 
phosphorylated state, would then be important in maintaining the free cholesterol 
level in the cell and in turn overall cholesterol homeostasis. However, Ae 
mechanism by which cellular cholesterol levels might affect tiie phosphorylation 
status of the various enzymes in a coordinated fashion has not been demonstrated. 
It is possible that this mode of regulation responds to the nutritional status or otiier 
humoral factors affecting hormone levels, rather than to cholesterol levels per se 
(Fig. 4.2). 
Knowledge of the molecular mechanisms involved in the regulation of CEH 
may provide new insight into the coordinate control of cholesterol metabolism and 
may ultimately lead to the development of potential drugs for the treatment of 
patients with hypercholesterolemia and premature coronary heart disease. 
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A. Increased Cholesterol Need (Cholesterol Deprivation) 
1. 1 HMG-CoA Reductase Activity 
2. i 7 a-Hydroxylase Activity 
3. i ACAT Activity 
4. I CEH Activity 
B. Decreased Cholesterol Need (Cholesterol Excess) 
1. i HMG-CoA Reductase Activity 
2. I 7 a-Hydroxylase Activity 
3. I ACAT Activity 
4. i CEH Activity 
Fig. 4.2 Proposed regulatory adjustments (arrows) by phosphorylation/dephospho-
rylation of four key enzymes involved in cholesterol metabolism for 
cholesterol deprivation (A) or cholesterol excess (B). 
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